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Abstract
Galvanically coupling enzymatic bioelectrodes with drug loaded conducting
polymers to develop a controlled drug delivery system is investigated. The system
is designed to be a novel and sophisticated approach to in vivo drug delivery for the
treatment of epilepsy. There is a suite of anti-epileptic drugs (AEDs) that are
extremely effective at suppressing seizure activity however; their use is restricted
due to debilitating side effects. As such, it is of interest to develop novel drug
release methods to deliver the AEDs directly to the target area in the brain and in
small doses to minimise, and ideally eliminate, the side effects. The significance of
using an enzymatic power source lies in its ability to operate off simple sugars
naturally present in the human body. Additionally, the on/off switching behaviour
of the conducting polymer, polypyrrole (PPy), can be accessed to release the drug
when the oxidation state of the polymer is changed. By exposing the glucose
oxidase (GOx) bioelectrode to glucose in solution, the catalytic current generated
can be harnessed to charge the polymer and instigate drug release on cue.
Experiments were carried out to develop and characterise GOx bioelectrodes based
on a direct electron transfer (DET) mechanism facilitated by carbon nanomaterials,
namely multi-walled carbon nanotubes (MWNT) and reduced graphene oxide
(rGO).
Chapter 3 investigates the development of solvated graphene electrodes (SGE), a
hydrogel-like system based on graphene, with immobilised GOx. It is proven
through biological protein and kinetic assays that the GOx is stable within the
graphene structures and the electrodes can be reproducibly fabricated. Through
electrochemical techniques, including cyclic voltammetry, impedance, amperometry
and fourier transform alternating current voltammetry, it was revealed, however,
that the enzyme is not electrically wired to the solvated graphene matrix, and as
such, cannot directly transfer the electrons generated from the oxidation of glucose
to the nanostructured electrode. As a result of its inability to access the catalytic
current, no useable charge is generated and the structures cannot be used to power
drug release from a conducting polymer scaffold.
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In Chapter 4, aqueous dispersions of rGO and MWNT are fabricated through a
modified chemical reduction method. The significant advantage of the method
developed is the omission of any stabilizing compound or organic solvent to obtain
stable rGO-MWNT dispersions. Significantly biological entities, such as GOx, can
be successfully incorporated into the dispersion. These dispersions were
characterised using XPS, SEM, zeta potential and particle size measurements which
showed that the dispersion stability is not sacrificed with the addition of GOx, and
significantly, the electrical properties of the rGO and MWNTs are maintained. In
this study, rGO acts as an effective dispersing agent for MWNTs and does not
affect the solubility or electroactivity of the GOx. Bioelectrodes fabricated from
these rGO-MWNT-GOx dispersions were characterised electrochemically to test
their feasibility in facilitating direct electron transfer (DET) from the redox centre
of the enzyme to the electrode. The DET results showed that the specific catalytic
current generated at an optimized rGO-MWNT-GOx electrode was 72 µA/µg
GOx, which is 3 times more efficient than other literature values for similar
systems. The remarkable specific catalytic current can be attributed to the use of
purified enzyme, the efficiency of charge transfer within the rGO-MWNT
composite and the ability of the electrode to facilitate direct electron transfer. The
optimised electrode developed and characterised in Chapter 4 is used in Chapter 5
to power the release of drug from PPy.
The release of the anti-inflammatory drug, Dexamethasone-21-phosphate (DEX),
and the anti-convulsant drug, Fosphenytoin (FOS), from PPy films are
characterised in Chapter 5. This work investigates, for the first time, the controlled
release of FOS from a conducting polymer and galvanically connects the optimised
rGO-MWNT-GOx bioelectrode (presented in Chapter 4) to drive the release, also
the first of its kind. When the two half cells are connected and the conditions are
changed in the bioelectrode cell from 0 mM to 150 mM glucose, there is an increase
in the charging current generated, as a result of the additional catalytic current. A
corresponding increase in the rate of FOS released was measured in the release cell
from 24 to 47 ng/mL. This result shows that the concept of galvanically coupling
enzyme-based bioelectrodes with drug loaded conducting polymers to fabricate a
controlled drug delivery device is valid.
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To accomplish great things, we must dream as well as act
- Anatole France
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1. Introduction
1.1 The treatment of epilepsy
In 2012 the World Health Organization (WHO) published that over 50 million
people worldwide suffer from epilepsy1. The International Bureau of Epilepsy
defines an epileptic seizure as “a transient occurrence of signs and/or symptoms due
to abnormal and excessive neuronal activity in the brain”. Epilepsy is defined as a
disorder of the brain characterised by an enduring predisposition to generate
epileptic seizures2. Figure 1.1 shows a typical Electroencephalography (EEG) signal
for a normal patient (a) and a patient undergoing an epileptic seizure (b).
(a)

(b)

Figure 1.1 (a) An EEG signal for a normal patient and (b) an EEG signal for a patient
undergoing an epileptic seizure. Note the labels to the right of each graph represent the
bipolar EEG channels selected for analysis. Adapted from Ref3.

Seizures can significantly affect a person’s quality of life and, of the 50 million
epilepsy sufferers worldwide, only 70% are responsive to current treatment options
leaving 15 million people to cope with a life of uncontrolled seizures. The most
common treatment involves the administration of anti-epileptic drugs (AED) that
patients take orally at least once a day. If AEDs are ineffective and the seizures are
too severe to go untreated, there are alternate, but higher risk, options including
surgery to remove the brain tissue most active during seizures (termed the epilepsy
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focus), stimulation of the vagus nerve (using a device which continuously sends
electrical pulses through the entire brain as a counter stimulation), or, especially in
children, the ketogenic diet (a diet that encourages the production of ketones to
replace sugar as the main energy source for the brain).
There is a suite of AEDs that are commonly used to treat epilepsy with many
patients responding well to a specific drug, while others respond better to a
combination of drugs4. There are also a few select anti-epileptic medications that
are potent and pose the risk of worsening the condition, among other side effects5.
Some of these types of medications are restricted and usually administered
intravenously6. Although AEDs generate debilitating side effects, they can be
extremely effective at suppressing severe seizure activity.
If the AEDs are delivered directly to their intended site of action in the body, then
undesirable actions on other parts of the body, resulting in side effects, will be
minimised7. Also to be considered are parameters like the potency of the drug (i.e.
the minimium dose to achieve the desired response) and the therapeutic window (i.e.
the difference between the minimum effective level and the dose at which the drug
becomes toxic). Consequently, a controlled drug delivery device of this type could
increase the portion of the afflicted population that can be treated through AEDs
and avoid the more risky treatments.

1.2 Thesis overview
This thesis aims to develop a prototype of an implantable controlled drug delivery
device designed specifically for the treatment of epilepsy. It will investigate the
release of clinically relevant medications from intelligent material constructs and,
ultimately, integrate an implantable power source of an enzyme-based bioelectrode.
This project is primarily concerned with the fabrication and characterisation of
electrodes for the intended application and attention will be paid throughout the
thesis to outline the significance of chosen methodologies and materials to the
ultimate visionary goal – to treat epilepsy.
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1.3 Current state of drug delivery devices
The concept of controlling the delivery of therapeutics in the human body has been
investigated since the 1960’s8. Traditional drug delivery methods include the
application of ointments and creams to the surface of the skin9, the use of capsules
or tablets to be taken either orally or inserted into the gastrointestinal tract, or
direct administration into the systemic circulation by intravenous injection10.
Although systemic methods, those drug delivery systems that administer drug to
the entire body, are still the most commonly used drug delivery routes, they have
their limitations. Systemic delivery can result in the presence of a large
concentration of drug in the circulatory system that can adversely affect the rest of
the body because the drug reaches toxic levels, as shown in Figure 1.2 (a).
Although the procedure can be optimised, by reducing the amount administered to
ensure the level of drug reaches the minimum effective level threshold but does not
reach a toxic level, as shown in Figure 1.2 (b), the drug in the circulatory system
passes through the body and quickly drops below the effective level. Hence it is
necessary in systemic administration to frequently readminister the drug to
maintain the minimum effective drug concentration. In the case of AEDs that are
intended to act on brain tissue, the concentration of drug penetrating the blood
brain barrier is significantly less than that in the circulatory system7,11. For this
reason, daily systemic dosing is required to maintain a therapeutic concentration of
drug in the target area12, which also presents patient adherence issues13. Hence, it is
of interest to develop new methods of delivering drugs to address these problems
and maintain a constant level of drug, as shown in Figure 1.2 (c).
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Drug concentration

(a)

Toxic level
(c)
(b)

Minimum effective level

Time
Figure 1.2 Drug concentration following absorption of a therapeutic agent as a function of
time showing the profile for (a) an unsafe systemic dose, (b) a safe systemic dose and (c) a
safe controlled release. Adapted from Ref14

Targeted delivery of therapeutics presents the following advantages over
traditional drug delivery methods13:
•

Improved efficiency

•

Smaller targeted doses sufficient to elicit treatment

•

Reduced side effects, and

•

Enhanced patient compliance

Many controlled drug delivery devices are on the market for a range of applications
with the majority based on the release of drug from polymer constructs (for a
comprehensive review see Table 1.1 on page 6). For many years the focus was on
inert polymers, for example silicone, which require surgery to remove the polymer
skeleton after the drug is fully released. More recently, biodegradable polymers
have attracted attention for this application because of their ability to release drug
during their breakdown and for the breakdown products to naturally be excreted
from the body. Naturally occurring polymers like peptides, nucleic acids and
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polysaccharides, such as alginate, collagen and chitosan, as well as a suite of
synthetic polymers have been used for these applications and are listed by Pillai et
al15.
Although polymeric materials form the majority of controlled drug delivery
devices, recent research has focused on modifying polymer properties by using
existing and novel manufacturing techniques to more accurately control the release
of drug. For example, Halliday et al. outline a range of manufacturing techniques
such as electrospinning, casting, 3D printing, spray drying and particulate
formulations7. The formation of novel polymer structures through advanced
manufacturing techniques allows new uses of pre-existing polymer materials which
have already undergone Food and Drug Administration (FDA) approval, and hence,
offer a less hindered route to commercialisation than using new materials.
There is also a suite of new material composites that release drug in response to
external stimuli such as infrared light, magnetic fields and ultrasound, as listed by
Timko et al.16 For example, gold nanoparticles coated with a drug loaded polymer
(poly(N-isopropylacrylamide)) can absorb near-infrared light and convert the light
energy into heat. As the underlying gold nanoparticles heat up past a critical
temperature, the polymer matrix collapses and releases the drug (Figure 1.3). This
type of on-cue drug release offers a distinct clinical advantage over systems that
release drugs passively or through natural breakdown in the body. These remotely
triggered delivery systems allow the control of dose, timing and duration of drug
release and offer more advanced treatment options16.

Figure 1.3 Macroscale poly(N-isopropylacrylamide)-gold nanoparticle composites collapse
when heated beyond a critical temperature, expelling drug (green spheres). Adapted from
Ref16.
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Table 1.1 categorizes controlled drug delivery systems into four general
classifications, namely, diffusion controlled, water penetration controlled,
chemically controlled and regulated systems. Moreover, it outlines the mechanism
of drug delivery and examples of commercially available devices. The table is
designed to give an overview of the current delivery methods for all applications,
not specifically for the treatment of epilepsy, which still utilise systemic delivery
methods.
In addition to examples given in Table 1.1 there is an intense research drive to
advance existing devices and to develop novel intelligent drug delivery systems to
respond to in vivo stimuli, identified as self-regulating17 or closed-loop systems18. In
the case of treating epilepsy, this would mean delivering a drug in a timely manner
in response to the onset of seizure activity Figure 1.1 (b) shows that a seizure starts
in less than one second and, consequently, a device designed to treat epilepsy is
required to have a switching speed in a similar time frame. In order to do this, the
prediction19 or detection3 of a seizure would have to be built into the drug delivery
device, a concept which is outside the scope of this thesis but a consideration worth
mentioning.
Conducting polymer scaffolds have been extensively researched for their application
in controlled drug delivery systems20, which will be discussed in the following
section. The research in this thesis will look at the biologically relevant conducting
polymer polypyrrole (PPy), for its ability to release AEDs on-cue and in a timely
manner for application in a drug delivery device to treat epilepsy.
Table 1.1 Classification of controlled drug delivery systems including the mechanism of
release and examples of commercially available products. Adapted and updated from Ref14
Type of drug delivery
system
Diffusion Controlled

Mechanism of release and commercial examples

•

Reservoir

Diffusion of drug through a membrane from a reservoir
E.g. Ocusert: for the treatment of glaucoma21
E.g. Mirena: Intrauterine device releases contraceptive medication22

•

Bulk

Diffusion of drug through a bulk polymer
E.g. Nexplanon: a subdermal rod implant that releases contraceptive
medication by diffusion through a bulk ethylene vinylacetate copolymer23
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Water penetration controlled
•

Osmotic

The osmotic transport of water through a semi permeable
membrane activates an osmotic pump and hydrostatic pressure
builds up in the system, forcing the drug out
E.g. OROS systems by ALZA corp24

•

Swelling

Water uptake by a multilayered polymer construct, which
releases enclosed drugs at a rate dependent on the swelling rate
of the polymer layers
E.g. Geomatrix by Skyepharma25

Chemically controlled
•

Based on polymer systems and involves either pure polymer
degradation, or a combination of degradation and bulk diffusion
E.g. Resomer® by Sigma-Aldrich is a polymer blend of poly(glycolide)
(PGA) and poly(lactide) (PLA) whose by-products are bioresorbable.

Bulk degradation

Regulated systems
•

Magnetic, infrared or
ultrasound

External application of magnetic field, infrared or ultrasound to
the device to instigate drug delivery26,27
E.g. Diffucaps by Eurand

•

Chemical

Enzyme-substrate reactions
E.g. Zuplenz: Oral strip made of a cellulose derivative that is broken
down in the mouth by enzymes and designed to treat nausea and
vomiting after chemotherapy28

•

Electrochemically
(Conducting
polymers)

Drug delivery controlled by charge transfer as a function of the
conducting polymer oxidation state
E.g. To the author’s knowledge no commercial examples exist (see
section 1.4 for more details)

1.4 Polypyrrole for controlled drug delivery
1.4.1 Introduction to conducting polymers
Alan MacDiarmid, Alan Heeger and Hideki Shirakawa won the Nobel Prize in
Chemistry (2000) for their work on conductive polymers29,30 since their discovery in
the 1970’s. The discovery that some polymers, traditionally classed as insulting
materials, could conduct electricity saw the expansion of a new and exciting field of
scientific research. The most practically useful and stable conducting polymers that
have emerged in the last few decades of study are based on polypyrrole (PPy),
polythiophene (PTh) and polyaniline (PAni)31. These materials have since found
applications

in

energy

storage32,

photovoltaics33,

electrochromics34,
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electromechanical actuation35, separation membranes36, corrosion protection37,
chemical sensors38, and, of course, controlled delivery devices39. Polypyrrole will be
studied extensively in this thesis; therefore, it will be introduced in the following
sections.

1.4.2 Electrochemical polymerisation
The synthesis of conducting polymers can be achieved through chemical or
electrochemical methods39, the latter of which was utilised in this study and will be
discussed in detail. A three-electrode electrochemical cell is generally used for
polymerisation and comprises of a reference electrode, an auxiliary (or counter)
electrode and a working electrode (discussed in more detail in Chapter 2 – section
2.2.3.2). The working electrode is the conducting substrate where the polymer film
will ‘grow’. The oxidation of pyrrole monomer in solution can be achieved
electrochemically by applying a constant current (galvanostatic), constant voltage
(potentiostatic) or changing voltage (cyclic voltammetry) to the working electrode.
In the monomer solution it is critical to have a suitable doping anion that is
incorporated into the insoluble polymer product to balance the charges generated
on the polymer during oxidation (discussed in section 1.4.3). The result of this
process is a conducting film of polypyrrole doped with the anion on the working
electrode. This is shown schematically in Figure 1.4.

n

H
N

N

H

A-

+

Oxidation

A-

H
N

N

H

A-

+

H
N

n
m

Figure 1.4 Schematic of the electrochemical oxidation of pyrrole monomer in the presence of
an anion (A-) to form doped polypyrrole, where n is the number of monomer units per dopant
anion and m relates to the polymer chain length that determines molecular weight. Adapted
from Ref39
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Initially, polymerisation starts in solution and eventually oligomers (several
monomer units) adsorb onto the working electrode surface when they reach a given
molecular weight and become insoluble. These sites are known as nucleation sites
and subsequent polymerisation spreads from these points on the electrode surface
until the entire working electrode is covered40,41. Sadki et al detail the mechanism of
polymerisation for polypyrrole extensively in their review paper42. Pyrrole
monomer is partially soluble in aqueous mediums making it suitable to use in
biomaterial applications because biomolecules, which can be incorporated as anions
(A-) (Figure 1.4), are usually water-soluble. In electrochemical polymerisation of
pyrrole, many experimental parameters can effect the properties of the final film,
including dopant/monomer concentrations, temperature, substrate type, solvent,
electrodeposition protocol, different dopants and growth time40,43. In this thesis,
galvanostatic electrochemical deposition was used to prepare polypyrrole films and
the process was monitored through measuring charge (A.s) and potential (V) as a
function of time. The charge passed was monitored to ensure that the same amount
of polymer was deposited for each sample. Fonner et al. show that the correlation
between the charge passed and the amount of polypyrrole deposited is a linear
relationship40. The voltage channel also gave information on the quality of the film
deposited. Polypyrrole oxidises at approximately +0.8 V (vs. Ag|AgCl) and if the
growth potential exceeds +1.0 V it indicates the formation of an over-oxidised
polymer that will have insulating electrical properties. The monitoring of the
growth process is critical to troubleshoot and identify problems with the system44.

1.4.3 Structure and electrical conductivity
The fundamental difference between traditional insulating polymers and
conducting ones is the conjugation found in conducting polymers that allow charge
delocalisation. Conjugation is the repetition of single and double bonds between
carbon atoms, as highlighted for polypyrrole in Figure 1.5.
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Figure 1.5 The structure of polypyrrole.

The conjugation of conducting polymers allows the overlapping of sp2-hybridised
orbitals, which is critical for electrical conduction. In its neutral (undoped) state,
polypyrrole is a moderate insulator because these overlapping sp2 orbitals are full.
This is represented in band theory (Figure 1.6 a) with a large band gap of 4.0 eV for
polypyrrole, as calculated using valence-effective Hamiltonian methods45. The band
gap of a material is the difference between the conduction band (highest occupied
molecular orbital, HOMO) and the valence band (lowest unoccupied molecular
orbital, LUMO), which is the energy required for an electron to transition across
this gap. This transition defines the electrical properties of material. The addition
or subtraction of charge from these orbitals is the act of doping, and is the
mechanism by which polypyrrole becomes electrically conducting. For polypyrrole,
p-type doping is achieved through oxidation of the polymer in the presence of a
‘doping’ anion, which is incorporated into the structure to balance charge (Figure
1.4). P-type doping results in the formation of a polaron (a positive charge) that is a
charge carrier delocalised across, on average, 4 monomer units in the backbone46
(represented in Figure 1.7 as a red positive charge). When another polaron is
generated it is energetically favourable to form a bipolaron, or a pair of polarons.
This is shown schematically in Figure 1.7.
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4.0 eV

(a)

(b)

(c)

(d)

Figure 1.6 Band structure evolution upon doping of polypyrrole (a) undoped, (b) low doping
level with non-interacting bipolarons present of the polymer chain, (c) intermediate doping
level where bipolaron bands form in the gap and (d) high doping levels. Adapted from Ref45.

At a low doping level there is very little interaction between bipolarons along the
polypyrrole backbone. This is represented in band theory as the appearance of
bipolaron states in the gap (Figure 1.6 b). As the doping level is increased to an
intermediate level the bipolarons start interacting and form bipolaron bands in the
gap (Figure 1.6 c). At high doping levels bipolaron bands merge with the
conducting band and the valence band, and the band gap is sufficiently low for the
material to be classed as conducting47 (Figure 1.6 d).
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Figure 1.7 The formation of polarons and bipolarons on a polypyrrole chain; where (a)
represents the undoped state, (b) represents the formation of a single polaron and (c)
represents a bipolaron on the polypyrrole backbone. Polarons can be identified by the red
positive charge in this figure.

1.4.4 Electroactivity and drug release mechanism
The term ‘electroactive’ is given to a material that is responsive to electrical stimuli.
Conducting polymers are electroactive and can be reversibly switched between the
oxidised (conducting) and reduced (insulating) states. During electrochemical
switching there is movement of dopants (or counter ions) to balance the charge
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induced on the polymer backbone48. Figure 1.8 shows that when the polymer is in
an oxidised state, the anion is electrostatically attracted to the positive charge
(polaron or biopolaron) on the polymer backbone. Additionally, when the polymer
is in a reduced state the positive charge is removed and the relatively negative
polymer expels the anion. The mechanism of charge balance is dependent on the
size and hence mobility of the doping ion, which for the case of polypyrrole is an
anion. If the doping anion is very large it is sterically restricted from being expelled
from the polymer matrix upon reduction, and, as such, cations from solution
migrate into the structure to balance the charge. If the doping anion is sufficiently
small it is expelled from the structure during reduction, again, to balance charge.
The latter mechanism is represented in Figure 1.8 and underpins the process of
drug release utilised in this thesis because the doping anions (introduced in section
1.4.5) are relatively small. Significantly, the doping anion for this system can be a
therapeutic drug. During redox cycling conducting polymers also undergo other
property changes that may contribute to the release of the doping ion. These
changes include swelling/deswelling35, colour changes49 and changes in mechanical
properties50 and will be discussed in more detail in Chapter 5. It is impossible to
separate these changes to understand their individual involvement in the release
mechanism.
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Figure 1.8 Mechanism of charge balance by anion movement (in the case of a small anion)
upon oxidising and reducing doped polypyrrole. Adapted from Ref51
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1.4.5 Controlled drug release
Polypyrrole has been extensively researched for its application in controlled
delivery due its ability to incorporate biomolecules and therapeutic drugs, its
stability in aqueous environments52 and its biocompatibility53. Drug delivery from
conducting polymers differs from controlled delivery devices already on the market
(see Table 1.2) in that it is dependent on electrical stimulation; additionally, it offers
enhanced control, through its electroactivity, to facilitate the on/off release of drug,
a property critical for the proposed device to treat epilepsy.
The therapeutic drugs chosen for this thesis, to take the place of anion A- in Figure
1.8, were the pro-drugs dexamethasone-21-phosphate disodium salt (DEX) and
Fos-phenytoin (FOS), whose structures are shown in Figure 1.9. DEX is an antiinflammatory drug that has been studied extensively as a dopant for polypyrrole54–
56.

Delivering an anti-inflammatory drug directly to the site of trauma can treat the

damage induced on implantation of the proposed brain device. Alternatively, FOS is
a pro-drug AED currently used to suppress severe seizures in clinical settings and
is delivered intravenously57. Its wider use is prohibited due to it’s debilitating side
effects, including severe allergic reactions, aplastic anaemia, increased suicide risk,
irregular cardiac rhythms and deliria58 however, if a targeted delivery method is
discovered these side effects can be significantly reduced, if not eliminated7. Both
these molecules have a phosphate anionic side group, making them appropriate to
use as a dopant for polypyrrole (Figure 1.9).
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(a)

(b)

Figure 1.9 Chemical structure of (a) Dexamethasone-21-phosphate disodium salt and (b)
Fosphenytoin.

Table 1.2 provides an extensive list of literature that investigates the release of
therapeutic agents from polypyrrole under various stimulation protocols. Since
Zinger and Miller first studied the use of polypyrrole as a release substrate in
198459, many other groups have studied it for a range of drug delivery applications,
including the treatment of schizophrenia, neural electrode coatings and implantable
microchips for controlled drug release60–62. The number of publications in this area
significantly increased around the year 2000 and continues to interest scientists
looking at novel ways to deliver drugs in vivo. One of the primary concerns with
implanting drug loaded polypyrrole structures is the need to power them from
inside the body. This underpins the next section of this introduction dealing with
implantable power sources.
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Table 1.2 Literature summary of molecular release from polypyrrole electrodes under the stimulation protocols tabulated. Their intended application is also
identified.
Year

Molecule released

Stimulation Protocol

Application

Ref

1984

Glutamate (neurotransmitter)

Constant potential (-1.0 V for 120s)

Implantable electrode

59

1992

Adenosine triphosphate (ATP)

Constant potential (potential step from +0.6 to -0.6 V)

Controlled drug delivery

63

1994

Acetylsalicylate

Constant potential (-1.0 V)

Controlled drug delivery

64

1994 -1996

Adenosine triphosphate (ATP)

Constant potential (Polarised at +0.6 V, then the film was

Ionic drug and biomolecule release

65,66

reduced by stepping the potential down to 0V then to -0.6 V)

systems

Chlorpromazine (used to treat

Pulsed potential (between +0.2 V and -0.8 V for 2 minute

Feasibility of QCM as measuring

schizophrenia)

intervals)

technique

Salicylate (anti-acne drug), naproxen

Constant potential (Polarised at +0.5 V, then the film was

Ion gate membrane

52

(anti-inflammatory drug), nicoside

reduced by stepping the potential down to -0.5 or -0.8 V )

1997

1998

67

(vitamin-B) and tosylate (model
molecule)
2000

Adenosine triphosphate (ATP)

Constant potential (-0.7 V)

Drug delivery device

68

2001

Sulfosalicylic acid

Constant potential (-0.5 V)

Controlled drug release

69

16 | P a g e

Chapter One | Introduction

2002

Dexamethasone-21 Phosphate

Constant potential (-0.7 V)

Controlled drug release

70

disodium salt (DEX)
2005

Heparin (anti-coagulant)

Constant current

Controlled drug release

71

2006

Hexacyanoferrate (model drug)

Constant potential (Polarized at +0.5 V then stepped to

Feasibility study of a measuring

72

increasingly negative potentials (0, -0.1, -0.3, -0.5 and -0.7 V

technique

for 10 s and back)
2006

Nerve growth factor

Constant potential (0.1 V for 2 hours)

Nerve conduits and neural probes

60

2006

Biotin and neural growth factor

Constant potential (3 V, applied for 30 sec or 150 sec)

Neural electrode coatings

73

2006

Dexamethasone-21 Phosphate

Cyclic voltammetry between -0.8 and +1.3 V

Neural electrode coatings

56

Neurtrophic protein neurotrophin-3

100 µs biphasic current pulses at 250 Hz and at a current

Cochlear implant

51,74–76,77

(growth factor)

density of ± 1 mA/cm2.

Sodium salicylate and sodium

Constant potentials (between -0.4 and -0.7 V)

Drug-eluting membrane for

78

disodium salt (DEX)
2006-2010

2007

naproxene
2007

Adenosine triphosphate (ATP)

coronary stents
Cyclic voltammetry (between 0 and -1.1 V)

Measurement feasibility study

79
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2009

Sulfosalicylic acid (anti-acne

Constant potential (-0.5, -0.8 and -1.0 V)

prodrug) and Adenosine

Implantable microchip for controlled

61

drug delivery

triphosphate (ATP)
2009

Flourescein (model drug) and

Constant potential (-0.5 or -2.0 V)

Controlled drug release

80,81

Dexamethasone-21 phophate
disodium salt (DEX)
2009

Sulfosalicylic acid

Electric field (0.0 or +1.0 V)

Transdermal drug delivery

82

2010

Dexamethasone-21 Phosphate

Cyclic voltammetry (between -0.8 and +0.9 V)

Neural electrode coatings

54

disodium salt (DEX)
2010

Risperidone (Anti-psychotic)

Constant potential (-0.6 or +0.6 V)

Implantable drug delivery device

83,84

2010

Ibuprofen (anti-inflammatory)

Diffusion

Drug delivery from nanoparticles

85

2011

Antibiotics (penicillin/streptomycin)

Cyclic voltammetry (-1.0 to +1.0 V at 100 mV/s)

Controlling cellular behaviour for

55

and Dexamethasone-21 phosphate

orthopaedic applications

disodium salt (DEX)
2011

Adenosine triphosphate (ATP)

Constant potential (-0.8 V)

Controlled release from nanowires

86

2011

6-cyano-7-nitroquinoxaline-2,3-

Cyclic Voltammetry (-1.0 to +0.8 V )

Implantable neural electrode arrays

87
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dione (CNQX) (Neurochemical)
2011

Risperidone (anti-psychotic)

Constant potential (-0.6 or +0.6 V)

Treatment of schizophrenia

62

2011

Dexamethasone-21 phosphate

Cyclic Voltammetry (-1.0 to +1.0 V )

Orthopaedic implants

88

disodium salt (DEX)
2012

Naproxen (anti-inflammatory)

Constant potential (-0.6, -0.4, -0.2, 0.0, +0.2 and +0.4 V)

Controlled drug release

89

2012

Praziquantel and trichlorofon (anti-

Constant potential (OCP,-0.3, -0.4 and -0.5 V)

Treatment of Schistosomiasis

90

schistosomiasis agents)

2012

Fluorescein (model drug)

Electric field (-0.5 or -1 V applied across two electrodes)

Drug delivery from nanoparticles

91

2013

Risperidone (anti-psychotic)

Constant potential (+0.6 or -0.6 V) or alternating pulsed

Implantable drug delivery device

92

High drug loading implantable

93

potential (±0.6 V; 0.5 Hz)
2013

Adenosine triphosphate (ATP) or
Dexamethasone-21 phosphate

Cyclic voltammetry (-0.9 to +0.6 V)

delivery

disodium salt (DEX)
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1.5 Implantable power sources
1.5.1 Current state of implantable power sources
Implantable electronics have attracted significant research and commercial
attention over the last few decades94. All electronic circuits need a power source and
thus a fundamental requirement of a bionic device is a power source that is mobile
with the patient, for example a battery. Bionic devices currently on the market
include pacemakers, deep brain stimulation devices and cochlear implants. Each of
these devices have large power requirements and as such need specialised power
sources that are either implanted in the body (housed within the pulse generator for
pacemakers and deep brain stimulators) or work externally (in the ear piece for the
cochlear implant) as shown in Figure 1.10. Batteries that are currently used for
these devices use Lithium ion or zinc air technology95. Some of the requirements of
an implantable battery are long operation lifetimes, small size, high energy density
and for the chemical reaction to produce no gas96. The cochlear implant uses
batteries that are housed in the external ear piece, and hence, are easily replaced by
the patient when the battery expires. Pacemakers and deep brain stimulation
devices, however, use implantable power sources and require invasive surgery once
the battery’s lifetime expires to replace them. New research in this field aims to
increase the lifetime of power sources to avoid additional high-risk surgery. In the
past more hazardous battery components were used, like radioactive plutonium
23896, but their implantation was discontinued when their risks were fully
discovered. The nuclear battery, for example, has a lifetime of >19 years and
showed no increase in the rate of cancers with it’s patients (which was the main
concern). There were, however, many regulations for disposing of the battery after
use. Most importantly, if the battery casing failed, plutonium 238 is extremely toxic
and just 1 µg in the blood stream could be fatal97. For these reasons the risk was
considered too high for widespread use of nuclear batteries as implantable power
sources.
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(a)

(b)

(c)

(d)

Figure 1.10 Schematic representations of current implantable bionic devices including (a) a
pacemaker (image from drugline.org), (b) a deep brain stimulator (image from medgadget.com) and
(c) a cochlear implant (image from medel.com). For pacemakers and deep brain stimulators the
battery is housed in the pulse generator device. For the cochlear implant the battery is
housed outside the body on the external ear piece, as shown in (d) (image from smh.com.au).

In the above mentioned implantable power sources, internal components are
isolated from the in vivo environment by protective casings. There is, however, a
growing demand for completely implantable power sources that do not need to be
replaced or pose serious risk to the patient. Theoretically, this could be achieved
through power sources that are not isolated, but operate by consuming fuels
naturally replenished in the body. If the power source interacted with the internal
environment it would have to be engineered to be completely biocompatible, to pose
a lower toxicity risk, to last longer than current battery technologies (ideally the
lifetime of the patient) and to provide sufficient power to operate the device
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(approximately 100 mW for a cochlear implant and just tens of microwatts for a
conducting polymer film).

1.5.2 Bioelectrodes
1.5.2.1 Biofuel cells
A conventional fuel cell converts chemical energy into electrical energy through
electrochemical processes. The cell is comprised of a cathode, where reduction
occurs, and an anode, where oxidation occurs, with an electrolyte separating the
two components. The distinguishing factor between batteries and fuel cells is that a
battery operates off the energy stored within the casing, and when it ‘dies’ the
battery is either discarded or needs to be recharged. Fuel cells, however, rely on
fuel from the external environment and will operate as long as the fuel is supplied98.
Biofuel cells operate in a similar way to fuel cells but biocatalysts replace metal
catalysts99 at the electrodes. These biologically modified electrodes are called
bioelectrodes. Bioelectrodes are electrode materials modified with living organisms
and designed to generate power. They function by exploiting biochemical pathways
to transform chemical energy into electrical energy using renewable natural fuels,
like simple sugars found in the body100. They are considered ideal for implantable
devices because they operate most efficiently at biological temperatures and
conditions, and the electrodes do not need to be isolated from physiological
medium101. The active component of a bioelectrode is usually enzymes or
microorganisms, which work to extract and transfer electrons from the fuel
molecule and convey them to the underlying electrode material. One major
advantage of bioelectrodes is that they are based on naturally occurring cofactors,
all of which can be broken down by natural metabolic pathways. The two major
advancing technologies that utilise bioelectrodes are biofuel cells and biosensors102.
The use of enzymes offers great benefits in catalytic activity, specificity and optimal
performance at physiological temperatures. They do however demonstrate some
barriers in terms of lifetime103, low power density and, for implantable systems,
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biofouling; where the accumulation of biological material on the electrode surface in
vivo could isolate the electrodes104,105.

e-

e-

Electrolyte
4eFcMeOH

GOx(red)

Glucolactone
+ H 2O 2
H 2O
BOD

FcMeOH+ + e-

Anode

GOx(ox)

Glucose
+ O2

O2

Cathode

Figure 1.11 Schematic of a biofuel cell used to convert a fuel (glucose) to electricity.
Ferrocenemethanol (FcMeOH) is a redox mediator for the enzyme glucose oxidase (GOx)
that works at the anodic electrode, while another enzyme bilirubin oxidase (BOD) works at
the cathodic electrode to complete the electrical circuit.

A schematic of a typical biofuel cell using two well-documented enzymes, glucose
oxidase (GOx) and bilirubin oxidase (BOD), is shown in Figure 1.11. The anodic
component uses GOx to catalytically oxidise glucose in solution (the fuel) to
produce glucolactone and H2O2 by-products. The electrons gained by the enzyme
during this reaction are subsequently transferred to the anode through a redox
mediator, ferrocene methanol (FcMeOH). The electrons are driven by the potential
difference between the two electrodes and are conveyed through the external
circuitry. The cathode component is based on BOD, which accepts electrons from
the cathode and uses them to reduce molecular oxygen to water. The circuit also
contains a supporting electrolyte to aid in electron transfer. In biofuel cells the
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limiting electron transfer process is generally associated with the cathodic side due
to the tendency of enzymes, appropriate for this application, to have redox centres
buried deep within their tertiary structure. Because the electron tunnelling distance
is large, the electron transfer rates are hindered and the power density of the biofuel
cell is ultimately limited106–108. Biofuel cells based on the oxidation of glucose by
glucose oxidase have been studied extensively for application as implantable power
sources since the fuel (glucose) is naturally present in the human body and is
replenished through diet and healthy metabolic processes109.

1.5.2.2 Biosensors
A biosensor is an analytical device that can operate on the same principles as an
enzyme-based bioelectrode. Essentially taking the GOx anode component of the
above biofuel cell and calibrating the current generated as a function of glucose
concentration, a glucose-sensitive biosensor can be realized. Biosensors are
characterised based on the sensitivity to the analyte, the detection range and the
response time, and also benefits from the selectivity of enzymes to a particular
analyte. It is common practice to immobilise the enzyme onto the electrode for
biosensor applications and is used for measuring blood glucose (sugar) levels. The
concept of immobilisation will be discussed in section 1.5.5.2. There are a number of
commercially available glucose biosensors based on the amperometric response of
glucose oxidase including elegance® CT-X12 (Convergent Technologies,
Germany) and MiniMed® Paradigm Revel™ (Medtronic, USA)110,111. The area of
enzymatic glucose biosensors has been extremely active over recent decades with
researchers investigating new electrode materials, genetically modified enzymes
and avenues to immobilise redox mediators to form stable biosensors112–115.
Enzymatic biosensor literature is relevant to this thesis because it incorporates
methods and materials common for bioelectrodes, whether their application is in
biofuel cells or biosensors.
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1.5.2.3 Bioelectrodes - A new approach
For enzymatic biofuel cells the process at the anode, usually involving the use of the
well-documented enzyme glucose oxidase (section 1.5.4), is the most efficient
electron transfer process, while the electron transfer at the cathode is the ratelimiting step., which ultimately lowers the power density of the final biofuel cell. In
biosensors, the cathode component of a biofuel cell is essentially eliminated and the
literature describes the output of a single bioelectrode based on its access to fuel.
Hence it may be possible to use the anode component of the biofuel cell, or similarly
the single bioelectrode of an enzymatic biosensor, to supply power to a low power
consumption device, eliminating the need for traditional power sources.
Moulton et al. galvanically coupled a drug doped conducting polymer to a
biodegradable magnesium electrode to control the release of a therapeutic drug. As
the magnesium alloy corroded in biological conditions, the potential difference
between the electrodes and the current generated drove the release of
dexamethasone (DEX) from a polypyrrole (PPy) film116 (Figure 1.12). Magnesium
is a highly corrosive metal and even with protective coatings the material has a
limited lifetime and, therefore, limited electrons to power the release of drug. Using
the same concept, a single enzymatic bioelectrode could be used to replace the
magnesium electrode in this system, and if it generates enough power to control the
release of drug, it could be a promising alternative to increase the lifetime of the
drug delivery device and eliminate the need for traditional power sources.
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Figure 1.12 Cell design used by Moulton et al. to galvanically release DEX from a PPy.DEX
polymer. The reactions occurring at the cathode (PPy.DEX) and anode (Mg) are included.
Adapted from Ref116

1.5.3 Introduction to enzymes
Enzymes are defined as proteins that catalyse chemical reactions and are central to
every biochemical process in the body. They demonstrate a high degree of
specificity for their particular substrate, which is a direct function of their protein
structures. Enzymes work by forming a region in their protein structure, called the
active site, which is lined with amino acids in such a conformation that they bind
the substrate. The enzyme’s catalytic activity depends on the integrity of their
native protein conformation, because it ensures this active site is available to
substrate binding. If an enzyme is denatured, the catalytic activity can be destroyed.
Enzymes are classified by the type of reaction that they catalyse and these are
summarised in Table 1.3117.
Table 1.3 International Classification of Enzymes. Adapted from Ref117
No.

Class

Type of reaction catalysed

1

Oxidoreductases

Transfer of electrons

2

Transferases

Group transfer reactions
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3

Hydrolases

Hydrolysis reactions by the transfer of functional groups to water

4

Lyases

Addition of groups to double bonds, or formation of double bonds by
removal of groups

5

Isomerases

Transfer of groups within molecules to yield isomeric forms

6

Ligases

Formation of C-C, C-S, C-O and C-N bonds by condensation
reactions coupled to ATP cleavage

1.5.4 Glucose oxidase
Glucose oxidase (GOx) is a class 1 oxidoreductase enzyme that catalyses the
oxidation of ß-D-Glucose to D-glucono-1,5-lactone and hydrogen peroxide by
using molecular oxygen as an electron acceptor (Figure 1.13 a). GOx is a dimeric
protein consisting of two identical peptide chain subunits (shown in light and dark
blue, Figure 1.13 b) with two flavin adenine dinucleotide (FAD) cofactors buried 13
Å within each protein shell (shown in pink, Figure 1.13 b). FAD is a redox centre
that is responsible for extracting the electrons during the oxidation of glucose118
and in some cases genetic modification of the enzyme has increased its sensitivity,
selectivity and electrocatalytic current for biosensor applications115.
The GOx used in this study is produced by Aspergillus niger and has a molecular
weight of 160 kDa. GOx has been used extensively in biosensor and biofuel cell
research because of its stability, its specificity and its high electrocatalytic
activity109,119. Like all enzymes, GOx has specific environmental conditions that
need to be optimised to achieve the most efficient catalytic activity. For example
GOx works optimally at 37ºC but will denature at temperatures higher than 40ºC.
Similarly, its optimum pH range is 4-7 and outside of this range the activity drops
significantly. This becomes very important during practical application in
bioelectrodes. Additionally, the purification of GOx can significantly enhance the
catalytic current generated up to three-fold compared to the un-purified
equivalent120. Gao et al. measured that commercial powders contained about 20% of
non-protein compounds, which will have a detrimental effect on the efficiency of the

27 | P a g e

Chapter One | Introduction
!
bioelectrodes produced. A purification protocol was used in this thesis and is
outlined in detail in Chapter 2.
(a)
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Figure 1.13 (a) The reaction scheme for the catalytic oxidation of glucose by glucose oxidase.
(b) A schematic of the 3D structure of glucose oxidase, indicating the identical protein
subunits (dark and light blue) and the FAD redox centres (pink). Adapted from Ref121

1.5.5 Mechanism of electron transfer
As an oxidoreductase enzyme, GOx transfers electrons during the oxidation of
glucose. It is these electrons that are extracted from the biochemical pathway and
conveyed to an electrode that allows a current to be generated from a bioelectrode.
There are two mechanisms by which the electrons can be collected, direct electron
transfer (DET) or mediated electron transfer (MET), as shown in Figure 1.14.
These two mechanisms will now be discussed in detail.
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Figure 1.14 Alternate electron transfer mechanisms. Direct electron transfer (DET) from the
active site of the enzyme to the electrode material, also known as the tunnelling mechanism,
and mediated electron transfer (MET) via a redox mediator. Adapted from Ref122

1.5.5.1 Mediated electron transfer (MET)
MET utilises a redox active species to shuttle the electrons from the enzyme to the
electrode. A redox mediator may be required if the redox centre is buried too deep
within the quaternary structure to be able to directly communicate with the
electrode and, in some cases, can enhance the rate of electron transfer of the
bioelectrode. For a redox mediator to be suitable for a specific enzyme, the
difference in redox potential between the mediator and the enzyme must be nonzero so there is a driving over-potential123. Ideally, for the GOx system, the
mediator will have a redox potential more positive than the oxidation potential of
GOx, which is approximately -450 mV (vs. Ag|AgCl, for neutral pH)124. The redox
mediator used in this thesis was Ferrocene methanol (FcMeOH), which has an
oxidising potential of approximately +200 mV (vs. Ag|AgCl). In some cases,
diffusion limits can hinder the effectiveness of a mediator and for the purpose of
biosensors, where it is optimal to have all components confined to the surface of the
electrode, a ‘free’ mediator may not be ideal. For this reason many research groups
have looked into immobilising the mediator onto the electrode to not only increase
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the mediator concentration at the electroactive surface area but also to avoid
diffusional limitations. Materials used for this purpose include conducting
polymers125 and redox mediator polymers126 but one major disadvantage affecting
the efficiency of these systems is the tendency of the matrix to hinder substrate
diffusion to the immobilised enzyme. Mano et al. fabricated an Os-redox polymer
hydrogel to address this issue and achieved efficient electron transfer rates using
this system113.

1.5.5.2 Direct electron transfer (DET)
Direct electron transfer involves direct communication between the enzyme and
the electrode material. This usually entails the immobilisation of the enzyme at the
electrode surface to satisfy a small electron tunnelling distance (Figure 1.14)127. The
DET mechanism bypasses some of the limitations associated with MET outlined
above and simplifies the overall reaction pathway to generate a more efficient
electron transfer process. DET systems are restricted to a monolayer of enzyme in
intimate contact with the electrode due to the globular structure of the protein shell
and this limits the number of catalytic centres accessible to the electrode. To
address this problem research has been directed at the application of nanostructured
electrodes to immobilise GOx, and bioaffinity chemistry to favourably orient the
enzymes with respect to the electrode surface105. Nanostructured electrodes offer an
extremely large electrode surface area available to bind enzymes and not
surprisingly have proven to outperform flat electrodes in terms of current density
for DET systems128. Literature concerning electronic coupling of GOx directly to
electrodes covers a large range of materials. This thesis is concerned with
allotropes of carbon for this application, in particular multi-walled carbon
nanotubes and graphene, and the following section is dedicated to outlining the
current state of the literature in this area.
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1.5.6 Materials for bioelectrodes
1.5.6.1 Allotropes of carbon
Carbon exists in a number of allotropes: diamond, graphite, fullerenes, amorphous
carbon, carbon nanotubes, and graphene, most of which are shown in Figure 1.15,
where BC8 represents a thermodynamically stable form of carbon at high
pressures129. Some of these forms of carbon have been investigated for their use as
biomaterials, and more recently for their application in bionic devices, in particular
carbon nanotubes (CNTs) and graphene31. Properties that make CNTs and
graphene appropriate for such applications include their long-range π-conjugation
for electrical conductivity, incredible mechanical and thermal properties, low
density and biocompatibility. It is still under debate whether these nanomaterials
are toxic in the body with concern for their use in vivo130.

Figure 1.15 The allotropes of carbon. Adapted from ref31
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1.5.6.2 Carbon for bioelectrodes
Carbon nanotubes (CNTs) have been investigated for their ability to facilitate direct
electron transfer (DET) in bioelectrodes112. It has been hypothesized that the
reason they are so effective is that the CNTs enter the protein shell of the enzyme
to make electrical contact directly with the redox centre, without affecting the
affinity of the active site to bind to its fuel substrate. In 2002, Guiseppi-Elie et al.
described the phenomenon as a long sharp needle piercing a balloon without
popping it131. Since then, other forms of carbon materials have proven to be able to
facilitate DET just as effectively, including the new wave of literature in the area of
graphene. As such the hypothesis about piercing the balloon seems to be less
appropriate. It could, however, be attributed to the copious quantities of edge plane
defects that are present in both allotropes, which have also been associated with
high levels of electroactivity132–134.
Functionalization has played a major part in the processability of CNTs and
graphene. This is particularly the case for CNTs because of their insolubility in
aqueous systems due to a lack of hydrophilic functional groups. It is critical for
these materials to be processed in an aqueous environment for bionic applications to
increase their biocompatibility; especially for enzymes whose environment greatly
alters their catalytic activity101. A simple method that has been widely adopted to
disperse carbon nanotubes in water is through the use of surfactants or dispersing
agents135. Although these dispersing agents can be in the form of biopolymers like
chitosan or gellan gum to increase the biocompatibility of the composite material,
the addition of such polymers is generally detrimental to the electrical properties
before a percolation threshold is reached136. On the other hand, graphene can be
readily dispersed in aqueous mediums due to oxygen functionalised basal plane
defects, in addition to peripheral functional groups137. Figure 1.16 shows the
chemical reduction of graphene oxide (GO) to reduced graphene oxide (rGO) by
hydrazine and represents the reduction method utilised in this thesis. Its name,
graphene oxide (GO), is given due to the large amount of oxygen in this form of
graphene. The processability of GO, and its more conducting form rGO as aqueous
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based systems make them appropriate to use in bionic applications, without the loss
of electrical properties. It is reported that rGO is more conducting than its
predecessor GO because the reduction process removes some of the oxygen
functional groups and restores conjugation in the basal plane structure,
subsequently enhancing the electrical properties (shown in Figure 1.16). Graphene
and CNTs will be discussed in more detail in Chapters 3 and 4 in reference to their
ability to facilitate DET with GOx.
Graphene Oxide (GO)

Reduced Graphene Oxide (rGO)

Reduction
(Hydrazine)

Figure 1.16 Structural changes of graphene after hydrazine reduction. The reaction scheme
shows the structure of graphene oxide (GO) and reduced graphene oxide (rGO).

Table 1.4 summarises major contributions to the field of carbon nanomaterials in
enzymatic bioelectrodes, but is not exhaustive. It includes DET systems only and
reports on work done exclusively with GOx in order to narrow down the literature
field to research relevant to this thesis. The existing method of comparing the
output of bioelectrodes uses the current density (current per cm2), although this
introduces some calculation errors. Electrodes produced in a lab environment are
usually smaller than 1 cm2 and to scale the current density up to this dimension by
calculation may not reflect the real current density of a manufactured device.
Additionally, it is difficult to calculate the actual area with the use of nanomaterials
that have extremely large electroactive surface areas. As such, it is most common to
use the dimensions for the entire electrode rather than the area of the nano-features,
which also skews the real current density value. A more accurate measure of
comparison in this field of bioelectrodes is the current generated per microgram of
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biocatalyst immobilised. This gives an indication not only of the actual current
output, but also of the efficiency of electron transfer and activity of the biocatalyst
in the given system. This data is represented in Table 1.4 and provides a context for
which the electrodes presented in this thesis will be discussed. In 2012 Alwarappan
et al. reported the highest specific catalytic current for a bioelectrode in this field at
25 µA/µg GOx using a graphene electrode material138. Interestingly, they didn’t
use any other insulating support materials, which can hinder the bioelectrode
output.
Table 1.4 Literature summary of specific catalytic current generated by glucose oxidase
bioelectrodes based on carbon allotrope direct electron transfer systems.
Carbon

Current per biocatalyst

Other materials

Ref

material

(µA/µg GOx)

MWNT

0.08

Cellulose

139

MWNT

0.003

Platinum-MWNT-Alumina-coated silica

140

nanocomposite
MWNT

3.3

Nafion®

106

Mesoporous

0.06

Nafion®

119

GO

0.12

Chitosan matrix

141

MWNT

0.05

Toray® carbon paper substrate with

142

carbon

polyethylenimine support
MWNT

0.5

Nafion®

124

MWNT

0.01

Toray® carbon paper substrate with

143

Nafion® support
MWNT

0.008

Nitrogen doped MWNT with Nafion®

144

support
Exfoliated

0.42

Chitosan and platinum nanoparticles

145

GO
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rGO

>0.001

-

146

MWNT

0.02

Nafion®

147

MWNT

>0.001

Chitosan matrix

148

Mesoporous

0.38

Platinum nanoparticles, cross-linked

149

carbon
MWNT

gelatin

>0.001

Electro-oxidised polypyrrole in the

150

presence of functonalised MWNT and
GOx
MWNT

0.5

Alumina-coated silica with Nafion®

151

support
MWNT

0.08

Nafion®

152

MWNT

3.3

Sol-gel matrix

153

MWNT

0.1

Platinum nanoparticles on gold electrodes

154

with Nafion® support
rGO

0.009

Polyvinylpyrrolidone, polyethylenimine

155

functionalised ionic liquid
rGO

1.44

Gold nanoparticles and chitosan

156

Sulfonated

0.4

Gold nanoparticles, Nafion®

f157

rGO

0.008

Polymeric ionic liquid

158

Graphene

0.05

Chitosan

159

rGO

0.008

Ionic liquid

160

Exfoliated

0.01

-

161

GO &
MWNT

platelets

GO
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rGO

>0.001

-

162

rGO &

0.25

Nafion®

163

>0.001

-

164

rGO

25

-

138

Graphene

1

-

165

MWNT
rGO &
CNT

quantum
dots
*Data presented in this table was extracted from the given references. The specific current was calculated by
either taking the maximum current generated with the lowest GOx loading (if it wasn’t specified), or the
anodic peak height at 50 mV/s again with the specified (or lowest) GOx loading. If GOx was adsorbed onto
the electrode surface the calculation was based on the soaking solution concentration.

1.6 Overview and thesis aims
The aim of this thesis is to develop an operational drug delivery system powered by
a naturally occurring biofuel, glucose. This thesis reports on the development of
GOx bioelectrodes and their specific catalytic current in reference to the literature
presented in Table 1.4. These electrodes are based on chemically reduced graphene
oxide and multi-walled carbon nanotubes. A GOx bioelectrode will be used
exclusively to power the release of therapeutic drug from a conducting polymer
scaffold. This will be the first prototype for a completely implantable drug delivery
device that will operate off glucose. Throughout the results and discussion chapters,
reference will be made to the practical treatment of epilepsy, which is the intended
application for this device.
Specifically, the objectives of this thesis were to:
− Develop

aqueous

carbon

nanomaterial

dispersions

and

fabrication

techniques suitable to incorporate GOx without destroying the integrity of
the enzyme.
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− Engineer and characterise GOx bioelectrodes using the above-mentioned
dispersions. Chapter 3 investigates the fabrication of solvated graphene
bioelectrodes while Chapter 4 focuses on a simple drop casting method to
investigate the efficiency of an rGO-CNT composite material to facilitate
direct electron transfer from immobilised GOx.
− Chapter 5 examines the feasibility of using the composite electrode
presented in Chapter 4 to power the release of drug from a polypyrrole
structure. This is shown schematically in Figure 1.17 with the red box
highlighting the GOx bioelectrode side, and the purple box showing the
drug loaded conducting polymer side. Chapter 6 specifically targets the
overall aim of this thesis to develop an operational drug delivery system
powered by glucose.
Drug loaded conducting
polymer

FcMeOH(red)

FcMeOH(ox)+ e-

Auxiliary

Reference

GOx bioelectrode

GOx(red)

Glucolactone

GOx(ox)

Glucose

Salt bridge

Drug release

Figure 1.17 Cell design used in this thesis to power the release of drug from a conducting
polymer film using an enzymatic bioelectrode.
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2. General experimental
2.1 Overview
This chapter aims to outline materials and characterisation techniques that were
common throughout the results presented in this thesis. It is also an opportunity to
introduce the protocol used to purify the glucose oxidase; a critical milestone
achieved for the foundations of this work.

2.2 Experimental techniques
2.2.1 UV-Visible spectrophotometry
When a molecule absorbs a photon of light the energy of the molecule increases and
it is said to be in an excited state. This is unique for the UV-visible region of light
with other regions causing rotational motion or vibrations initiated by microwave
and infrared light, respectively. Some substances dissolved in solution will absorb a
certain wavelength of white light and the intensity of this absorbance is directly
proportional to the concentration according to Beer-Lambert’s Law:
Equation 2.1 Beer-Lambert’s Law

! = ε!"
where A is the measured absorbance, l is the path length of the cell, c is the concentration of analyte
in mol/L and ε is the molar extinction coefficient (the absorbance of a 1 M solution of analyte).

The absorbance of a dissolved substance is linear with concentration as long as the
concentration is not too high to cause shadowing effects if the molecules are in the
same optical path. A calibration curve can be constructed based on a standard series
with solutions of known concentrations and a linear relationship can be fitted. From
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this relationship the concentration of an unknown sample can be measured. The
experiments in this thesis were conducted using the Shimadzu UV-1601
spectrophotometer with UVprobe (v.2.10) software. Specific experimental protocols
will be introduced in the relevant chapters.

2.2.2 Scanning electron microscopy
Scanning electron microscopy (SEM) was performed using the JEOL Cold Field
Emission Gun Scanning Electron Microscope. The SEM was operated at an
accelerating voltage of 5 kV and secondary electron images were taken with a semi
in-lens detector at a working distance of 8 mm and a spot size setting of 8. Specific
sample preparation for the different electrodes will be outlined in the relevant
experimental sections in the following chapters.

2.2.3 Electrochemistry
2.2.3.1 Electrochemical theory
During an electrochemical experiment two types of processes occur at the electrode
that contribute to the overall current generated or stored, depending on the
electrode potential. Faradaic processes occur when an analyte in solution undergoes
oxidation or reduction at the electrode and involves the transfer of charge from
solution to the electrode material. Faradaic processes are governed by Faraday’s 1st
law that states that the amount of a substance that undergoes electrolysis at an
electrode is proportional to the current generated. Non-Faradaic processes do not
involve a transfer of charge as such but are defined by the formation of an electrical
double layer at the electrode surface166. This storage of charge depends on the
potential of the electrode and it’s electroactive surface area, and is also known as the
capacitive current.
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2.2.3.2 Electrochemical cell
For all electrochemical characterisation techniques a 3-electrode cell configuration
was used as schematically represented in Figure 2.1. A platinum mesh counter
electrode and a Ag|AgCl reference electrode were used in each experiment
however, the working electrode and nature of the electrolyte was varied depending
on the type of experiment.
Reference electrode
Working electrode
Ar gas inlet
Counter electrode

Water bath

Figure 2.1 Schematic representation of the 3-electrode cell used to electrochemically
characterise electrodes

If the working electrode was a conducting polymer film the experiment was
performed at room temperature. Degassing of the electrolyte using argon was only
necessary if the reducing potential used was greater than -0.4 V (vs. Ag|AgCl), the
potential region where oxygen reduction would interfere with the results166. If the
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working electrode was an enzyme-loaded bioelectrode the degassing step was
critical to remove the oxygen that would otherwise compete with the glucose
substrate. A 15 minute degassing procedure was implemented before each
experiment and an argon gas blanket was maintained for the duration of each
electrochemical characterisation technique. Additionally, for the analysis of an
enzyme loaded bioelectrode the electrochemical cell would be kept at 38°C (using a
water bath) to maximise enzyme activity.

2.2.3.3 Cyclic voltammetry
Cyclic voltammetry (CV) is an electrochemical technique where an applied potential
is swept at a constant rate between two limiting potentials and the current
generated is measured. For a non-faradaic experiment, i.e. when no redox active
species is present in solution or associated with the electrode, the CV generated will
have a rectangular current response and demonstrate sharp charging and
discharging behaviour (Figure 2.2 a).
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Current

!!

Potential
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Current
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2
!Ep
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Figure 2.2 (a) A schematic representation of a CV showing a typical non-faradaic response,
and (b) A CV of graphene-carbon nanotube composite electrode submersed in a mediator
electrolyte showing a Faradaic response.

When a redox active species is present in solution the CV generated will have a
distinct set of peaks associated with the oxidation and reduction of that species
(Figure 2.2 b). At the beginning of the potential sweep only non-Faradaic currents
flow, provided that the initial potential is sufficiently more negative than the formal
potential of the redox species (point 1). As the potential sweep approaches the
formal potential of the redox species oxidation starts to occur at the electrode
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surface and Faradaic current begins to flow (point 2). At the oxidation peak
potential the system is instantaneously oxidising the redox species and the process
is limited by the diffusion rate of the reduced redox species in solution to the
electrode surface (point 3). Point 4 indicates the potential at which the scan is
reversed and the oxidised species produced in the previous scan starts to undergo
reduction as the scan approaches the formal potential of the redox couple (point 5).
For a completely reversible redox system the oxidation and reduction peaks should
have identical peak heights, widths and overall shape, and also indicates efficient
electron transfer between the redox species and the electrode. The anodic (Ipa) and
cathodic (Ipc) peaks in a CV will be separated by approximately 59 mV as given by
the Nernst relationship (Equation 2.2) for single electron transfer processes, with
the peak height ratio being close to 1. The shape and relative separation of peaks in
a CV can also give some indication if the redox process is surface confined, which
will be of interest when investigating the electrochemistry of the enzyme-loaded
bioelectrodes where the glucose oxidase is immobilised on the electrode structure.
Equation 2.2 The Nernst Equation

0.059
!!!
!=! +
!"# !
!
!!
!

where E° is the formal redox potential of the redox species, Cs is the concentration of electroactive
species at the electrode surface in either the reduced (R) or oxidised (O) state at the electrode, E
indicates the potential measured between the electrodes and n is the number of electrons transferred.

2.2.3.4 Open circuit potential
Open circuit potential (OCP) is a technique that measures the potential difference
between the working and counter electrodes without applying any current. There is
an initial relaxation period as the electrodes establish their electrical double layers
before coming to a stable state. An open circuit potential experiment plots the
potential as a function of time. All experiments were performed in 50 mM PBS and
generally a potential reading was taken every 0.5 seconds until a stable potential
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was observed. CH Instrument potentiostat and CHi software were used for all OCP
experiments.

2.2.3.5 Electrochemical impedance spectroscopy
Ohm’s law defines resistance (R) as the ratio between voltage (E) and current (I)
according to Equation 2.3. This is a well-known relationship, however, it is limited
to an ideal resistor and in the real world, circuit elements exhibit much more
complex behaviours.
Equation 2.3

! =!

!
!

Resistance - R and Impedance – Z(ω) are similar in that they are a measure of the
ability of a circuit to resist the flow of electrical current however, impedance is not
limited to an ideal resistor. Electrochemical impedance spectroscopy (EIS) is an AC
technique whereby a small sinusoidal perturbation (i.e. 5 mV) is applied to the
electrode potential and the current through the circuit is measured. Experimentally,
the electrode potential is initially measured through OCP, as outlined in section
2.2.3.4. The potential and current can be expressed as complex functions as given in
Equation 2.4 and Equation 2.5, respectively. Consequently, the impedance measured
can be represented as a complex number containing a real and an imaginary part, as
shown in Equation 2.6167.
Equation 2.4

!! = ! !! !"#(!!")
where Et is the potential at time t, E0 is the amplitude of the signal, j is the imaginary unit and ω is
the radial frequency.
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Equation 2.5

!! = ! !! !"#(!!! − ø!)
where It is the response current at time t, I0 is the amplitude of the signal, j is the imaginary unit, ω
is the radial frequency and ø is the phase shift between voltage applied and the response current.

Equation 2.6

! ! =!

!!
= !! exp !∅ = ! !! (!"#∅ + !"#$∅)
!!

where Z(ω) is the impedance, Et and It are the potential and current at time t, Z0 is the magnitude of
impedance, j is the imaginary unit and ø is the phase shift.

A Nyquist plot is a representation of the resulting data that plots the real (x-axis)
and imaginary (y-axis) part of the impedance, with each point on the plot
representing the impedance at one frequency. A Nyquist plot is schematically
represented in Figure 2.3. The point at which the plot intercepts the x-axis first
(R1) is a measure of the solution resistance –Rs, while the next intercept (R2)
indicates the charge transfer resistance –Rct and is calculated by finding the
difference between the two intercepts (i.e. Rct = R2 – R1). The charge transfer
resistance of an electrode gives an indication of the conductivity of the material.
The specific parameters used for each EIS experiment will be outlined in the
respective chapters.
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Figure 2.3 A schematic representation of a typical Nyquist plot.

2.2.3.6 Amperometry
Amperometry is an electrochemical technique used to investigate the sensitivity,
response time and performance of enzyme-loaded bioelectrodes. A current-time (i-t
curve) response is measured as a function of an applied voltage and usually the
applied voltage is an oxidising potential. When the generated current stabilizes at
the applied voltage for a bioelectrode system, glucose is spiked into the electrolyte
and the response recorded is analysed as the catalytic current. Specific experimental
parameters will be outlined in the relevant chapter sections.

2.2.3.7 Ferrocene methanol as a mediator for glucose oxidase
In some of the above-mentioned electrochemical techniques, in order to characterise
the enzyme-loaded bioelectrodes effectively a mediator had to be incorporated into
the system. Ferrocene methanol (FcMeOH) is a redox mediator that can be used to
characterise glucose oxidase systems168. A mediator works to shuttle electrons from
the oxidation of glucose, at GOx, to the electrode and in this case the mediator is in
solution. The CV shown in Figure 2.4 (black trace) represents data collected for a
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glassy carbon electrode (GCE) submersed in PBS with FcMeOH (5 mM) and
saturated glucose (150 mM) in solution. It shows characteristic reversible redox
behaviour of FcMeOH on a flat electrode. When GOx is added to solution (green
trace) the CV takes on a hysteresis shape and shows a plateau current that is a
function of mass transport limitations; i.e. the mediator diffusing to the electrode169.
The increase in magnitude of the oxidative current represents the catalytic current
generated by the oxidation of glucose by the enzyme. This type of response
demonstrates that FcMeOH is an effective mediator for glucose oxidase.
It is also important to note that the glucose used in all experiments was prepared at
1 M concentration as a stock solution in 50 mM phosphate buffer solution (PBS)
and allowed to mutarotate for 24 hours before use. Mutarotation is a critical step
used to allow the α- and β-anomers of D-glucose to equilibrate.
5
4
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3
2
1
0
-1
-2
-0.1
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0.1

0.2

0.3

0.4
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Figure 2.4 Cyclic voltammograms of a glassy carbon electrode (3 mm diameter) in PBS with
FcMeOH (5 mM) and saturated glucose (150 mM) with (green trace) and without (black
trace) glucose oxidase in solution.
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2.2.3.8 Fourier transform alternating current voltammetry
Faradaic currents generated during an electrochemical experiment are usually nonlinear and the mathematical translation of such complex terms is generally avoided
in theoretical modelling of experimental results. In electrochemical impedance
spectroscopy (EIS) for example, a small AC perturbation is superimposed on top of
a constant DC potential and this allows the assumption of a linear faradaic response.
As a result, simplified equivalent circuits can be used to simulate the results. In
fourier transform alternating current voltammetry (FTACV) a large AC
perturbation is superimposed on top of a sweeping DC potential (i.e. a cyclic
voltammogram) and through mathematical algorithms the analysis of the resulting
data can provide a wealth of information on the contributing electrode mechanisms,
for example, it can separate the capacitive and faradaic contributions. The waveform
(Et) of a single sine wave of amplitude ∆E and frequency ω at time t, superimposed
onto a DC potential ramp (EDC) is given in Equation 2.7.
Equation 2.7

Et = EDC + ∆Esin(ωt)

Such a waveform will generate a response that contains both DC and AC
contributions, the latter of which is represented in a series of harmonics, namely
first (ω), second (2ω), third (3ω) etcetera. In order to analyse the data generated, the
resulting current shown in Figure 2.5 (a), generated from a FTACV experiment, is
transformed from the time domain to the frequency domain through the use of a
Fourier transform (FT) algorithm (process indicated by the blue arrow). From the
power spectrum shown in Figure 2.5 (b) the individual components (i.e. DC, first
harmonic, second harmonic etc) can be separated through the implementation of an
inverse FT procedure (process indicated by the coloured arrows to each
component)170,171.
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(a)

(b)
(i)
(v)

(ii)

(iii)

(iv)

Figure 2.5 Large-amplitude ac cyclic voltammogram obtained for reduction of 0.5 M
ferrocenemonocarboxylic acid on a glassy carbon electrode: (a) total current and (b) the log
power spectrum after Fourier transformation. (i), (ii), (iii), (iv) and (v) show the
components highlighted by coloured boxes after inverse Fourier transformation and
represent the DC, first harmonic, second harmonic, third harmonic and fourth harmonics,
respectively. Adapted from Ref170

The resulting current data is represented in the time domain and can provide
information on the faradaic and non-faradaic current contributions. The double
layer capacitive contributions are generally linear systems, as given by Equation
2.8, and as such, will only be represented in the DC and first harmonic components.
The capacitive current is highlighted in Figure 2.5 (ii) and (iii) using circles to
identify the presence and absence of the non-faradaic background component,
respectively. If the capacitance is non-linear, which can occur for higher
electroactive surface area electrodes, residual non-faradaic current is observed in
higher harmonics. The non-linear faradaic contributions are represented in the
higher order harmonics in the absence of the capacitive current. Hence, the data can
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be used qualitatively to determine if any faradaic current is generated for electrode
systems where the capacitive current is large and might swamp the relatively small
faradaic response. Alternatively, and if the faradaic response is clear in the higher
harmonics, electrochemical simulation can be used to extract kinetic parameters for
the given electrode system.
Equation 2.8

i = vCdl
where v is the scan rate in a cyclic voltammogram, i is the anodic or cathodic current and Cdl is the
electrode double layer capacitance.

2.3 Materials
2.3.1 Glucose oxidase
2.3.1.1 Purification protocol
Glucose Oxidase aspergillus niger (GOx) was purchased commercially from Sigma
and 100 mg was dissolved in 2.5 mL of Buffer 1 (from Table 2.1). The buffers were
prepared using potassium phosphate monobasic and dibasic salts (Sigma) with the
desired pH and ionic strength precisely calculated. Diammonium sulphate (Sigma)
and sodium chloride (Sigma) were added according to Table 2.1. All buffers were
sonicated and filtered through a 0.22 µm membrane before use.
Table 2.1 Ionic strength, pH and composition of the buffers used in HPLC for enzyme
purification.

Buffer 1

50 mM Phosphate Buffer (pH7.5) + 3 M diammonium sulphate

Buffer 2

50 mM Phosphate Buffer (pH7.5)

Buffer 3

50 mM Phosphate Buffer (pH8)

Buffer 4

50 mM Phosphate Buffer (pH8) + 1 M sodium chloride
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The GOx in Buffer 1 solution was loaded onto a disposable PD-10 desalting column
(GE Healthcare) followed by another 5 mL of Buffer 1. Approximately 4.5 mL of
the eluent was collected and syringe filtered using a 0.22 µm membrane before
loading onto a high-performance liquid chromatography (HPLC) column.
HPLC is an analytical technique used to separate a mixture into its different
components. It uses high pressure to force a liquid mobile phase through an
enclosed column containing a porous stationary phase. Samples are loaded onto the
column in the mobile phase and interact with the column depending on the sample
properties and the type of column166. The eluent is collected in fractions and
monitored by UV-Vis for protein elution (see 2.2.1 for an introduction to UV-Vis).
During these experiments the HPLC system was kept in a cool room at 4°C and the
enzyme purification involved two separations using different types of columns.
1. A hydrophobic column (Hi Trap Phenyl HP column – 1 mL)
2. An anion exchange column (Hi Trap QFF column - 1 mL)
Initially the 4.5 mL of GOx collected from the desalting column was loaded onto a
pre-equilibrated hydrophobic column using Buffer 1. Hydrophobic columns work by
attracting hydrophobic regions of proteins under high salt aqueous conditions (i.e.
Buffer 1). When the salt concentration is dropped (i.e. the addition of Buffer 2) the
forces of attraction between the hydrophobic proteins and the column are weakened
and the proteins are eluted based on their relative hydrophobicity172. Figure 2.6 (a)
shows the successful binding of GOx onto the column as indicated by the strong
yellow colour characteristic of GOx. Buffer 2 was loaded according to the gradient
profile shown in Figure 2.6 (b) and the volume fraction eluents were collected in 1
mL aliquots.
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Figure 2.6 (a) A photograph showing glucose oxidasae (yellow) bound to the hydrophobic
column, and (b) is a schematic representation of the buffer gradient profile utilised between
Buffer 1 & 2.

The collected aliquots were monitored by UV-vis at 280 nm to identify which
fractions contained GOx. This is represented by the blue trace in Figure 2.7. The
green trace represents the gradient profile introduced in Figure 2.6 (b) while the
brown trace is a measure of the conductivity of the column. The red markings show
the 1 ml aliquots collected. It is evident that the GOx comes off the column between
36-49 mL and these fractions were collected for further purification. There are
small peaks on the blue trace between 23–27 mL and 55-58 mL, which represent
contaminant protein. It is specified on the Sigma technical sheet when GOx was
purchased that the material may contain contaminants including amylase (≤ 0.5%),
catalase (≤ 2 Sigma units/mg solid), galactose oxidase (≤ 3%), glycogenase (≤
0.5%), invertase (≤ 0.5%) and maltase (≤ 2%). It is for this reason that the
purification step is required to achieve a high specific activity of GOx. The fractions
collected from the hydrophobic column were concentrated to 5 mL using a 10,000
molecular weight centrifugal filter unit (Merck-Millipore) and put through another
syringe filter in preparation for loading onto the anion exchange column.
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Figure 2.7 The fractions collected from the hydrophobic phenyl column (red) according to
the elution of protein as measured at 280 nm by UV-vis (blue). The green and brown trace
show the buffer gradient program used and the conductivity of the column, respectively.

The anion exchange column was equilibrated with Buffer 3 before the GOx sample
was loaded. The elution gradient of Buffers 3 & 4 is represented schematically in
Figure 2.8 (a) and the actual elution of GOx detected at 280 nm is represented by
the blue trace in Figure 2.8 (b). The green trace represents the elution gradient,
also shown in Figure 2.8 (a), and the brown trace is the column conductivity.
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Figure 2.8 (a) A schematic representation of the buffer gradient program used for the anionic
exchange column between Buffer 3 & 4, and (b)the fractions collected from the anionic
exchange column (red) according to the elution of protein as measured at 280 nm by UV-vis
(blue). The green and brown trace show the buffer gradient program used and the
conductivity of the column, respectively.

Fractions 24 to 44 mL were collected as the protein containing aliquots. The spike
in protein absorption in the first few fractions can be attributed to column
overloading. These fractions were collected and passed through the column again.
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The protein containing aliquots were again concentrated using a 10,000 molecular
weight centrifugal filter unit down to the smallest volume possible to remove as
much Buffer 4 as possible. The purified GOx was then resuspended in phosphate
buffer (50 mM, pH 5) for characterisation and storage.

2.3.1.2 Characterisation
2.3.1.2.1 Gel electrophoresis
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was used
to confirm that the GOx was sufficiently purified. SDS-PAGE separates proteins
based on their molecular weight and there was a clear band at 160 kDa
corresponding to the molecular weight of GOx indicating that the purification was
successful.

2.3.1.2.2 Storage
16 batches of GOx were purified using the protocol (2.3.1.1) and after gel
electrophoresis they were combined to make one large batch. 1.5 mL aliquots were
stored in epindorf tubes at -80°C while one 1.5 mL aliquot was kept at 4°C for
further characterisation and use.

2.3.1.2.3 Concentration
The concentration of GOx in solution can be calculated using UV-Visible
spectrophotometry. GOx has a characteristic absorption spectra with the protein
shell showing a strong absorbance at 280 nm and the FAD redox active centre
absorbing at 450 nm. If the intensity of the FAD peak at 450 nm is 10x less than
the protein peak at 280 nm it indicates that the enzyme is in its native state (i.e. two
FAD centres per protein shell, as discussed in Chapter 1). This was evident when
55 | P a g e

Chapter Two | General experimental
!
the purified GOx was characterised during UV-Vis and the concentration was
calculated using the Beer-Lambert Law (Equation 2.9).
Equation 2.9
!=

!!"
!"

where A is the measured absorbance (at 280 nm), l is the path length of the cell (cm), c is the
concentration of analyte (mg/mL), ε is the extinction coefficient (ε =16.7 for a 1% solution of GOx)
and the adjustment factor of 10 is used to express the concentration in units of mg/mL173.

From the absorption of the purified GOx sample it was calculated that the
concentration of GOx in the stock solution is 0.5 mg/mL. This was also confirmed
through protein assay experiments using the bicinchoninic acid (BCA) Pierce Assay
(2.3.1.2.5).

2.3.1.2.4 Catalytic activity
The 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) (ABTS) assay is used to
study enzyme kinetics and can quantify the activity of glucose oxidase in a given
sample. To briefly describe the reaction mechanism, GOx catalyzes the oxidation of
glucose to glucolactone and when the reduced form of the enzyme is converted back
to the oxidized form it transfers two protons and two electrons to molecular
oxygen to generate hydrogen peroxide (reaction scheme 1). Horseradish peroxidase
(HRP) catalytically reduces H2O2 and this process is coupled to the oxidation of
ABTS (reaction scheme 2), which undergoes a corresponding colour change. The
oxidation of glucose can therefore be measured by monitoring the generation of
ABTS(Ox) at 405 nm.
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In an ABTS assay, a reaction cocktail of 180 µM ABTS, 150 mM Glucose and
2U/mL of HRP in phosphate buffer (50 mM, pH 7.4) was prepared on ice. 300 µL
of reaction mixture was added to each required well in a 96-well plate and
equilibrated at 37°C before 10 µL of enzyme sample was added and briefly stirred.
The calibration curve was measured in the range of 1 – 0 mg/mL GOx. The
absorption is measured continuously at 405 nm for 5 minutes and the slope of the
linear region (ΔDO) is used to calculate the enzyme activity, as in Equation 2.10.
Equation 2.10
!"#$%$#&! !. !"!! =

∆!"!"#! ! − ! ∆!"!"#$% !×!!!"#$%! !×!!"
!!"#$ !×!!!"!#!$%

where ΔDOtest and ΔDOblank are the linear increase in absorbance measured for the sample of interest
and the enzyme free buffer, respectively. Vfinal is the final volume of the assay solution in mL. DF is
the dilution factor of the enzyme stock solution, ξABTS is the molar extinction coefficient for ABTS
and is 36.8 mM/cm, and Vinitial is the volume of enzyme solution added to the assay in mL. Note that
one unit of activity is defined as the amount of enzyme that catalyzes the conversion of 1µmole of
substrate per minute.

The measured activity for the purified GOx is 450 U/mg while the non-purified
GOx measured an activity of 23 U/mg (~ 20 times less). The purified GOx was
used for all experiments in this thesis and from now on if the abbreviation ‘GOx’
appears it refers to the purified material.
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2.3.1.2.5 Pierce BCA protein assay
The Pierce BCA protein assay was utilized to determine the protein concentration
in a solution. It depends on two steps. Firstly the well-known biuret reaction where
Cu+2 is reduced to Cu+1 by protein in an alkaline environment, and secondly, the
purple coloured reaction product is formed when two molecules of bicinchoninic
acid (BCA) chelate with one cuprous ion (Cu+1). The Cu(BCA)2 complex exhibits a
strong absorbance at 562 nm and is sensitive to 20-2000 µg/mL protein. The
reaction takes plate at 37°C over 30 minutes and a calibration curve was generated
using both glucose oxidase and bovine serum albumin (BSA) standard series. The
protocol from Thermo Scientific was followed precisely174.

2.3.2 Graphene
2.3.2.1 Dispersion preparation
Graphene Oxide (GO) was synthesized from natural graphite powder using a
modified Hummers method175,176. The carbon material was received as a thick paste
and weighed out to make a 0.5 mg/mL solution in milliQ water. This solution was
pulse sonicated for 1 hour using a Branson Digital Horn Sonifier (500W) at 30%
amplitude (2 seconds ON, 1 second OFF) in an ice bath to dissipate the heat
generated. For the graphene-carbon nanotube composite electrodes fabricated and
characterised in Chapter 4, the above dispersion was used as the starting material
and the experimental section (4.3) describes the specific protocol followed. For the
solvated graphene electrodes presented in Chapter 3 the following reduction
process was used.
The chemical reduction of GO to the more conducting form reduced graphene
oxide (rGO) by hydrazine was described in Chapter 1 (1.5.6.2). The experimental
protocol followed was first introduced by Li et al. and describes the critical ratio of
hydrazine:GO (7:10) to achieve a stable rGO dispersion177. For these experiments,
10 mL of 0.5 mg/mL GO(aq) dispersion was diluted with 10 ml of milliQ water. 10
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µL of Hydrazine (35 wt%) and 70 µL of ammonia solution in water (28 wt%) were
added and the mixture was shaken for a few minutes immediately before being held
at 95°C in a water bath for 1 hour. Larger quantities of rGO aqueous dispersion
were prepared by scaling up the above ratios. Aggregates that form on the surface
during the reduction process were removed by careful decanting and the stable 0.25
mg/mL rGO dispersion was stored under nitrogen gas and kept in an airtight shot
bottle.

2.3.2.2 Dispersion characterisation
2.3.2.2.1 Optical microscopy
A drop of rGO dispersion was cast onto a glass slide with a glass cover sheet placed
on top for qualitative optical analysis using a Leica optical microscope. An opaque
white plastic sheet was placed underneath the glass slide to achieve a representative
image, as it was difficult to distinguish dispersion features with the microscope
stage behind the sample.

2.3.2.2.2 Particle size analysis and zeta potential
Zeta potential and particle size analysis were performed using the Zetasizer
Nanoseries (Malvern Instruments). A dilute rGO sample was added to a universal
dip cell quartz cuvette and the sample was analysed. The mechanism of particle size
analysis is considered in detail in Chapter 3 (3.4.3.4) to support the discussion
around experimental results.
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2.3.2.2.3 pH
The pH of the rGO dispersion was measured using a TPS pH Meter (WP-80) after
it had been calibrated using known pH standards. The pH of the rGO dispersion
was >10.
2.3.2.2.4 Electrode fabrication
Specific details on electrode fabrication are outlined in the respective experimental
sections of each results and discussion chapter.

2.3.3 Dexamethasone 21-phosphate disodium salt
Dexamethasone is a corticosteroid that inhibits the release of substances that cause
inflammation in the central nervous system. Dexamethasone 21-phosphate
disodium salt is a pro-drug of dexamethasone and the presence of the phosphate
group gives the structure an anionic charge, allowing it to act as a dopant during
the electrochemical growth of conducting polymers48,54,56, as described in Chapter 1
(1.4.5). Figure 2.9 (a) shows the chemical structure of dexamethasone, the insoluble
form of the drug, and Figure 2.9 (b) shows dexamethasone-21-phosphate disodium
salt, the soluble anionic form. For the experiments carried out in this thesis the prodrug dexamethasone-21-phosphate disodium salt was used. Henceforth, if a
reference is made to dexamethasone it will refer to the pro-drug chemical structure
(Figure 2.9 b) and will be given the abbreviation DEX.
(a)

(b)

Figure 2.9 The chemical structure of Dexamethasone (a) and its pro-drug Dexamethasone21-phosphate disodium salt (b).
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2.3.4 Fos-phenytoin
Fos-phenytoin is a strong anti convulsant drug administered to epileptic patients
intravenously as discussed in Chapter 1 (1.4.5). The chemical structure of
Phenytoin is shown in Figure 2.10 (a) and the pro-drug form Fos-phenytoin is
shown in Figure 2.10 (b). Fos-phenytoin was formulated to address the solubility
issues of Phenytoin that requires a basic solution with ethylene glycol for
intravenous injection. The addition of the phosphate group not only increases the
drug’s solubility effectively decreasing drug administration time, a critical quality
when seizures need to be controlled quickly; but the anionic nature also makes it
appropriate to use as a dopant for conducting polymer structures. Fos-phenytoin
(Figure 2.10 b) is used in this thesis and is given the abbreviation FOS.

(a)

(b)

Figure 2.10 The chemical structure of Phenytoin (a) and its pro-drug Fos-phenytoin (b).

2.3.5 Polypyrrole
2.3.5.1 Instrumentation
Electrochemical polymerisation of polypyrrole and controlled release experiments
were performed using an eDAQ potentiostat/galvanostat with eDAQ Chart
software (v2.0.7).
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2.3.5.2 Electrochemical polymerisation
Pyrrole monomer (Merck, >99%) was distilled prior to use and stored under
nitrogen at -20°C. A 0.2 M aqueous solution of pyrrole was used for all
electrochemical

polymerisation

experiments

with

varying

dopant

anion

concentrations and growth conditions that will be outlined in the respective
chapters. The dopants used were para-toluene sulfonic acid (PTS), dexamethasone21-phosphate disodium salt (DEX) or Fos-phenytoin (FOS). A 3-electrode
electrochemical cell was used for all growth experiments and is shown
schematically in Figure 2.11 (a). Gold mylar (CP Films Inc., USA) was used as a
substrate for polymer growth (working electrode) and was washed in three steps
before use; these steps included detergent water, ethanol and finally milliQ water
before being dried using a nitrogen stream. Platinum mesh was used as a counter
electrode and positioned directly opposite the gold mylar working electrode, as
shown in
Figure 2.11, and a Ag|AgCl reference electrode completes the configuration. This
3-electrode set up was used to galvantically grow polypyrrole (PPy) onto gold
mylar electrodes for controlled release studies. For PPy-FOS growth the volume of
this cell was reduced to cater for the limited amount of drug available and it’s
relative cost. The specifics of this experiment are outlined in Chapter 5 (5.3).
Figure 2.11 (b) shows a PPy-DEX film on a gold mylar substrate directly after
growth. All films were rinsed extensively with MilliQ water to remove any loosely
bound dopant and excess monomer.
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(a)

Reference electrode
Counter electrode

(b)

Polypyrrole/dopant
film

Monomer/dopant
solution

Figure 2.11 (a) A schematic of the 3-electrode electrochemical cell used to grow the
conducting polymer films, and (b) a photograph of an as formed PPy-DEX film.

2.3.5.3 Controlled release experiments
Calibration curves were initially established for DEX and FOS using UV-Vis (2.2.1)
so that when drug release was detected from the polypyrrole films it could be
quantified. For controlled release experiments a 3-electrode cell was designed in a
UV-Vis quartz cuvette to completely fit inside the UV-vis instrument chamber
(Figure 2.12). The electrodes were connected to a potentiostat that would apply a
potential to the polymer film and the drug release would be simultaneously
measured in the release cell. It was critical to stir the release solution in order to get
an accurate drug release reading and this was achieved using a flea stirrer bar inside
the cuvette that was agitated by a small motor with a large stirrer bar attached, as
represented in Figure 2.12. This was necessary to disperse the drug that would
otherwise take a long time to diffuse away from the working electrode and give a
real time representation of how much drug was released as a function of time at the
given potential.
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Reference electrode
Working
electrode

Motor with
stirrer bar
attached

Counter electrode

Stirrer bar
Path of spectrophotometer beam through the release solution

Figure 2.12 Schematic representation of the three-electrode cell designed to fit inside the
UV-vis chamber and analyse the release of drug from the polypyrrole samples during
electrochemical stimulation.

2.3.5.4 Drug release from polypyrrole powered by an enzyme
bioelectrode
The protocol used to fabricate enzyme bioelectrodes will be outlined in the
experimental section of Chapters 3 and 4. Additionally, an extensive description of
the experimental set up used to characterise the release of drug from polypyrrole
powered by an enzyme bioelectrode can be found in Chapter 5.
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3. Solvated graphene bioelectrodes
3.1 Chapter aims
This chapter aims to investigate the feasibility of incorporating purified glucose
oxidase into solvated graphene electrodes and to characterise the performance of
the resulting bioelectrode. The results are analysed in the context of powering an
implantable controlled drug delivery device for the treatment of epilepsy, as
described in Chapter 1.

3.2 Classification and terminology
Slaughter et al. define hydrogels as “three-dimensional networks formed from hydrophilic
homopolymers, copolymers or macromers (preformed macromolecular chains) cross-linked to
form insoluble polymer matrices”178. Adhering to this definition, the graphene electrode
structures presented in this chapter do not fall under the traditional classification of
‘hydrogel’ as they are not formed from polymers, even though they retain a high
percentage of water similar to gels. The electrodes presented in this chapter are
fabricated from aqueous dispersions of graphene (that DO NOT contain any
surfactants or other polymeric dispersing agents), which are suction filtrated
similar to a ‘buckypaper’, however, the filtration is stopped prematurely to retain
water within the structure. They will be from here on referred to as solvated
graphene electrodes (SGE).

3.3 Introduction
In Kopecek’s 2007 review on hydrogel biomaterials, he outlines the many
applications of the water–swollen materials including advanced tissue engineering,
synthetic extracellular matrix, implantable devices, biosensors, controlled drug
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delivery,

separation

systems,

smart

microfluidics,

and

energy-conversion

systems179. Coincidentally, their inherently soft mechanical properties make waterswollen materials especially suitable for implantation due to their similarities with
natural human tissue180. A critical challenge with implantable biomaterials, such as
hydrogels, is the ability to incorporate functionalities so they are responsive to the
surrounding environment181. Hydrogel materials have been investigated for their
application in biosensors and biofuel cells100,101 with the intention of supplying
charge to low power consumption in vivo devices.
The objective of this chapter is to fabricate a solvated graphene electrode,
comparable to traditional hydrogels, with the additional bonus of exceptional
electrical properties. The aim is to incorporate glucose oxidase (GOx) and facilitate
direct electrical communication between the underlying graphene electrode and the
immobilised GOx.
Traditionally, hydrogels were fabricated from cross-linked polymer networks and
research is still being directed at these materials182. With the rise in popularity of
carbon nanotubes and graphene, considerable work has focussed on adding
conducting fillers to polymer matrices to achieve conducting hydrogels183. The
difficulty with using conducting fillers is reaching a percolation threshold that will
allow electrical conductivity by overcoming the insulating properties of the
polymer matrix184,136. Using an alternative approach, researchers investigated
conducting polymers, such as Poly(3,4-ethylenedioxythiophene) (PEDOT), to
create conducting polymer-hydrogel composites with graphene fillers so the
material electrical properties are enhanced by the conducting polymer matrix185.
Hydrogels can be used as a supporting matrix for the immobilisation of
biocatalysts, such as enzymes or microbes, within the scaffold. This ability has
benefits over conventional non-hydrated electrodes in that the reactants and
products of the catalytic process can easily diffuse in and out of the
structure186,187,185 and continuously supply the required fuel for the reaction. A
significant amount of research interest is directed at achieving high energy density
hydrogel biosensors and biofuel cells.
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The major challenge in fabricating such complex electrodes is to use materials and
processes that are not detrimental to the activity of the enzyme to be incorporated
into the electrodes. Lehr et al. investigated the fabrication of a GOx-epoxy hydrogel
cross-linked with polyethylene glycol diglycidyl ether (PEGDGE) and observed a
decrease in GOx activity with curing time, which they attributed to the high
crosslink density either denaturing the enzyme or restricting substrate mobility188.
Jang et al. looked at the activity of enzymes as a function of covalent immobilisation
on silica nanoparticles within a hydrogel matrix and showed a 60% decrease in
enzyme activity if the enzymes were not anchored to the nanoparticles189. Once the
enzymes are successfully immobilised within a hydrogel their activity can be
retained due to the formation of a stable microenvironment of suitable solvent or
buffer within the porous network of the hydrogel material190.
It was hypothesized that some of the complications associated with traditional
hydrogels for applications in biofuel cells and biosensors may be overcome if the
insulating polymer matrix was eliminated and a hydrogel-like structure could
support the enzyme based solely on the highly conducting nanomaterial, graphene.
There are many fabrication processes reported in the literature to fabricate
‘hydrogels’ from graphene. A common fabrication method relies on hydrothermal
processes191 where a reducing agent is added to a graphene oxide dispersion. For
example, Sheng et al. added sodium ascorbate to the GO dispersion and then the
mixture was heated to > 90°C for 1.5 hours for sufficient reduction. Gelation occurs
upon cooling192 (Figure 3.1). As enzymes are sensitive to heat, pH and a suite of
chemicals, hydrothermal processes such as this are not appropriate for maintaining
enzyme activity during the fabrication process.
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Figure 3.1 (a) Photograph of an aqueous dispersion of GO (2 mg/mL) and sodium ascorbate
before (left) and after (right) the hydrothermal treatment. (b) SEM image of the fabricated
graphene hydrogel. Image adapted from Sheng et al 192.

Sheng et al., who utilised the sodium ascorbate reduction method above, discussed
that the same gelation can occur at 37°C if the reaction is left for > 30 hours,
however, the half life of native enzyme is only 7-8 hours in solution128. As a result,
there would be a significant reduction in enzyme activity over this time period.
Another graphene gelation mechanism involves increasing the GO concentration
up to 30 mg/mL for the fabrication of a hydrogel at room temperature193.
Unfortunately, the electrical properties of this gel were not characterised. A similar
method investigated by Qiu et al. showed that electrical conductivity could be
achieved for a GO-CNT composite194.
Figure 3.2 represents the electrode fabrication procedure used in this chapter. In
2011, Yang et al. showed that during vacuum filtration, a reduced graphene oxide
(rGO) dispersion undergoes gelation at the solid-liquid interface forming a
hydrogel of ~ 92 wt% water, composed completely of the conducting rGO. Figure
3.2 (a) illustrates the gelation process as the rGO sheets order themselves into a
highly structured assembly during filtration. Figure 3.2 (b) shows the resulting
hydrogel being handled. In theory, as long as the enzyme added to these dispersions
did not cause aggregation or inhibit the gelation mechanism of partial π-π stacking,
this could be a feasible method of immobilising an enzyme within a graphene
hydrogel matrix for biosensor applications.
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(a)

(b)

(c)

Figure 3.2 (a) A schematic representation of the filtration and gelation process, (b) a
photograph of an as-formed hydrogel and (c) an SEM cross section microghraph of a freeze
dried hydrogel. Sacle bar: 1µm. Adapted from Ref195

Figure 3.2 (c) shows a SEM micrograph of the cross section of a freeze dried gel. If
the hydrogel were formed in the bulk solution one would see a randomly crosslinked 3D structure, however, the highly uniform layered structure observed
supports the hypothesized gelation mechanism. The rGO sheets cannot be fully
packed down to form graphite because the sheets are highly solvated, which causes
intersheet electrostatic repulsions between water molecules. Competing with the
repulsive forces are the attractive forces of partial π-π stacking and this delicate
balance gives the hydrogel material its extraordinary electrical and mechanical
properties. It is the most conducting hydrogel recorded with a conductivity
measured at 0.87 S/cm with the highest tensile strength reported at 75 MPa,
compared to 0.01 to 10 kPa for other hydrogel materials of similar hydration195.
Solvated graphene electrodes have also been tested for their application as a
supercapacitor and show exceptional charge/discharge rates with a measured
capacitance of up to 273 F/g196.
In addition to the above-mentioned characteristics, the filtration process presented
in Figure 3.2 (a) has been chosen to fabricate biosensors in this thesis due to its
extreme versatility. The simple filtration method allows the addition of functional
molecules, like glucose oxidase. Filtration also demonstrates control over film
thickness by adjusting the volume of the dispersion. Additionally, there is no
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insulating polymer filler present to interfere with the electrical properties of the
final electrode. The resulting hydrogel is porous to reaction reactants and products
and is a soft material that is relevant for the intended application of an implantable
device.

3.4 Experimental
3.4.1 Materials
Reduced graphene oxide (rGO) dispersions and purified glucose oxidase (GOx)
were used as described in Chapter 2. A 1.0 M stock solution of D-(+)-glucose was
made up in phosphate buffer solution (PBS) (50 mM, pH 7.4) prepared from
potassium phosphate monobasic and dibasic salts (Sigma). This solution was
allowed to mutarotate197 for 24 hours and stored at 4°C when not in use. Ferrocene
methanol (FcMeOH) (97%, Sigma) was made up to 5 mM using the same buffer. A
standard series (0.016 to 2.5 mg/mL) of bovine serum albumin (BSA) (minimum
96% electrophoresis, Sigma) was prepared in milliQ water for use in the biological
assay experiments. The QuantiPro BCA protein assay kit (Sigma) was used to
perform the Pierce BCA assay. Peroxidase, Type II: From Horseradish (Sigma) and
2,2’-Azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) diammonium salt (ABTS)
(Sigma) were used in the ABTS enzyme kinetic assay.

3.4.2 Electrode fabrication
A micro filtration system was set up as shown in Figure 3.3 (a) with a 0.05 µm pore
size mixed cellulose filter paper. The Buchner flask was connected through a safety
collection flask to a Vacuubrand 80 mbar vacuum pump. 20 mL of 0.25 mg/mL
rGO aqueous dispersion was transferred into the glass filtration set up using a glass
syringe to minimise aggregation. The amount of enzyme added to the dispersion
was calculated as a weight % of the amount of rGO present and the samples
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analysed in this study were 20%, 10%, 5%, 2% and 0%. The labelling system, SGEGOx (5%), will be used for these samples and the percentage value will indicate the
weight % of GOx to the weight of graphene in the sample. The required amount of
GOx was made up to 2 mL with milliQ water; a procedure also required to
minimise aggregation, before the GOx was loaded into the rGO dispersion and
gently mixed by syringe mixing. Syringe mixing is the process by which a solution
is drawn into a pipette tip and expelled again. This is repeated a number of times
and the volume should be sufficient to instigate effective mixing. For example, for
the 22 mL rGO-GOx dispersion used in this study, a 2 mL pipette was used for
syringe mixing. The syringe mixing served two purposes, firstly to ensure complete
transfer of the entire enzyme contents into the dispersion, and secondly to disperse
the GOx evenly throughout the solution to be filtered. Filtration was performed at
room temperature and stopped at a predetermined point to identify the meniscus
level immediately before the solvent was completely drawn through. This was
critical to ensure the SGE structure was maintained in its hydrated state.
The filtrate was collected and refrigerated for future bioassay characterisation while
the sample was washed with milliQ water and stored in 50 mL of PBS (50 mM, pH
7.4) in the refrigerator at 4°C. The SGEs were sliced into 0.5 x 0.5 cm (0.25 cm2)
square samples for electrochemical and bioassay characterisation.
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rGO (aq)- GOx
dispersion
(a)

0.05 µm mixed
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Enzyme loaded
SGE

(b)

Filtrate
Soaking
solution
Figure 3.3 (a) The micro filtration set up, and (b) an enzyme-loaded SGE ready for storage.

For electrochemical characterisation, a 0.25 mm2 section of solvated graphene was
sandwiched between two pieces of gold mylar as illustrated in Figure 3.4. The
active surface area of each gold mylar strip was isolated using adhesive tape and the
assembly was secured together using parafilm that wrapped around the electrode
sandwich, leaving the bottom of the electrode exposed for electrochemistry.
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Electrode assembly

Side view

Bottom view
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SGE
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Figure 3.4 Schematic diagrams representing the assembly of SGEs for electrochemical
characterisation, including side and bottom views.

3.4.3 Characterization methods
3.4.3.1 Water content
Solvated graphene sections were cut and weighed using a high precision
microbalance. The sections were subjected to freeze drying using the CHRIST
Alpha 2-4 LSC freeze dryer for 48 hours and the samples were weighed again with
the mass loss calculated to be the water content as a percentage of the original
hydrated mass (Equation 3.1).
Equation 3.1
!"#$%!!"#$%#$! % = !

!! − !!
!!

where WH is the hydrated weight of the solvated graphene sample and WD is the dehydrated weight
measured after freeze drying.
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3.4.3.2 Scanning electron microscopy
Scanning electron microscopy (SEM) (JEOL Cold Field Emission Gun Scanning
Electron Microscope) was performed on the freeze-dried samples, providing
information on the cross-sectional structure of the material. The specimens were
sputter coated with 10 nm of platinum using the Edwards sputter coater before
analysis.

3.4.3.3 Optical analysis
The Leica Optical Microscope was used to characterise dispersion properties by
depositing two drops of dispersion onto a glass slide and covering it with a glass
cover slip. The microscope was used at x10 magnification to qualitatively observe
the formation of aggregates and dispersion stability.

3.4.3.4 Particle size
Particle size analysis using the Zetasizer Nanoseries-ZS particle analyser (Malvern
Instruments) was conducted to quantitatively analyse dispersion stability as a
function of enzyme loading. Dynamic light scattering (DLS) is a technique where
particles in solution scatter a laser beam at different intensities due to their
Brownian motion. The translational diffusion coefficient can then be extracted and
used to calculate the relative particle size using the Stokes-Einstein relationship
(Equation 3.2).
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Equation 3.2

!!! = !

!! !
!"#!!

The Stokes-Einstein relation where Dh is the hydrodynamic diameter (or particle size), Dt is the
translational diffusion coefficient (given by DLS), kB is Boltzmann’s constant, T is the temperature
and η is the dynamic viscosity.

The challenge with analysing graphene dispersions using this technique is that the
theory is based on the solution containing homogenous spherical particles. The
graphene dispersions however, are composed of sheets of rGO that are somewhere
between flat and randomly wrinkled structures in solution depending on their level
of purity141 and hence the data generated through this particle size analysis
technique is only relevant for comparative studies within each experimental data
set. In order to understand the extent of agglomeration of the graphene particles
more thoroughly and to support particle size analysis the polydispersity index
(PDI) was also measured. PDI is a measure of the particle size distribution within a
sample with an ideal spherical, narrow monomodal system having a PDI < 0.1. The
values presented in this thesis are much larger than this and can be attributed to the
non-spherical nature of graphene in solution. The PDI values presented in this
chapter will also be comparatively studied relative to the immediate data set.

3.4.3.5 Biological assays
Biological assays were used to determine the amount of enzyme immobilised within
the solvated graphene electrode (SGE) samples and also how much was collected in
the filtrate during electrode fabrication. Assays were also performed on the sample
soaking solution (identified in Figure 3.3) to establish if the enzymes are sufficiently
entrapped within the SGE samples (i.e. how much leaks out into the soaking
solution). A kinetic assay was used to determine if the enzymes survived the
processing and remain in their biologically active conformation. All biological
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assays used a UV-vis plate reader to measure the absorbance and control the
temperature of the experiments.

3.4.3.5.1 Pierce BCA protein assay
The Pierce BCA protein assay was utilized to determine the protein concentration
in a sample. The protocol published in the Thermo Scientific technical sheet was
followed precisely174. The Pierce BCA protein assay was presented in detail in
section 2.3.1.2.5 of this thesis.

3.4.3.5.2 Glucose oxidase/peroxidase kinetics (ABTS assay)
The ABTS assay is used to study enzyme kinetics and can quantify the activity of
glucose oxidase in a given sample. The ABTS assay was introduced in detail in
section 2.3.1.2.4 of this thesis. For SGE analysis, the samples were soaked in the
assay reaction cocktail and at each time point the solution was pipette transferred
out into another 96-well plate for analysis in the plate reader. Afterwards it was
returned to the same well with the SGE sample and incubated at 37°C until the
next time point where the procedure was repeated. At each time point the solution
was mixed using the pipette to ensure all the reaction products were collected for
analysis198.

3.4.3.6 Electrochemistry
All electrochemistry was performed in a 3-neck round bottom flask submersed in a
thermo-coupled water bath maintained at 38°C, as shown in Figure 3.5. Before each
experiment the electrolyte was degassed using argon or nitrogen gas for a
minimum of 15 minutes, and during electrochemical experimentation a constant gas
blanket was used to eliminate oxygen. Platinum mesh was used as the counter
electrode and all experiments were performed with reference to an Ag|AgCl
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reference electrode (3 M NaCl). Each neck of the cell was stoppered with a rubber
plug to secure the electrodes in place and to minimise oxygen contamination.
Experiments were performed in a faradaic cage to minimise noise.
Ag|AgCl reference
electrode
rGO-GOx SGE
working electrode
Ar gas inlet
Pt mesh counter
electrode

Water bath

Figure 3.5 Schematic representation of the 3-electrode cell used for electrochemical
characterisation of rGO-GOx solvated graphene electrodes (SGE).

3.4.3.6.1 Electrochemical impedance spectroscopy
Electrochemical impedance measurements were conducted using a CH instruments
potentiostat with accompanying software. Experiments were performed in PBS (50
mM, pH 7.4) or PBS with 5 mM FcMeOH. For the PBS experiments, the open
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circuit potential was measured for each electrode before hand until a stable value
was reached and this potential was used as the applied DC voltage for the
impedance measurements. The FcMeOH experiments were driven at the oxidation
potential of FcMeOH (+0.28 V vs. Ag|AgCl). All samples were measured over the
frequency range 100 kHz to 0.1 Hz at an AC amplitude of ±5 mV.

3.4.3.6.2 Cyclic voltammetry
Direct electron transfer (DET) and mediated electron transfer (MET) mechanisms
of electron transfer were introduced in Chapter 1 (1.5.5). Cyclic voltammetry was
used to identify if DET peaks could be observed for the immobilised GOx over the
capacitance of the SGEs and also to establish if the electrodes could facilitate MET
with FcMeOH. The parameters for each experiment will be outlined when the data
is presented in the results and discussion section.

3.4.3.6.3 Amperometry
Current vs. time curves were utilised to measure the amperometric response of the
immobilised GOx in the SGEs. Experiments were conducted for 33 minutes with
the first 10 minutes utilised to stabilise the electrode, before spiking the relevant
glucose concentration. Usually, amperometric studies would show a sequential
addition of glucose with a current increase corresponding to the glucose
concentration. Due to complicated mass diffusion and electron transfer kinetics in
the SGE system, it was necessary to measure each glucose concentration
individually. Figure 3.6 represents a typical GOx loaded SGE response to a spike in
glucose and identifies the data analysis method employed. Briefly, the baseline
current was subtracted from the highest current measured and this was taken as the
catalytic current generated from that electrode (Δi) at the given glucose
concentration. Experiments were done in triplicate.
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Figure 3.6 Schematic representation of an amperometric response recorded for a SGE-GOx
sample after the addition of glucose and the method used to measure the maximum catalytic
current generated.

3.4.3.6.4 Fourier transform alternating current voltammetry
Fourier transform alternating current voltammetry (FTACV) experiments were
performed using a custom built FTACV instrument at Prof. Alan Bond’s
electrochemistry research group at Monash University in Melbourne, Australia.
The theory of this technique was introduced extensively in Chapter 2 (2.2.3.8). A
three-electrode cell was used for all experiments similar to that presented in Figure
3.5 and controlled at 38ºC under nitrogen gas. A highly concentrated buffer of 0.5
M PBS (pH 7.4) was used as the electrolyte to minimise solution resistance.
Experiments were performed at a frequency of 9 Hz and amplitude of 120 mV.

3.5 Results and discussion
3.5.1 Electrode fabrication and storage
An attempt was made to fabricate a SGE using graphene oxide, i.e. before the
reduction step removed a portion of the oxygen groups. However, this approach
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was unsuccessful due to the large amount of oxygen containing functionalities
causing electrostatic repulsions, which dominate the interaction and inhibit the
formation of a stable gel. The balance between attractive and repulsive forces that
underpin the stability of SGEs was postulated by Yang et al.. Their group suggests
that partial π-π stacking is responsible for the forces of attraction while the oxygen
functionalities, and hence the tightly packed water molecule layer, prohibit the
sheets from being fully compact. Hence, if the repulsive forces are large compared
to the attractive forces, the graphene will not pack into a SGE structure. The
motivation behind trying to fabricate a SGE out of GO arises from concerns
associated with the integrity of the glucose oxidase (GOx). Factors that could affect
the GOx integrity, and ultimately, its catalytic activity, include survival through
the filtration process and denaturation caused by the high pH value from the added
ammonia (used for stabilization) or the hydrazine (used for chemical reduction). If
the SGE could be fabricated using GO it would be unnecessary to expose the
enzymes to these chemicals. Unfortunately, this was not feasible and the ultimate
advantage of the reduction step is that it warrants a more electrically conductive
final product.
Another attempt was made to avoid exposing the enzymes to the harsh reducing
chemicals by filtering the enzyme solution on top of an already formed SGE. It was
believed that the enzyme may penetrate into the SGE, however, SEM analysis
showed that the enzyme actually packed down on top of the graphene electrode, as
shown in Figure 3.7. Ideally, the enzyme will be evenly distributed throughout the
structure to ensure efficient electrical wiring to the graphene sheets.
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Glucose Oxidase

Graphene sheets

Figure 3.7 SEM micrograph showing discreet layers of graphene sheets and enzyme when
GOx is filtered post SGE formation. Scale bar represents 1µm.

An attempt was also made to reduce the pH of the dispersions to a level suitable for
the enzymes using dilute acetic acid. Figure 3.8 (a) shows the relative activity of the
purified GOx over the range pH 2 – 10.5, as measured through an ABTS kinetic
assay, and it is evident that the optimal range for glucose oxidase activity is pH 4 7. An rGO dispersion has a pH ~ 10 due to the addition of ammonia for
stabilisation. When dilute acid is added to the dispersion there is immediate and
visible aggregation caused by the ionization of carboxylic acid functional groups.
This can be seen in Figure 3.8 (b) where (i) is the stable rGO dispersion (pH 10) and
(ii) is the same dispersion after the pH was gently lowered (final pH ~6.5). It is
evident that extensive aggregation has occurred.
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Figure 3.8 (a) Relative glucose oxidase activity (purified) as a function of pH, and (b) aqueous
rGO dispersions before (i) and after (ii) a pH adjustment using dilute acetic acid at pH 10 and
pH 6.5, respectively.

When electrolytes are added to an electrostatically stabilised dispersion the
repulsion forces are supressed due to electrical double layer screening, as discussed
in Chapter 2. If the double layer is hindered too much the dispersion will
agglomerate and destabilise. Based on the same theory, the SGEs undergo
volumetric changes in the thickness direction when the ionic strength of the
soaking solution changes, as the repulsive forces are dependent on the ionic
strength of the solution195. Significantly, Yang et al. reported that the as-formed
SGE can be stored in buffer without disruption of the SGE stability. The ability to
store the SGEs in buffer is of relevance to this study because enzymes are stored in
buffers to maintain their activity at a relevant pH. In this way storage in a buffer
solution was critical.
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3.5.2 Dispersion properties
3.5.2.1 Optical analysis
It was critical to understand if the addition of enzymes and their supporting buffer
salts would cause aggregation in the dispersions, as this may affect SGE formation.
To avoid instabilities, the enzyme that was added to the dispersion before filtration
was made up to 2 mL with milliQ water to dilute the salts, with the exception of the
20% sample which required 2 mL of enzyme stock solution and hence no dilution.
Optical analysis of the dispersions showed qualitatively that for each GOx loading,
no significant aggregation is observed, with Figure 3.9 (a) showing an example of
the highest tested GOx loading in an rGO dispersion, namely rGO-GOx (20%). It
is evident that no aggregates are present in the optical micrograph. The qualitative
analysis is based on comparison to an aggregated example at the same
magnification (Figure 3.9 b).

(a)

(b)

Figure 3.9 Optical analysis of rGO dispersions, with micrograph (a) showing an rGO-GOx
(20%) dispersion, while micrograph (b) shows an example of an aggregated system (rGO - pH
6.5). Scale bars represent 1000 µm.

3.5.2.2 Particle size analysis
The enzyme-loaded dispersions were characterised by particle size analysis to
further examine the degree of aggregation, which may not be detected through
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qualitative optical analysis. As mentioned in the experimental section of this
chapter, the data generated by this technique can only be used comparatively within
experimental data sets, and is not accurate as an absolute value. Taking this into
consideration, on analysis of the nominal number average particle size data there is
very little difference, and certainly within experimental error, between rGO
dispersions with different GOx loadings (Figure 3.10). Theoretically, aggregated
particles would be detected as larger particles as they would have significantly
slower Brownian motion compared to freely dispersed graphene sheets. This result
would suggest that there is no significant increase in particle size, and hence,
aggregation, with the addition of GOx and salts. The large error bars arise due to
the fact that rGO is not a spherical shape and therefore, as the sheet moves under
Brownian motion, light interacting with the faces and edges of the sheets result in
large variations in scattered light intensity. These variations produce large
discrepancies in average particle size values.
Figure 3.10 also graphs the polydispersity index (PDI) of the samples and a
significant increase in PDI for the 20% GOx loaded sample compared to the other
samples was noted. PDI gives an indication of the size distribution of particles
within a solution, suggesting a larger range of particle sizes in the 20% sample.
This may be attributed to the fact that during the addition of GOx there was no
dilution of the salts, alternatively the system may have reached a critical salt
threshold, which would initiate the onset of aggregation. In addition, the enzyme
may tend to agglomerate together when added to the dispersion, which would also
be detected as large particle sizes.
The degree of aggregation for the tested samples was not considered a concern for
these experiments, especially since there was no significant decrease in dispersion
quality through optical analysis (Figure 3.9), and as such electrodes were fabricated
for all tested GOx loadings.
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Figure 3.10 Nominal number average particle size and PDI analysis of rGO-GOx dispersions
at different GOx loadings.

3.5.3 Electrode characteristics
A series of SGEs were fabricated using rGO (pH 10) with different loadings of
enzyme, namely 0%, 2%, 5%, 10% and 20% (as a weight % of rGO). For each GOx
loading, three samples were freeze dried and weighed to determine their percentage
hydration. There was very little discrepancy between the values and interestingly
no trend between the different enzyme loadings. It was calculated that each SGE in
the series contained 96.7 ± 0.09% water.
To determine the distribution of enzymes throughout the final SGE-GOx sample a
cross sectional analysis was performed using SEM. Figure 3.11 shows an rGO-GOx
(2%) sample and it is evident that the enzymes form discreet layers within the
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structure. A similar structure was observed for all enzyme loadings. These layers
tend to encourage delamination of the graphene sheets and this may be detrimental
to the conductivity of the final electrode. On closer analysis of the interface between
the enzyme and graphene, it is evident that there is some physical interaction
between the two components (Figure 3.11 b), which may be critical for direct
electron transfer (DET).
(a)

(b)

Figure 3.11 SEM micrographs of an SGE-GOx (2%) electrode sample at (a) low (scale bar 1
µm) and (b) high (scale bar 100 nm) magnification showing discreet layers of enzyme and
delaminated graphene sheet bundles.

The tendency of the GOx to agglomerate into these discreet layers is not surprising
given that there may be hydrazine and ammonia associated with the graphene
sheets. Tung et al. suggest the formation of hydrazinium compounds consisting of
negatively charged carbon nanotubes surrounded by N2H5+ ions199 and this may be
similar for the negatively charged graphene sheets, as supported by data extracted
from the pierce BCA biological assay. The BCA assay relies on the reduction of
Cu2+ to Cu1+ through interactions with certain amino acids on the protein shell of
glucose oxidase; however, as hydrazine is a strong reducing agent it overrides the
reaction with protein and gives a strong indication of where the hydrazine is in the
filtration process. No protein or hydrazine was detected in the filtrate or the
soaking solution (Figure 3.3) for the formed electrodes using this assay.
Furthermore the SGEs gave a very strong response to the assay, even when no
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protein was present, indicating that the hydrazine is still associated with the
graphene sheets and may support the formation of the suggested hydrazinium
compounds in solution. After the electrodes were stored in PBS (pH 7.4) the pH of
the electrode was tested to be approximately pH 7 and the filtrate had a pH of 10
indicating that the ammonia does not remain in the SGE structure.

3.5.4 Biological assays
For all enzyme-loaded SGE compositions, no GOx was detected in the PBS (pH 7.4,
50 mM) soaking solution, not only from the BCA protein assay, where the
concentration could have been below the detection limit of the test, but also pH 7.4
with the ABTS activity assay which should have detected all active enzyme. This
indicates that once the enzyme-loaded SGEs are formed, the GOx remains
immobilised within the structures.

3.5.4.1 Peirce BCA protein assay
The Pierce BCA assay gave interesting results in response to the hydrazine present
in the samples; however, the collected filtrates were still too dilute for the
sensitivity of this assay. The hydrazine has an overriding effect on the reduction of
the copper, and hence the amount of GOx immobilised within the SGEs was
inconclusive.

3.5.4.2 Glucose oxidase/peroxidase kinetic assay (ABTS)
Given that the data from the protein assay was inconclusive in determining how
much enzyme is entrapped in each SGE-GOx electrode, the results presented in
Figure 3.12 were extrapolated from the ABTS kinetic assay calibration curve.
Briefly, the enzyme activity measured during the ABTS assay for each SGE
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concentration (i.e. 0, 2, 5, 10 and 20% GOx loading) was calculated against the
standard curve to determine the amount of active GOx present (in mg) in the assay.
Based on the initial active enzyme loading (also in mg) a percentage value was
extrapolated to give the results in Figure 3.12. As such the data is not only a
representation of how much active GOx is immobilised in the SGE structures, but
also how much of the initial enzyme loading mass is active.
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Figure 3.12 The amount of enzyme retained in each SGE-GOx electrode composition as a
percentage of the initial loading.

Figure 3.12 represents the amount of enzyme retained in each SGE-GOx electrode
as a percentage of the initial loading amount. Interestingly a similar amount is
observed for 2%, 5% and 10% samples. When the enzyme loading is increased to
20% there is a much larger retention of enzyme and one explanation for this is the
tendency of GOx to agglomerate within the structure, forming large particulates
that cannot be filtered out. This data is consistent over multiple repeats of the
experiment within the standard deviation represented in Figure 3.12, and coupled
with the consistency in water content of 96.7 ± 0.09% among all SGE-GOx
88 | P a g e

Chapter Three | Solvated graphene bioelectrodes
!
electrode compositions; it demonstrates good reproducibility for electrode
fabrication.
The ABTS kinetic assay was chosen to determine if the enzymes were still
biologically active after the electrode fabrication process; i.e. if GOx survived the
high pH environment and also the filtration step. Figure 3.13 shows the enzyme
activity for each SGE-GOx electrode composition and the positive result indicates
that the enzymes retain some of their activity (also supported by Figure 3.12).
Plotted on the same graph is the amount of enzyme calculated in each assay
experiment and there is some correlation between the amount of enzyme present
and the amount of units of activity that were measured through the kinetic assay.
The amount of GOx measured per assay sample was calculated from the retention
value (given in Figure 3.12) and the size of the SGE-GOx sample used for the assay,
i.e. 0.25 cm2, as a function of the total area (and loading) of the as-formed SGE-GOx
electrode (17.4 cm2).
Given that the purified enzyme measures an enzyme activity of 4.5 U/mL it is
evident that there is a decrease in enzyme activity during the electrode fabrication
process; which may be caused by exposure to hydrazine and extreme basic
conditions.
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Figure 3.13 Measured enzyme activity as a function of enzyme loading within the SGEs. Also
plotted is the amount of GOx calculated to be in an assay sample for each rGO-GOx
composition.

3.5.5 Electrochemical characterisation
3.5.5.1 Cyclic voltammetry
Cyclic voltammograms were used initially to determine if a DET signal could be
detected from the electrochemical oxidation and reduction of glucose oxidase,
without the need for a mediator. Glucose oxidase undergoes redox chemistry at E°
= -0.46 V124 (vs Ag|AgCl) and as such reversible peaks should be observed around
this potential when the active site of the enzyme is wired to the conducting
material. Figure 3.14 shows the voltametric response for an rGO-GOx (10%)
sample with and without glucose present, green and black trace, respectively. It is
evident that no defined redox peaks are observed. This may be due to the enzyme
not being directly wired to the graphene in this configuration. Other literature has
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shown a DET response using rGO-GOx146 however, the electrodes are not in a
hydrated form such as the SGEs. Additionally, the capacitive response of the rGO
may be too large to detect the relatively small faradaic response of the GOx.
60
PBS
PBS + Glucose

40
20
0

I (µA)

-20
-40
-60
-80
-100
-120
-140
-0.7

-0.65

-0.6

-0.55

-0.5
E(V)

-0.45

-0.4

-0.35

-0.3

Figure 3.14 Cyclic voltammogram of an SGE-GOx (10%) sample cycled at 10 mV/s in PBS
(black trace) and PBS + 150 mM glucose (green trace) at 37°C under an argon blanket from 0.65 to -0.35 V (vs. Ag|AgCl)

In order to determine if the GOx remained catalytically active within the SGEs, 0.5
mM FcMeOH was added to a PBS electrolyte solution (pH 7.4, 50 mM) to
demonstrate if a mediated electron transfer (MET) response could be measured for
a SGE-GOx (10%) sample. FcMeOH undergoes a reversible one-electron redox
reaction and successfully shuttles electrons for GOx, as indicated in Equation 3.3200.
On a planar GCE electrode FcMeOH undergoes redox chemistry with an E° value
of 0.15 V201 (vs. Ag|AgCl). Mediated electrochemistry on the SGE-GOx electrodes
is represented in Figure 3.15 and shows a non-reversible redox process with a
significant shift in E° to ~0.52 V (black trace). When 150 mM glucose is added to
the system (green trace) the sigmoidal shape representative of a mediated electron
transfer response is only slightly obvious and on analysis a small increase in
catalytic current is observed, but for some samples it was not measurable. All data
was analysed at a scan rate of 10 mV/s on the 10th cycle of a series of potential
sweeps for each electrode. Before this analysis the electrochemistry was stabilised
91 | P a g e

Chapter Three | Solvated graphene bioelectrodes
!
with 20 cycles at 100 mV/s, 20 cycles at 50 mV/s and finally 10 cycles at 10 mV/s
for each electrode. This was determined to be sufficient cycling to generate stable
and representative electrochemistry for data analysis. Cycling the electrode
between the relevant potentials before analysis is critical to ensure both the
oxidised and reduced forms of the mediator are present to produce reproducible
cyclic

voltammograms.

This

system

conditioning

is

widely

used

in

electrochemistry. The peak height was measured relative to the extrapolation of the
capacitive baseline current, as represented by the dashed lines in Figure 3.15, and
the catalytic current is the difference between the peak heights before and after
glucose is added.
Equation 3.3

GOx(Red) + FcMeOH(Ox) ! GOx(Ox) + FcMeOH(Red)
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Figure 3.15 Cyclic voltammogram of an SGE-GOx (10%) sample cycled at 10 mV/s in
FcMeOH/PBS (black trace) and FcMeOH/PBS + 150 mM glucose (green trace) at 37°C
under an argon blanket from 0 to 0.8 V (vs. Ag|AgCl)
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The CV’s and their respective peak heights were inconsistent between samples of
the same rGO-GOx composition and it was difficult to draw conclusions from the
data. The discrepancies may arise from the electrode configuration (Figure 3.4), as
it is difficult to secure good electrical contact with a soft SGE in order to test its
electrochemical properties. The configuration used was the most effective of the
samples tested, however, it still consisted of a crude assembly procedure with little
control over how effectively the gel and the gold mylar were in electrical contact.
This could lead to large contact resistances and be detrimental to the electrical
properties of the working electrode. Additionally, it was thought that FcMeOH
may not penetrate into the SGE sufficiently to mediate the shuttle of electrons from
GOx to rGO, however, in a study conducted on poly(ethylene glycol) hydrogels,
Jeerage et al. suggest that for a small neutral species like FcMeOH it is reasonable
to assume that the concentration of species within the hydrogel is equivalent to the
concentration in the external electrolyte, given that the pore sizes of the hydrogel
are sufficiently big and do not physically obstruct its mobility202. Yang et al. outline
for similar SGEs, as used in this study, small ions are not hindered by pore size196.
It is inconclusive from cyclic voltammograms if the enzyme is catalytically active
and hence an alternative form of amperometry was used to characterise the system
electrochemically.

3.5.5.2 Amperometry
Initially, the I-t curve was used to monitor the change in current with sequential
additions of glucose. This is a common method used to characterise the sensitivity,
range and response time of a biosensor, however, it was difficult to do this for the
SGE-GOx electrodes as the response time was several minutes and the increase in
current was not a stepwise response, but rather a slow deviation from the baseline
current. Figure 3.16 shows an example of the amperometric response recorded for
an SGE-GOx (5%) electrode sample with 5 mM of glucose added to the 0.5 mM
FcMeOH in PBS solution at 600 seconds. It took this sample roughly 5 minutes to
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respond to the glucose addition, even though it was mixed thoroughly, and the
maximum current (minus the baseline current) was recorded. From this data it is
evident that the enzyme shows some catalytic activity, however, the transfer of
charge within the SGE and across the SGE-gold mylar interface seem to be the
limiting factors, given that the FcMeOH can penetrate into the SGEs unrestricted.
This hypothesis will be explored further through electrochemical impedance
analysis in the following section.
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Figure 3.16 An example of the amperometric response measured when an i-t curve
experiment is done on a SGE-GOx (5%) sample. The spike at 600 seconds represents the
addition of 5 mM glucose to the electrochemical cell (vs. Ag|AgCl).

Analysis of the amperometric data generated from testing the range of enzymeloaded SGEs with a 5 mM spike of glucose showed that there was very little trend
between the amount of enzyme present in the SGE and the maximum catalytic
current generated. In fact, the error bars associated with this data set prohibit any
meaningful conclusions to be drawn (Figure 3.17). It is interesting to note that the
sample with no GOx present (i.e. 0%) generates the highest maximum current
(although not statistically different) and it suggests there is a significant amount of
baseline drift within the system which was completely housed in a faradaic cage and
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grounded to minimise experimental error. The disruption of the electric double
layer at 600 seconds when the glucose is spiked into the system causes a slight shift
in the baseline current, which is shown in Figure 3.16, and this may be the source of
discrepancy. Care was taken to minimise the disruption by gentle and quick pipette
mixing and every precaution was taken during data analysis to utilise the ‘new’
baseline for corrections, however, the ability of charge to pass through the hydrated
electrode and its contact resistance with the gold mylar was difficult to control and
may play a significant role in the errors observed.
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Figure 3.17 The maximum catalytic current generated as a function of GOx loading as
measured through amperometric experiments in response to the addition of 5 mM of glucose
for SGE’s.

Similarly, when different enzyme loadings were analysed, namely 0%, 5% and 10%,
and spiked with different amounts of glucose it is difficult to draw conclusions from
the resulting data (Figure 3.18). A new sample was used for each experiment and
the data presented is the average of a minimum of 3 samples for each glucose
concentration and enzyme loading. The data presented in Figure 3.18 was
normalised against an SGE-GOx (0%) reference data series at 0 mM glucose (i.e.
PBS) and is identified by an asterisk (*). There is a significant increase in catalytic
current for both SGE-GOx (5%) and SGE-GOx (10%) when 0.5 mM glucose is
added, however this increase is not observed for samples of the same composition at
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higher glucose concentrations. This effect is not an artefact of laboratory procedure
as the experiments were carried out one SGE-GOx composition at a time and the
glucose additions were in an intentionally random order. It is difficult to rationally
explain the increase in catalytic current for both samples at 0.5 mM glucose. There
is also an unexplained decrease in catalytic current for the SGE-GOx (5%) and
SGE-GOx (10%) samples with increasing glucose concentration from 0.5 mM. The
amperometric results are inconclusive as to whether the enzyme is measurably
catalytically active. The fact that in most cases there is an increase in ‘catalytic’
current for samples with enzymes present may support the activity of the enzyme
(as quantified through biological assays) however, the lack of trends in the data set
may suggest that the enzyme is in fact not efficiently electrically wired to the
graphene electrode material.
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Figure 3.18 The maximum catalytic current generated as a function of glucose concentration
for SGE-GOx electrode samples 0%, 5% and 10% GOx loading. Asterisk (*) indicates the
baseline data series used to normalise the data.
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3.5.5.3 Electrochemical impedance spectroscopy (EIS)
The charge transfer resistance (Rct) measured through EIS is a representation of
the electrical resistance within the SGE plus the contact resistance between the
sample and the gold mylar electrode. For this system it will be difficult to separate
the two. Figure 3.19 (a) shows a typical Nyquist plot for a SGE sample and the
method used to measure the Rct of each sample. The results presented in Figure
3.19 (b) represent at least 3 repeats for each data point. For SGEs produced by
Yang et al., they reported Rct in the range of tens of ohms where for this system the
resistances are measured in the range of hundreds of ohms (Figure 3.19). Yang et al.
configured their SGEs using platinum foil and used the device as a two-electrode
cell, rather than the working electrode in a three-electrode cell, as was the case for
the experiments in this thesis. Since the experimental procedure used in this thesis
is based on Yang’s initial results it may suggest that the contact resistance between
the SGE and the gold mylar is the biggest contributor to the electrode Rct.
Nevertheless, trends in Rct values between the different enzyme loading
compositions can be analysed. Figure 3.19 shows the Rct measured for each enzyme
loading with the PBS profile representing data generated when the electrode was
held at open circuit potential in a PBS (pH 7.4, 50 mM) solution and the FcMeOH
trace shows similar data for the electrodes held at an oxidising potential for
FcMeOH (0.28V vs. Ag|AgCl). The PBS trace is representative of the internal
resistance of the electrode and shows that there is very little statistical difference
between samples from SGE-GOx (0%) to SGE-GOx (10%), however, SGE-GOx
(20%) has a lower Rct than the other compositions. This may be related to a larger
amount of supporting salts being added to the electrode when GOx was added
which would decrease the repulsive forces between the rGO sheets, forming a more
compact electrode and ultimately aiding charge transfer195. In the mediated system
(FcMeOH) the electrodes generally exhibit lower charge transfer resistances which
is not surprising given the system is being driven by the oxidation of FcMeOH in
solution. This also tells us that the shuttle of electrons from FcMeOH to rGO is not
the limiting factor in this system and supports the discussion in section 3.5.5.1 to
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explain the inconclusive cyclic voltammetry results. The EIS results also support
the amperometric response of SGE’s (section 3.5.5.2), which hypothesize that the
errors observed may be due to a large charge transfer resistance within the SGE
itself and between the SGE sample and the gold mylar.
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Figure 3.19 (a) A Nyquist plot for a SGE-GOx (20% GOx loading) sample indicating the
method used to calculate the charge transfer resistance (Rct). (b) Charge transfer resistance of
SGE-GOx electrodes as a function of enzyme loading.
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It is difficult to draw conclusions from other electrochemical techniques including
cyclic voltammetry, amperometry and impedance on the contribution of the
immobilised GOx to the current generated. As such, fourier transform alternating
current voltammetry (FTACV) was used to separate and identify the faradaic GOx
current from the capacitive current.

3.5.5.4 Fourier transform alternating current cyclic voltammetry
FTACV, which was introduced in chapter 2, is a technique that extracts faradaic
and capacitive currents separately. Essentially, this allows the analysis of the
individual contributions of the GOx faradaic response and the rGO capacitive
current, and ultimately, will determine if the enzyme is directly wired to the SGE.
Briefly, the technique relies on applying an AC perturbation superimposed on a DC
cyclic voltammogram and data is extracted through fourier transform algorithms.
The data is converted from the frequency domain to the time domain for analysis
and represents a response that contains a DC contribution as well as a series of
responses at the fundamental, second, third and higher harmonics. If the GOx is not
electrically wired to the graphene the harmonics will be very similar to the control
sample when no enzyme is present. Alternatively, if the GOx is electrically wired to
the graphene, features will be visible in the higher order harmonics. Figure 3.20
shows the results for SGE-GOx sample at 20% GOx loading (green traces) and the
control profile of SGE with no enzyme present (black traces). Figure 3.20 (a) shows
the DC component, which is exactly the same as a cyclic voltammogram (CV) and
correlates to previously presented CV electrochemistry for similar samples (Figure
3.14). It is evident that when enzyme is present smaller cathodic and anodic
currents are observed and this may be due to the delamination observed previously
in SEM analysis (Figure 3.11). Figure 3.20 (b) and (c) show the first and second
harmonics, respectively, and information on the electrical wiring of the enzyme
cannot be extracted due to the large capacitive current still present in the profile.
This capacitive contribution is identified in Figure 3.20 (c) with red arrows and
equates to 10-15 µA for SGE-GOx (0%) and 3-10 µA for SGE-GOx (20%). A
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harmonic can be used to determine the GOx contribution when this capacitive
current is close to zero, as in Figure 3.20 (d). This residual capacitive response is
common for electrodes with large non-linear capacitive contributions like the SGE’s
presented in this piece of work.
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Figure 3.20 FTACV data for SGE-GOx (0%) and SGE-GOx (20%) samples showing (a) the
DC component, and the (b) first, (c) second, (d) third, (e) fourth and (f) sixth harmonics in the
time domain. Experiments were performed at 9Hz and 120 mV in 0.5M PBS at 38ºC under
nitrogen.
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The third and fourth harmonics represented in Figure 3.20 (d) and (e), respectively,
show more defined harmonics for the SGE-GOx (20%) sample compared to the
control case with no enzyme present (black trace), as indicated by blue and red
asterisks groups. This response can be attributed to the faradaic contribution from
the immobilised enzyme however, the weak response may suggest that most of the
enzyme is not electrically wired or not accessible by glucose. It is possible that this
response may be attributed to the surface GOx that is accessible to glucose in
solution; however, the positive biological assay results suggest that the glucose is
penetrating into the SGE structure and also confirms that the enzyme shows
reasonable enzyme activity for the amount of GOx initially immobilised. For
comparison, the same experiments were performed on an optimised rGO-MWNTGOx-PEi electrode, introduced and characterised in Chapter 4 of this thesis. Figure
3.21 (a) and (b) show well-defined third and fourth harmonics, respectively. This
system also represents 70% less GOx immobilised per geometric area than the
SGE-GOx (20%) sample and shows a much clearer faradaic response. The rGOMWNT-GOx-PEi system showed a clear direct electron transfer (DET) response
through cyclic voltammetry electrochemistry (section 4.4.2) and the data in Figure
3.21 is shown here purely for comparative analysis with the SGE electrodes. Figure
3.20 (f) shows the sixth harmonic and it is evident that no faradaic response is
measured, also supporting claims that the GOx is not effectively wired to the SGE.
It can be concluded from FTACV experiments that although some GOx is wired to
the SGE to show a faradaic response in the third and fourth harmonics, the
response is small indicating that most of the GOx is not effectively wired. The
electrodes do not respond reproducibly to environmental increases in glucose
concentration, as discovered through CV and amperometric electrochemistry, and
as such, will be inappropriate to use in biofuel cells, biosensors and for the purpose
of driving the release of drug from a conducting polymer scaffold.
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Figure 3.21 FTACV data for optimised rGO-MWNT-GOx-PEi electrodes showing the (a)
third and (b) fourth harmonics for comparison with SGE electrodes presented in Figure 3.20.
Experiments were performed at 9Hz and 80 mV in 0.5M PBS at 38ºC under nitrogen.

3.6 Conclusions
Solvated graphene electrodes (SGE) loaded with GOx were characterised to
determine their final composition and structure, as well as their ability to facilitate
direct electrical communication with the immobilised enzyme. The SEM
micrographs suggest good physical interaction between the immobilised GOx and
the rGO sheets however, does not show conclusively that the enzyme is electrically
wired to the SGE. The CVs performed in PBS did not show a DET signal,
suggesting that the GOx is not electrically wired however, this is also inconclusive
as the capacitive current could be swamping the relatively small faradaic response
from the enzymes. To determine if the enzymes remain catalytically active a
mediator (FcMeOH) was added to the system to bypass the direct wiring
mechanism, since the FcMeOH will shuttle electrons from the enzyme to the
electroactive surface of the electrode. Unfortunately the resistance within the
system prohibits the detection of meaningful catalytic data from cyclic
voltammetry. Mediated amperometry was used to determine the maximum current
generated when a given amount of glucose was spiked into the electrochemical
system and again the results were inconclusive. Fourier transform ac voltammetry
showed conclusively that the electrical communication between the immobilised
GOx and the SGE scaffold was poor, as determined by analysing the higher order
harmonics, which distinguish faradaic currents from non-faradaic components.
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From electrochemical techniques the data was convincing in suggesting that the
enzymes are not sufficiently electrically wired to the SGE. Biological assay
experiments showed that the immobilised enzymes remain catalytically active. For
the given application of powering a controlled drug delivery device the SGE-GOx
electrodes will be inappropriate given that there is no significant catalytic current
generated in the presence of glucose, which is the controlling factor for the drug
release experiments. Even if a suitable catalytic current was generated the response
time seems to be in the order of several minutes, which is unacceptable for epilepsy
management. It is critical for seizure activity to be treated in the first couple of
seconds due to the quick onset of a seizure as outlined in Chapter 1 (1.1).
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4. Reduced graphene oxide- carbon
nanotube composite
bioelectrodes
This chapter is based on a manuscript accepted in CARBON (2013)
(DOI: 10.1016/j.carbon.2013.05.029)

4.1 Introduction
Unique electrode architectures have been fabricated from processable solutions of
carbon nanotubes. These include fibres203, films204 and hydrogels205, the formation
of which usually requires a surfactant or organic solvent206 to suspend the highly
insoluble carbon nanotubes135. The addition of surfactants has detrimental effects
on the electrical properties of the final electrodes and whilst organic solvents
provide an alternative dispersing media to surfactants, these have limitations in
terms of being inappropriate to use with biological systems207. Therefore it would
be highly beneficial for carbon nanotubes to be suspended in an aqueous solution,
without the need for such surfactants or organic solvents.
Recently, graphene has been praised as a new nanomaterial with the potential for
large scale production in aqueous media177. Graphene oxide (GO) is a highly
dispersible form of graphene due to its surface functionalities, with chemical
reagents208, high temperatures209 and electrochemical methods widely used to
reduce GO into a more conducting form with less basal plane oxygen-containing
functionalities210. Of significant importance is that the conducting reduced GO
(rGO) is stable in an aqueous dispersion and as such has the versatility of being
amenable to a range of solution processing techniques.
Graphene oxide-carbon nanotube (GO-CNT) composites have been the subject of
significant research interest with studies aimed at characterising the enhanced
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electrical properties211,199,212,213 of the composites or modelling the complex
interaction between the two allotropes of carbon214,215,216. It has been shown that
graphene has a higher electroactive surface area than carbon nanotubes212,217,218.
However, carbon nanotubes can effectively bridge219 graphene sheets resulting in
improvements in sheet resistivity199 for composite materials. It is still unclear as to
how graphene and CNTs interact on a molecular level in solution with some
reports suggesting the graphene sheets wrap around carbon nanotubes217 while
others hypothesise that carbon nanotubes inhibit the aggregation of suspended
graphene sheets212. The formation of Schottky barriers play a significant role in
determining the electrical properties of the final composite, regardless of what type
of graphene or carbon nanotube system is being employed219,220. To date the
reduction

of

GO-CNT

composites

has

been

performed

chemically208,

electrochemically194 or through heat treatment217,221, and in most cases this
reduction is implemented after electrode fabrication or in the presence of stabilising
agents such as polyethyleneimine or hydrazine222.
Carbon nanotubes have been extensively used in electrode structures for enzymatic
biosensors223,148,143 and biofuel cells106,142,100. The high aspect ratio and good
electrical properties makes them ideal candidates for use with bio-catalysts due to
their ability to access the enzyme’s active site and facilitate direct electron transfer
(DET)148,151. Graphene has also received some attention in this regard141,146.
However, to our knowledge composite graphene-carbon nanotube electrodes have
not been investigated for use in biological applications. Essentially, rGO’s ability to
act as an effective dispersing agent for the MWNTs and the enzyme in an aqueous
system allows the fabrication of novel bioelectrodes.
Organic solvents have been used to stabilise rGO-CNT suspensions199, however,
these systems are unsuitable for biological applications unless the solvent is
completely removed before biological entities are incorporated. It is therefore useful
to have a technique that allows for biologically relevant components to be
integrated during the solution-processing phase of electrode fabrication. It has been
extensively shown that cells224,225 respond to electrical stimuli and enzymes146 can
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be electrically wired to conducting materials, and as such achieving an intimate
connection between the biological entity and the materials is critical for the
performance of advanced medical devices. The ability to solution process
dispersions of conducting materials together with biological entities could facilitate
this intimate connection. Additionally, these dispersions allow for existing solution
phase fabrication techniques, including fibre fabrication for nerve regeneration226
and printable implantable electronics227, which could open the door to a new range
of bioelectrodes.

4.2 Chapter aims
In this chapter a novel method for the successful formation of aqueous rGOMWNT dispersion without the use of other stabilising agents is reported. In
addition, it is shown that it is possible to incorporate the enzyme glucose oxidase
(GOx) into the dispersion without compromising the biological activity of the
enzyme. The electrodes formed from these rGO-MWNT-GOx solutions achieve
very efficient DET signals and outperform many of the previously reported rGO
and MWNT based enzyme electrodes in terms of specific catalytic current (see
Table 1.4). An aqueous based “one-pot” processing strategy for the development of
biologically compatible carbon electrodes will have a profound effect on the
development of advanced electrodes for biomedical applications.

4.3 Experimental
4.3.1 Materials
Graphene Oxide (GO) was synthesized from graphite by a modified Hummers
method and suspended in MilliQ water 175176 before being chemically reduced using
hydrazine, as described in Chapter 2. Multi-walled carbon nanotubes (MWNT)
(purchased from NanoAmor at 99.9% purity) were used as received without further
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treatment. Purified glucose Oxidase (GOx) was used as outlined in Chapter 2. A 1
mg/ml solution of poly(ethyleneimine) (SigmaAldrich) was prepared in an aqueous
0.5 M solution of NaCl (SigmaAldrich). A 1 M solution of D-(+)-glucose in PBS
(pH 7.4, 50 mM) was prepared and allowed to mutarotate for 24 hours at 4˚C before
use109. Glassy Carbon Electrodes (GCE) with a diameter of 3 mm were used for all
experiments.

4.3.2 Dispersion properties
4.3.2.1 Dispersion preparation
MWNTs were weighed out and added to 10 mL of GO (0.5 mg/mL) in water with
the following weight% of MWNTs; 0 %, 10 %, 33 %, 50 %, 85 %, 90 % and 100 %.
In order to suspend the MWNTs effectively, the GO-MWNT solution was
subjected to horn sonication (Branson Digital Sonifier – 500W) for 1 hour (30%
amplitude, 2 sec ON, 1 sec OFF) in an ice bath to form a series of stable composite
dispersions. Each dispersion was chemically reduced by taking 10 mL of composite
dispersion and adding 10 mL of MilliQ water, 10 µL of 35 wt% hydrazine and 70 µL
of 28 wt% ammonia solutions. The mixture was then shaken vigorously for 5
minutes and left for 1 hour at 95˚C for reduction to take place. The final
concentration of rGO was 0.25 mg/mL after reduction and the weight fraction of
MWNTs for each sample is given by the following labelling system throughout the
rest of this thesis. rGO-MWNT10 represents a rGO-MWNT dispersion containing
10 weight% MWNTs or rGO-MWNT90 to represent a rGO-MWNT dispersion
containing 90 weight% MWNTs and so on. Additionally, when the label rGO is
used it signifies that no MWNTs are present and similarly, when MWNT is used it
signifies that no rGO is present.
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4.3.2.2 Dispersion characterisation
4.3.2.2.1 X-ray photoelectron spectroscopy
X-ray photoelectron spectroscopy (XPS) was used to confirm that the chemical
reduction of graphene oxide (GO) to reduced graphene oxide (rGO) was successful
in the presence of carbon nanotubes. Deconvolution of the C1s peak showed
characteristic binding energies for the different elemental states and gave
information on the extent of chemical reduction for each sample.

4.3.2.2.2 Optical microscopy
A drop of each rGO-MWNT dispersion was cast onto a glass slide with a glass
cover sheet placed on top for qualitative optical analysis using a Leica optical
microscope. To test if the dispersions remained stable when enzyme is present, the
GOx loading used for electrode fabrication was added to each dispersion and
analysed optically as described above. An opaque white plastic sheet was placed
underneath the glass slide to achieve a representative image since it was difficult to
distinguish dispersion features with the microscope stage behind the sample.

4.3.2.2.3 Scanning electron microscopy
Scanning electron microscopy (SEM) was performed using the JEOL Cold Field
Emission Gun Scanning Electron Microscope. The SEM was operated at an
accelerating voltage of 5 kV and secondary electron images were taken with a semi
in-lens detector at a working distance of 8 mm and a spot size setting of 8. Samples
were prepared by drop casting the dispersions onto aluminium foil and imaged from
directly above.

108 | P a g e

Chapter Four | Reduced graphene oxide-carbon nanotube composite bioelectrodes
!
4.3.2.2.4 Zeta potential and particle size analysis
Zeta potential and particle size analysis was performed on each dispersion before
and after the addition of enzyme using the Zetasizer Nanoseries (Malvern
Instruments). A dilute sample was added to a universal dip cell quartz cuvette and
the sample was analysed. Zeta potential studies did not show significant variation
or trend between samples and this is attributed to relatively good dispersion
properties. The data presented in this chapter deals with particle size analysis only.

4.3.2.2.5 Fourier transform infrared analysis (FTIR)
The dispersions were dried at 80ºC under vacuum overnight before FTIR analysis.
An IRPrestige-21 Fourier transform infrared spectrophotometer (Shimadzu) was
used to analyse the functional groups for each sample. KBr powder was used and
the scanning was performed in the range of 4000–400 cm−1.

4.3.3 Electrode properties
4.3.3.1 Electrode fabrication
Glassy carbon electrodes (GCE) of 3 mm diameter were polished using a series of
alumina powder slurries with various particle sizes, namely 1 µm, 0.3 µm, 0.1 µm
and 0.05 µm. The electrodes were then subjected to bath sonication in MilliQ water
for 10 minutes, before being dried by a nitrogen stream. 10 µL of the above rGOMWNT dispersions was added to 10 µL of purified GOx (0.5 mg/mL in 50 mM
PBS, pH 7.4 – unless otherwise stated) and gently mixed before drop casting 5 µL
onto a clean GCE. These electrodes were placed in the refrigerator at 5˚C and left
until dry before a final layer of poly(ethyleneimine) (PEI) (5 µL of 1 mg/mL in 0.5
M NaCl) was drop cast to entrap the enzyme, and again allowed to dry at 5˚C.
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4.3.3.2 Electrode characterisation
4.3.3.2.1 Electrochemical impedance spectroscopy
A series of electrodes were prepared in a similar fashion to section 4.3.3.1 for
electrochemical impedance spectroscopy (EIS) analysis, however the rGO-MWNT
aqueous dispersions were drop cast without the GOx and PEI layers. Once dry, the
electrodes were electrochemically tested in 10 mM ferrocenemethanol (FcMeOH)
in PBS (50 mM, pH 7.4) to characterise the charge transfer resistance of each rGOMWNT composition. EIS was performed at an oxidising potential for FcMeOH
(+0.28V vs. Ag|AgCl) in the frequency range 0.1 to 100000 Hz at an AC amplitude
of 5 mV.

4.3.3.2.2 Catalytic response
All enzyme electrochemistry tested with glucose in solution (henceforth referred to
as the catalytic response), was performed at 37˚C with a PBS (pH 7.4, 50 mM)
supporting electrolyte under a blanket of argon gas. Initially the dissolved oxygen
was removed from the electrolyte by bubbling argon for at least 15 minutes. Cyclic
voltammetry was used to characterise the electrodes both with and without enzyme
for 20 cycles at 50 mV/s, which was sufficient to achieve stable electrochemistry
before the sweep rate was dropped to 10 mV/s for steady state analysis. The
electrochemical cell used was introduced in Chapter 2 (2.2.3.2) and the specific
conditions will be outlined in the results and discussion of this chapter.
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4.4 Results and discussion
4.4.1 Dispersion and electrode properties
4.4.1.1 X-ray photoelectron spectroscopy
MWNTs were dispersed by sonication in an aqueous dispersion of GO prior to the
reduction process. GO-MWNT samples were characterized by X-ray photoelectron
spectroscopy (XPS) before and after hydrazine reduction to quantify the ratio of
carbon to oxygen containing groups in the final dispersion. It is evident in Figure
4.1 (a) and (b) that there is a significant decrease in C-O content (286 eV) relative to
the C=C/C-C peak (284 eV) after chemical reduction of a GO dispersion228,192. This
shows the extent of oxygen defects removed from the GO sheets that contribute to
the number of sp2 bonded carbon sites, directly affecting the electrical resistivity of
the material229,230. The peak at 288 eV corresponds to C=O groups, which are the
remaining oxygen containing groups responsible for keeping the rGO dispersion
electrostatically stable177.
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Figure 4.1 XPS data for GO samples before (a) and after (b) hydrazine reduction.

The same characterisation was performed on a GO-MWNT50 dispersion (data not
shown), however, the carbon-carbon peak at 284 eV dominated the spectra and the
carbon to oxygen ratio was difficult to determine. Using XPS analysis it is
inconclusive whether reduction of GO occurs in the presence of MWNTs.

4.4.1.2 Fourier transform infrared analysis
FTIR analysis (Figure 4.2) suggests that chemical reduction in fact does occur with
the disappearance of the broad carboxylic acid band at ~ 3100 cm-1 after reduction
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for samples with and without MWNTs present, as well as the feature at 1724 cm-1
which corresponds to a C=O stretching vibration peak that also diminishes after
reduction231. The disappearance of the oxygen containing group peaks indicate that
chemical reduction has occurred in the presence of MWNTs.
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Figure 4.2 FT-IR spectra of GO, rGO, GO-MWNT10 and rGO-MWNT10.

4.4.1.3 Electrochemical impedance spectroscopy
It has been reported177 that rGO has a higher conductivity than GO, and therefore,
electrochemical impedance spectroscopy (EIS) was used to investigate the electrical
properties (namely the charge transfer resistance - Rct) of films formed from GOMWNT dispersions before and after the chemical reduction treatment. A decrease
in the Rct after chemical reduction of a film formed from a GO-MWNT dispersion
indicates that the GO has been reduced to its more conducting rGO form. For the
GO dispersions with 0 wt% MWNTs, the Rct before and after chemical reduction
was 166 ± 31 Ω and 108 ± 2 Ω, respectively. This indicates that rGO is
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significantly more conducting than GO suggesting that reduction of GO has
occurred. Figure 4.3 shows that for all wt % MWNTs, the rGO samples exhibit a
lower Rct compared to the same samples before reduction, suggesting that reduction
has occurred in the presence of MWNTs and highlighting the fabrication of a
conducting composite dispersion. There is a notable decrease in Rct before reduction
(GO profile, Figure 4.3) as the amount of MWNTs was increased from 0 wt% to 33
wt% due to the MWNT’s inherently high conductivity. There is no statistical
difference for samples that have higher MWNT contents than 33 wt% in this data
set, suggesting the percolation threshold has been reached.
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Figure 4.3 Charge transfer resistance as a function of MWNT loading before (GO) and after
(rGO) chemical reduction.

4.4.1.4 Scanning electron microscopy & optical microscopy
The reduced dispersions were drop cast onto aluminium foil for SEM analysis
(Figure 4.4). The rGO (Figure 4.4 a) exhibits the characteristic wrinkle features of
drop cast graphene. As the MWNT content is increased from rGO-MWNT10
(Figure 4.4 b) through to rGO-MWNT90 (Figure 4.4 e), the MWNT features
become dominant with some rGO wrinkles still visible. For MWNT samples
(Figure 4.4 f), characteristic features of entangled MWNTs are evident and it seems
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to be a less homogenous film compared to when rGO is present. The insets in
Figure 4.4 are the optical micrographs of the respective dispersions used to form
the films for SEM. The optical micrographs demonstrate the quality of each
dispersion ratio and it is evident that rGO is very effective as a dispersing agent
given that when no rGO is present (inset Figure 4.4 f) MWNT aggregation is
obvious. It was also observed that the qualities of the dispersions before and after
chemical reduction were identical thus highlighting the attractive nature of this
rGO-MWNT dispersion synthesis route.
(a)

(b)

(c)

(d)

(e)

(f)

Figure 4.4 SEM micrographs of rGO-MWNT composite dispersions at various weight %
MWNTs drop cast on to Al foil. Inset: Optical images for each dispersion. White scale bars
represent 1 µm for SEM images and black scale bars represent 1 mm for optical images. (a)
rGO, (b) rGO-MWNT10, (c) rGO-MWNT33, (d) rGO.MWNT85, (e) rGO.MWNT90 and (f)
MWNT.

The dispersion properties were also characterised by SEM and optical microscopy
after the addition of the glucose oxidase (GOx) enzyme to the dispersions (Figure
4.5). The images in Figure 4.5 show the films formed from rGO-MWNT10 with (a)
and without (b) the addition of GOx and rGO-MWNT90 with (c) and without (d)
GOx addition. It is evident in both samples that rGO and MWNTs form a
homogenous film (Figure 4.5 a and c) and when the enzyme is present, the
biological entity is incorporated into the homogenous film (Figure 4.5 b and d).
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Carbon nanotube features are more predominant in the rGO-MWNT90 sample, as
expected, and show thorough interaction between the carbon nanomaterials and the
enzyme with MWNTs protruding through the characteristic features of GOx. The
optical micrographs (inset Figure 4.5) show that dispersion quality is not sacrificed
when enzymes are present. These results give some indication that firstly, the
enzyme does not destabilize the dispersion, and secondly, that there seems to be
extensive physical interaction between the enzyme and the carbon materials which
may facilitate DET.
(a)

(b)

(c)

(d)

Figure 4.5 SEM micrographs of rGO-MWNT and rGO-MWNT-GOx composite dispersions
drop cast on to Al foil. Inset: optical images for each dispersion. White scale bars represent
200 nm for SEM images and black scale bars represent 1 mm for optical images. (a) rGOMWNT10, (b) rGO-MWNT10-GOx, (c) rGO-MWNT90 and (d) rGO-MWNT90-GOx.

4.4.1.5 Zeta potential and particle size analysis
Zeta potential and size analysis was carried out on rGO dispersions of various
weight % MWNTs and each demonstrated similar and reproducible zeta potentials
averaged at -45.6 mV, all within an average standard deviation of 9.6 mV. Zeta
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potential values more negative than –30 mV are considered to represent sufficient
electrostatic repulsion to ensure a stable dispersion232. There was no trend in zeta
potential in relation to the amount of MWNTs present, which indicates the entire
rGO-MWNT concentration range represents electrostatically stable systems.
Particle size analysis gives more quantitative information given that through
optical analysis the MWNT sample was obviously not a stable dispersion (inset
Figure 4.4 f). The particle size distribution analysis showed good consistency for all
samples from rGO through to rGO-MWNT90, which had average polydispersity
index (PDI) values for day 1 and day 50 of 0.27 ± 0.04 and 0.32 ± 0.06, respectively
(Table 4.1). These relatively large PDI values arise from the nature of the analysis
which assumes spherical particles, with an ideal spherical, narrow monomodal
system having a PDI < 0.1. The dispersions, however, are composed of relatively
flat sheets of rGO and cylindrical particles of MWNTs so the following particle size
data analysis is only relevant for comparison within this experiment. It is evident
that there is a higher PDI value for the 50-day particle size analysis compared to
day 1 which indicates there is an increase in particle size distribution and may
indicate the onset of dispersion destabilisation, however, on analysis of the number
average particle size there is no statistical difference between day 1 and day 50.
There is no observable evidence of agglomeration after 50 days of standing and in
conjunction with particle size analysis this suggests that the dispersions, where
rGO is present (i.e. rGO to rGO-MWNT90), are stable for over 50 days. The poor
dispersion quality of the MWNT sample described previously was confirmed
through particle size analysis, which showed a PDI value of 1.000 from day 1. This
result highlights the necessity of rGO to act as a dispersing agent for the highly
insoluble MWNTs.
There is an interesting drop in nominal number average particle size between rGO
and rGO-MWNT10 at both day 1 and day 50. It is unclear as to why the particle
size is larger for rGO alone but may be attributed to the way the graphene sheets
and the CNTs interact in solution, which is still a topic of debate in the literature.
Some authors suggest the sheets can wrap around the CNTs217 while Shin et al.
suggest the CNTs are attached to the edges and surfaces of the graphene sheets233.
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When GOx was added to the rGO-MWNT composite dispersions on day 1 there
was no statistical variation in number average particle size between before and after
enzyme addition, 180 ± 80 nm and 164 ± 31 nm, respectively. This indicates that
enzymes do not cause instabilities in the rGO- MWNT dispersions.
Nominal number average particle size and PDI data collected at day 1 and
day 50 for the various compositions of rGO and MWNTs
Table 4.1

Day 1
Dispersion

Nominal

Day 50
PDI

Nominal

Number

Number

Average Particle

Average Particle

size (nm)

size (nm)

PDI

rGO

339 (± 172)

0.26

385 (± 220)

0.33

rGO-MWNT10

119 (± 71)

0.35

123 (± 66)

0.28

rGO-MWNT33

133 (± 68)

0.26

170 (± 105)

0.38

rGO-MWNT50

152 (± 78)

0.27

201 (± 120)

0.36

rGO-MWNT85

168 (± 86)

0.26

170 (± 80)

0.22

rGO-MWNT90

166 (± 79)

0.23

226 (± 138)

0.38

1603 (± 1603)

1.00

3279 (± 3279)

1.00

MWNT

4.4.2 rGO-MWNT-GOx electrode fabrication and characterisation
The aqueous nature of the rGO-MWNT dispersions makes them amenable to
incorporation of enzymes for use in biological applications. Graphene 146 and carbon
nanotubes148 have been investigated separately for their ability to facilitate direct
electron transfer (DET) in enzymatic systems. Here we test the validity of using a
composite of these materials to achieve an enhanced enzymatic catalytic response.
In order to investigate the ability of the composite electrodes to facilitate DET with
immobilised GOx, the enzymes were mixed in the given composite dispersion and
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drop cast onto a polished GCE, immobilised with a thin layer of PEI and
electrochemically tested in PBS (pH 7.4, 50 mM) at 38˚C under an argon blanket.
The pH of all the rGO-MWNT dispersion was measured to be 10.0 and it was
unknown if the GOx would remain in its active state in films formed from the basic
dispersions. We have observed a significant decrease in the enzyme activity when
moving from a pH of 7 to 10 (Figure 3.8 a). This decrease in activity is attributed to
a change in the enzyme structure117. Cyclic voltammetry (Figure 4.6) performed on
these rGO-MWNT-GOx electrodes in PBS (pH 7.4) clearly show a pair of well
defined redox peaks with anodic peak (Epa) and cathodic peak (Epc) at -455 mV and 470 mV respectively, corresponding to 15 mV for ΔEp and a E° of −0.463 V (vs.
Ag|AgCl). The E° value of GOx incorporated into the rGO-MWNT electrode is in
accordance with the typical characteristics of GOx electrochemistry in neutral pH
solution234. This result demonstrates that despite GOx being incorporated into an
rGO-MWNT dispersion at pH 10, it still maintains its electroactivity in films
formed from these dispersions. When GOx is drop cast directly onto GCE (i.e., no
nanomaterial present) no peaks are evident (Figure 4.6 d) which is to be expected
as many publications have investigated the relationship between carbon
nanomaterials and their capacity to facilitate DET compared to bare electrodes with
no nanomaterials143,124. Figure 4.6 shows other cyclic voltammogram profiles for
rGO, rGO-MWNT90 and MWNT bioelectrode samples (Figure 4.6 a, b & c,
respectively). A large capacitive response is observed for the rGO containing
samples, attributed to graphene’s high capacitance192. The ability to communicate
with immobilised enzymes is evident due to the oxidation and reduction peaks,
which indicate the oxidation of GOx (FAD) to GOx (FADH2) and its subsequent
reduction. The MWNT sample shows a slightly more resistive response and less
defined redox peaks, contrary to other literature where an obvious GOx redox
response144 on CNT drop cast films is evident. This may be the result of the
unstable nature of the dispersion with MWNTs preferring to agglomerate together
rather than interact with the enzyme, however, it is still unclear.
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The stability of the rGO-MWNT10-GOx electrodes were characterised for a period
of time under constant potential cycling at 10 mV/s in PBS (50 mM, pH7) between
-0.7 to -0.2 V (vs. Ag|AgCl). It was evident that without the immobilizing PEI
layer being present the electrode lost 100% of its DET signal after 1 hour, however,
when a PEI layer is used to secure the components, the electrode retains 73% of its
anodic peak height after 4 hours of cycling. This result highlights the importance of
the PEI layer to keep the enzyme immobilised.

2

(a)
(b)

1.5
1

(c)

I (µA)

0.5

(d)

0
-0.5
-1
-1.5
-2
-2.5
-3
-0.8

-0.7

-0.6

-0.5

E (V)

-0.4

-0.3

-0.2

-0.1

Figure 4.6 Cyclic voltammograms of electrodes (a) rGO-GOx (b) rGO-MWNT90-GOx, (c)
MWNT-GOx and (d) GOx immobilised with PEI with no carbon nanomaterials present, in
PBS at 37˚C under argon at a scan rate of 10 mV/s (vs. Ag|AgCl).

Enzymatic catalytic current can be analysed through the addition of glucose to the
PBS solution and monitoring the change in anodic peak (Ipa) height (after
subtraction of the appropriate capacitive background current) (Figure 4.7 a). This
data provides information on the effectiveness of each composite electrode to
facilitate DET, with larger changes indicating enhanced electron transfer efficiency
from the FAD redox centre of the GOx to the composite electrode material. The
catalytic current is plotted for each composite electrode (Figure 4.7 b) with
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significant variation associated with the higher weight % MWNT samples and
more reproducible catalytic currents recorded for low weight % MWNT. The
variable response with increasing MWNT content can be attributed to the increase
in film heterogeneity, which may be detrimental to the direct wiring of GOx.
Catalytic analysis was not possible for the MWNT sample since the Ipa was
undetectable.
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1
0.5
0
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-1
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PBS + 150mM Glucose
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-0.6

-0.5
-0.4
E (V)

-0.3

-0.2

-0.1

(b) 0.06
0.05

!I (µA)

0.04
0.03
0.02
0.01
0
0

10

33

50

85

90

wt % MWNT
Figure 4.7 (a) An example of an increase in Ipa in response to 150 mM glucose in solution for
an rGO-MWNT90-GOx sample vs. Ag|AgCl and (b) the catalytic current as a function of wt%
MWNTs.
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The observed catalytic responses presented in Figure 4.7 indicate that the glucose
can access the enzyme and that this enzyme is electrically wired to the electrode.
These values can be directly compared to analyse the efficiency of each rGOMWNT ratio to facilitate DET. In this case the largest reproducible catalytic
response came from the rGO-MWNT10 composition, although no observable
trends evolved as a function of the rGO-MWNT ratio. The rGO-MWNT10 system
was subsequently used to determine the optimal GOx loading in terms of current
generated per amount of GOx used (µA/µg). The average specific catalytic current
for our best performing electrode (rGO-MWNT10-GOx) composite, with an
optimised enzyme loading of 0.002:1 with respect to rGO (i.e., GOx: rGO), was 72
µA/µg GOx at 50 mV/s. Other literature values for DET systems to date, using
electrodes prepared using the same drop cast method, are identified in Chapter 1
(Table 1.4) and some of the more efficient systems report 25 µA/µg of GOx for a
graphene-GOx composite138, 1 µA/µg of GOx for graphene quantum dot-GOx
electrodes165, 0.5 µA/µg of GOx for a MWNT/CTAB/GOx/Nafion composite124
and 0.12 µA/µg GOx for a Graphene Oxide/Chitosan/GOx electrode184, at the
same scan rate. This equates to approximately a 3-fold increase in efficiency for the
electrodes prepared in this manuscript compared to the closest literature value.
The rGO-MWNT90-GOx and rGO-GOx samples measured 65 and 64 µA/µg of
GOx, respectively, also demonstrating an enhanced specific catalytic performance.
The significant improvement in specific catalytic current for the rGO-MWNT
composite electrodes compared to other literature values can be attributed to the
higher activity achieved through enzyme purification and the ability of the
composite to facilitate efficient direct electron transfer.

4.5 Conclusions
We have optimised the process of fabricating stable solutions of highly conducting
rGO and MWNTs in an aqueous system, without the need for additional stabilising
agents. Dispersion quality was studied before and after the addition of the enzyme
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glucose oxidase, and it was determined through SEM, optical microscopy, zeta
potential and size analysis that the dispersions remain stable for all rGO-MWNT
composites with MWNT content between 10 and 90 wt%. MWNTs alone did not
form stable dispersions under any conditions due to their extremely low solubility
in water. This result highlights how effectively rGO acts as a dispersing agent for
the otherwise insoluble MWNTs. The optimal bioelectrodes were determined to be
rGO-MWNT10-GOx which produced the largest reproducible catalytic response
for the compositions tested, and upon optimisation of enzyme loading proved to
out-perform other literature values by a factor of approximately 3 for specific
catalytic current generated. The exceptional specific performance of the electrodes
is attributed to the efficiency of the composite materials to facilitate direct electron
transfer and the high specific activity of the purified enzyme. The ability to fabricate
aqueous dispersions of highly conducting materials in conjunction with biological
entities, like enzymes, provides opportunities for implementing other solution
processable techniques to form a range of bioelectrodes
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5. Controlled drug delivery from
polypyrrole: powered by enzymebased bioelectrodes
5.1 Overview
This chapter investigates the controlled release of therapeutic drugs from
polypyrrole films, powered by the rGO-MWNT-GOx-PEi bioelectrode developed
in Chapter 4, by galvantically coupling the two materials. A long-term aim is to
produce an implantable device for localised controlled release of therapeutic drugs
within the brain to treat epilepsy. The galvanic device presented in this chapter
represents a proof of concept prototype for such a purpose.

5.2 Introduction
As discussed in chapter 1, the development of controlled drug delivery devices is an
active area of research since many drugs currently on the market when
administered by traditional methods, such as orally or intravenously16,235, can cause
severe side effects. In the treatment of epilepsy for example, the use of
Fosphenytoin (FOS) is restricted because of debilitating side effects, but otherwise
it is an incredibly effective anti-convulsant drug. When FOS is delivered
intravenously, 15-20 mg FOS/kg57 weight (of the patient) is used to supress a
seizure. This is delivered systemically around the whole body so the amount of FOS
reaching the brain may be different to the blood stream concentration. Walton et al.
suggest that phenytoin experiences rapid entry into the brain due to high lipid
solubility, rapid dissociation from the injection serum proteins and substantial
binding to multiple brain constituents, all of which cause the drug to be maintained
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within brain tissue and establish a higher concentration than the rest of the
blood236. As such, a novel method for its delivery could see it used more widely and
effectively.
A promising area of controlled drug delivery relies on the intrinsic properties of
conducting polymers and their ability to change oxidation state under a given
electrical stimulus. Polypyrrole (PPy) will be discussed in this chapter and Scheme
1 (a) shows the process of dopant (A-) incorporation during electrochemical
polymerisation. Scheme 1 (b) shows the release of this dopant when the oxidation
state of the polypyrrole backbone is changed. It has been shown that at a reducing
potential the anionic dopant is expelled from the conducting polymer structure, as
discussed in Chapter 1 (1.4.5). Significantly, a wide range of molecular dopants can
be incorporated into a polypyrrole film including antibodies, enzymes, whole living
cells, growth factors and of relevance here, therapeutic drugs237,51.
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Scheme 1 (a) Synthesis of polypyrrole showing the incorporation of the dopant A-, and (b)
release of the dopant A- when the oxidation state of the polypyrrole is changed. Adapted from
Ref51

The therapeutic drugs studied in this chapter were dexamethasone-21-phosphate
disodium salt (DEX) and Fosphenytoin (FOS). Their chemical structures are shown
in Figure 5.1. These particular drugs were specifically chosen due to the presence of
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the phosphate group, which imparts a negative charge on the molecule making
them suitable to act as a dopant in the electrochemical polymerisation of
polypyrrole56, effectively taking the place of A- in Scheme 1.
(a)

(b)

Figure 5.1 Chemical structure of (a) Dexamethasone-21-phosphate disodium salt and (b)
Fosphenytoin.

DEX reduces inflammation in the central nervous system while FOS works as a
strong anti-convulsant. Both of these drugs have relevance in the desired
application, given that a brain implant will cause some trauma during implantation
and a drug such as DEX could be locally administered to reduce an inflammatory
response. Additionally, reducing seizure activity from within the brain may be
achieved by the controlled delivery of FOS directly to the target area.
The incorporation of therapeutics drugs into polypyrrole, including DEX, has been
extensively characterised in recent literature56. To the author’s knowledge, this is
the first report of using FOS as a dopant for a conducting polymer. Studies have
shown that a nanostructured electrode architecture can enhance the release of drug
compared to a flat electrode substrate86,74. The release can also be tailored
according to the stimulation protocol used. Svirskis et al. show the difference in the
release of para-toluene sulfonic acid (PTS) from a polypyrrole film between
applying a constant oxidising potential, a constant reducing potential and a pulsed
potential protocol. The results are shown in Figure 5.2 and demonstrate that a
substantial amount of PTS is release under a pulsed program, however the biggest
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difference was observed between applying a constant oxidising or reducing
potential.

Figure 5.2 Para-toluene sulfonic acid release from PPy films under the application of
different stimulation protocols, where the 120s and 500s labels correspond to the time frame
of the experiment. Adapted from Ref83

Of interest is the increased amount of PTS released when the sample was held in a
reduced state. This confirms other literature findings that suggest that during
reduction the negative charge induced on the polymer backbone would generate
repulsive forces on the anionic dopant ions and cause them to be expelled from the
material238. The contraction and swelling of polypyrrole upon oxidation and
reduction due to the movement of ions and water molecules is also well documented
and contributes to the release of the dopant molecules51. Since the above
mechanisms occur concurrently, it is difficult to distinguish their relative
contribution to the release of the dopant, which explains why in Figure 5.2 dopant
is still released during oxidation and pulsed stimulation. These are the basic
mechanistic principles behind the data presented in this chapter. It is, however,
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widely accepted that electrical stimulation greatly enhances the release of dopant
molecules compared to unstimulated (passive) release61,54,90.
Although a significant amount of research has gone into characterising the release
of therapeutic drugs from conducting polymer electrodes with the promise of
completely implantable controlled drug delivery devices, few studies address the
issue of supplying power to the device. Some studies that investigate conducting
polymer coatings on already established devices, like the cochlear ear implant or
deep brain stimulation electrodes, claim the use of the existing power supply to
command the controlled release. Meanwhile, Moulton et al. and Ru et al. separately
investigated galvanically coupling a magnesium electrode to a polypyrrole film so
that when the Mg rapidly corrodes it charges the polymer and instigates
release86,116. It was observed however, that it was difficult to stop the decomposition
of the Mg electrode once initiated, and for the ultimate application of controlled
drug delivery from CPs, it is desirable to have the ability to access the switchability
of the conducting polymer system.
Traditional power sources for implantable devices largely include Lithium battery
technologies239. Currently, Li batteries power cardiac pacemakers and research is
invested in prolonging the life of the batteries to minimise invasive battery
replacement surgery. Although the current technology is adequate, there is a desire
to avoid unnecessary surgery and develop novel systems to power implantable
devices from inside or outside the body. Interest in wireless power transmission to
power implantable devices240 has gained momentum in recent years with cases
reported where blood pressure sensing implants241 and small silicon drug reservoir
devices242 have been powered wirelessly. There has also been some interest in
human body energy scavenging where, for example, energy is harvested using
piezoelectric generators that take advantage of human body movements to power
implanted devices243,244. Although promising, there is still some way to go to make
these technologies a feasible reality.
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Biofuel cells have been investigated for implantable power source applications for
many years due to their ability to operate off blood sugars and dissolved oxygen
already present and naturally replenished in the human body, as discussed in
Chapter 1. Low power density limitations have prohibited biofuel cells from
practical application128,245 and generally the limiting factor in the biofuel cell is the
cathodic electrode, which is extremely inefficient246. The anodic side of a biofuel
cell, however, has proven to be very efficient in converting reactants to products
and harnessing the electrons produced in the process. I have shown this for the
rGO-MWNT-GOx-PEi electrodes characterised in Chapter 4. It is the aim of this
chapter to utilize the catalytic output of the bioelectrode developed in Chapter 4 to
power the drug release from a polypyrrole film by galvantically coupling the two
components, much the same as the studies that used magnesium corrosion to power
drug release.

5.3 Experimental
5.3.1 Materials
Pyrrole monomer (Merck, > 97%) was distilled prior to use and stored under
nitrogen at -20°C. Dexamethasone-21-phosphate disodium salt (DEX, SigmaAldrich, >98%), para-toluene sulfonic acid (PTS, Merck) and Fosphenytoin (FOS,
Sigma, ≥98%) were all used as received and stored at 4°C. Phosphate buffer
solution was prepared in MilliQ water at a concentration of 50 mM (pH 7.4).
Enzyme bioelectrodes were used as characterised in Chapter 4 and the rGOMWNT-GOx-PEi (10%) composition with a GOx loading of 1.25 µg was used for
all experiments. Gold mylar (CP Films Inc., USA) was used as a substrate for
polymer growth and was washed in three steps with detergent water, ethanol and
finally milliQ water, before being dried using a nitrogen stream.
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5.3.2 Electropolymerisation
Polypyrrole films were electrochemically grown onto gold mylar electrodes by
galvanostatic deposition using an eDAQ potentiostat/galvanostat with eDAQ
Chart software (v2.0.7). The exact working area of the gold mylar electrode was
controlled using adhesive tape. 0.2 M pyrrole was prepared in MilliQ water with
PTS, DEX or FOS acting as a dopant. Table 5.1 outlines the optimised growth
parameters used for each dopant. Justification for the different growth parameters
will be outlined in the results and discussion section.
Table 5.1 Growth conditions for polypyrrole films with various dopants.

Dopant

PTS

DEX

FOS

Concentration (mM)

50

5

2.5

Electrode Area (cm2)

2

2

0.125

Current Density (mA/cm2)

2

0.5

0.8

Charge Passed (C/cm2)

0.18

1

0.24

Approx. Growth Time (mins)

1.5

33

5

During deposition, the potential was monitored vs. a Ag|AgCl reference electrode
to ensure the conducting polymer film was grown in the correct potential range.
Typically, polypyrrole grows at approximately +0.8 V however, if the potential
exceeds +1.1 V the film’s electrical conductivity will be sacrificed due to over
oxidation of the polypyrrole247. If the potential exceeded +1.1 V the experiment was
terminated and the solution was refreshed before proceeding with a new electrode.
For the PPy-FOS samples it was critical to replenish the growth solution between
each electrode to maintain consistency and sample quality, this will be discussed in
results and discussion (5.4.2). The polymerisation solution for PTS and DEX was
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degassed for 15 minutes with nitrogen before growth; however, the FOS growth
solution was not degassed due to the small volume (as restricted by the price and
quantity of the drug).
After growth, all films were washed extensively with milliQ water to remove excess
monomer and loosely bound dopant. For the PPy-PTS and PPy-DEX films the
samples were cut in half to form two 1 cm2 electrodes, and the PPy-FOS samples
were also halved to make two 0.0625 cm2 electrodes.

5.3.3 Drug release characterisation
5.3.3.1 Cyclic voltammetry
Initially, the samples were characterised through cyclic voltammetry to identify the
oxidation and reduction potentials of the drug loaded conducting polymer films.
Fresh samples were used for each experiment and the films were not re-used for
release experiments after CV analysis. The specific parameters for each experiment
will be identified when the data is presented; typically, a three-electrode
electrochemical cell was established using a platinum mesh counter electrode and a
Ag|AgCl

reference

electrode

in

PBS

(50

mM,

pH7.2).

An

eDAQ

potentiostat/galvanostat was used with eChem software (v2.0.7) for analysis.

5.3.3.2 UV-visible spectroscopy – a method for drug detection
UV-visible spectroscopy (UV-Vis) is a quantitative technique used to determine the
concentration of an analyte in solution, as described in Chapter 2 (2.2.1). The
release of DEX or FOS from polypyrrole films was monitored using UV-visible
spectroscopy. Standard calibration solutions of DEX and FOS were measured and
the linear range for each was determined to be 1 to 250 µM and 0.5 to 50 µM,
respectively, at their relevant wavelengths (given in Table 5.2). The standard
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curves were used to calculate the concentration of drug released during
experimentation and the results were subsequently converted into the mass of drug
released.

5.3.3.3 In-situ UV-Vis release experiments
A three-electrode cell was designed to fit inside the UV-Vis chamber in order to
characterise the release of drugs from the polypyrrole films during electrochemical
stimulation. The real time in-situ analysis of drug release was monitored using the
absorption function of the UVprobe software, which was programmed to take a
spectrum from 600 to 190 nm at each time interval to be analysed later at a
wavelength appropriate for the drug being analysed. Table 5.2 identifies the
respective absorption wavelengths for each drug used.
Table 5.2 Absorption wavelengths of DEX and FOS

Dopant or drug

Absorbance wavelength

DEX

242 nm54

FOS

210 nm248

The in-situ three-electrode cell is schematically represented in Figure 5.3. The cell
was arranged in a 3 mL quartz cuvette for DEX with the gold mylar-polypyrrole
working electrode and the Pt mesh counter electrode resting flush against opposite
frosted cuvette walls. The transparent cuvette sides were aligned with the direction
of the spectrophotometer beam, which was not obstructed by any of the cell
components. A Ag|AgCl reference electrode was suspended in the middle to
complete the electrochemical cell and PBS (50 mM, pH7.2) was used as the release
solution. A small motor modified with a large stirrer bar was placed inside the UVVis chamber (but outside the release cuvette as shown in Figure 5.3) to facilitate
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gentle solution mixing by magnetically moving the stirrer bar inside the cuvette.
This was done for the duration of all release experiments to assist the diffusion of
the released drug from the working electrode surface to the bulk solution in order
to take representative spectra.
Reference electrode
Working
electrode

Motor with
stirrer bar
attached

Counter electrode

Stirrer bar
Path of spectrophotometer beam through the release solution

Figure 5.3 Schematic of the three-electrode cell designed for in situ electrochemical
stimulation and recording of UV-vis spectra.

For FOS experiments, the release solution volume was reduced to 200 µL due to
the smaller film size. The release was done in a separate cell and the 200 µL aliquot
was then transferred to a 500 µL quartz cuvette for UV-vis analysis. The transfer of
solution in these experiments limited the time points to 1 minute intervals.
The electrochemical cell electrodes were connected to a potentiostat and eDAQ
software was used to apply an oxidising or reducing potential to the working
electrode. The current and charge profiles were recorded while simultaneously
collecting absorbance data from the UV-vis. The absorbance results were converted
to a mass of drug released using a calibration curve and the charge data was
converted to represent the charge passed per square centimetre in order to
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accurately compare different samples. All the results were plotted against time to
obtain release profiles.

5.3.4 Controlled drug delivery device assembly and characterisation

Monitor current, voltage and charge
Ag|AgCl reference

Ar gas
inlet

Pt counter
Salt bridge

Monitor absorbance

rGO-MWNTGOx-PEi
anode
PPy film

Anode Cell
37°C under Ar

Path of spectrophotometer beam
Release Cell
UV-vis

Figure 5.4 Schematic of the electrode configuration used to characterise the release of drug
from a PPy film as stimulated by the output of the bioelectrode anodic cell.

The device prototype utilised to characterise the feasibility of powering the release
of drug from a polypyrrole film using a working GOx bioelectrode is schematically
represented in Figure 5.4. The rGO-MWNT-GOx-PEi (10%) electrode used in
these experiments was fully characterised in Chapter 4 and for the remainder of this
discussion will be referred to simply as the bioelectrode. A 3-electrode
electrochemical cell was used in the bioelectrode cell, and during the release
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experiments, the current and potential of the bioelectrode|Pt couple were measured
using

the

zero-resistance

amperometry

(ZRA)

function

of

the

eDAQ

electrochemical system.
Zero-resistance amperometry (ZRA) is a nonperturbative electrochemical technique
used to measure time dependent current and potential profiles of a galvanic cell. By
placing a ZRA in the electrical circuit, the galvanic current and potential can be
measured against a Ag|AgCl reference electrode249. Measurements were made at
0.5 points per second and the program was set to accumulate data for the duration
of the release experiments. ZRA experiments were performed using eDAQ software
and the integral of the current was simultaneously calculated (i.e. the charge
passed). The charge profile was converted to charge passed per square cm for each
sample for ease of comparison between samples.
In order to power the release of drug, the PPy film was connected to the Pt counter
electrode that collects electrons produced by the bioelectrode in the anode cell. This
current is directly wired to charge the PPy film and the release cell, located inside
the UV-Vis, was gently stirred and measured for drug release. A 3 M Ag|AgCl salt
bridge connected the two cells. The data from these experiments was plotted as a
function of time and the amount of drug released was analysed with reference to the
current and potential generated by the bioelectrode|Pt couple measured by ZRA.
The system was tested at 0 mM and 150 mM glucose concentration. These
conditions were chosen to represent the absence of fuel (0 mM) and the saturation
concentration (150 mM). A more biologically relevant glucose concentration would
be 5 mM, however, the bioelectrode did not respond consistently to this
concentration. The release data was compared to the passive release of drug from
PPy (i.e. when the two cells were disconnected) and natural elution of drug was
recorded.
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5.4 Results and discussion
5.4.1 Dexamethasone release characterisation
DEX was originally chosen for drug delivery experiments as it is a commonly used
anti-inflammatory drug56 and release from PPy had been described previously116. A
series of PPy-DEX samples were grown on clean gold mylar according to the
parameters given in Table 5.1. Cyclic voltammograms for the deposited materials
show broad but defined oxidation and reduction peaks at +0.28 V and -0.28 V (vs.
Ag|AgCl), respectively (Figure 5.5). When PPy is in the reduced state (-0.28 V),
according to Scheme 1, it will release the doping anion, which in this case is DEX.
The potentials marked on Figure 5.5 (a) represent the voltages selected for in-situ
stimulated release characterisation and the experiment was set up as described in
Figure 5.3. In theory, when the PPy is held in a reduced state it should release a
larger amount DEX compared to when it is not fully reduced (i.e. at 0 V). -0.55 V
was also tested to see if more DEX was released when the film is reduced further
than the reduction potential.
Figure 5.5 (b) shows the DEX release profiles according to the potential applied to
the PPy film and as a function of time. Over 24 hours, no significant plateau in drug
release was observed indicating that there is enough drug incorporated into the
films to continuously release for that time frame. There is also no significant initial
burst release, which is common for drug release from conducting polymers48,55,
however it does tend to release at a faster rate for the first 5 hours. There is some
correlation between the amount of drug released and the charge density, however,
the large error bars associated with this data indicate that the control over the
release of drug is not reproducible. In all stimulated cases, the amount of drug
released is greater than the passive release profile (Figure 5.5 b - grey profile).
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Figure 5.5 (a) CV characterisation of a PPy-DEX film in PBS (pH 7.4 under Nitrogen at 100
mV/s) (b) Release (solid) and charge (dashed) profiles of DEX release from PPy-DEX films
when stimulated at -0.55 V (purple), -0.28 V (green) or 0V (black) vs Ag|AgCl. Passive
release is shown in grey. DEX release was monitored by in-situ UV-Vis at 242 nm.

Thompson et al51 described a two layer approach where a PPy-PTS prelayer was
deposited before a PPy-NT3 (Neurotrophin) layer. Such an approach demonstrated
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more homogenous film growth as well as enhanced incorporation of NT-3 in the
final layer compared to the equivalent system with no prelayer present. It was
hypothesized that the advantage of the two-layer system may be due to the
increased surface roughness or the shielding of the gold surface from the
biomolecule. The same approach was adopted for the PPy-DEX samples in this
work. A thin PPy-PTS layer was prepared on clean gold mylar, according to the
parameters outlined in Table 5.1, and after a thorough wash and dry, the PPy-DEX
film was grown on top. Figure 5.6 (a) shows the electrochemistry of the PPy-PTSDEX electrode with broad oxidation and reduction peaks at +0.2 V and -0.4 V,
respectively.
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Figure 5.6 (a) CV characterisation of a PPy-PTS-DEX prelayer film in PBS (pH 7.4 under
Nitrogen at 100 mV/s) (b) Release (solid) and charge (dashed) profiles of DEX release from
PPy-DEX films with a PPy-PTS prelayer when stimulated at -0.6 V (purple), -0.4 V (green) or
0V (black) vs Ag|AgCl. DEX release was monitored by in-situ UV-Vis at 242 nm.
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Release profiles were obtained at the potentials marked in Figure 5.6 (a) and the
results are presented as a function of time in Figure 5.6 (b). The error bars indicate
that when a PPy-PTS prelayer is present the results are much more reproducible
than when no prelayer is present (as shown in Figure 5.5). Thompson et al.
hypothesize that the presence of the prelayer improves polymer growth and may
contribute to a more homogenous release profile51. The maximum amount of DEX
is released when stimulated at the reduction peak potential (-0.4 V). When
stimulated at a more reducing potential (i.e. -0.6 v) the polymer sample experiences
more charge (purple charge profile), however not as much DEX is released in the
over-reduced state (purple release profile). When stimulated at a more oxidising
potential (i.e. 0 V) there is not as much charging current (black charge profile) and a
negligible amount of DEX is released (black release profile). From this data it is
evident that the applied potential governs the extent of DEX release from PPy,
rather than the amount of charge passed. The results presented agree with the
results and mechanism proposed by Svirskis et al. who reported an enhanced release
response when the polypyrrole film was held at a reducing potential83. These
results suggest that the controllable switching behaviour of drug release from
conducting polymers is a direct function of the change in oxidation state of the
polymer backbone and the corresponding ion exchange mechanism to balance the
charge250. An on-off switching feature such as this is desirable for an implantable
drug delivery device to demonstrate control over the release of therapeutic drug.
While the anti-inflammatory drug DEX has significance in novel drug delivery
devices it was of interest to find a suitable anti convulsant drug to make the
experiments relevant to the treatment of epilepsy.

5.4.2 Fosphenytoin release characterisation
Fosphenytoin (FOS) is a water soluble pro drug which has an anionic phosphate
group (Figure 5.1 b) making it suitable to use as a dopant in polypyrrole electrodes
for controlled drug release56.
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UV-vis spectrophotometry was used to detect the release of FOS. Figure 5.7 shows
the absorption spectra of FOS and it is evident that peak absorption occurs around
200 nm however, this wavelength overlaps with the absorption spectrum of the
quartz cuvette (190-200 nm). Cwik et al. have prepared a calibration curve for FOS
by measuring its absorption at 210 nm248. Subsequently, this wavelength was used
for the detection of FOS.
Initial experiments using the PPy-PTS-DEX samples showed that the output of the
rGO-MWNT-GOx-PEi bioelectrode was insufficient to charge and instigate
release from films of 2 cm2. As such it was decided to use 0.125 cm2 PPy-FOS
electrodes and grow much thinner films (as outlined in Table 5.1) so the device
could be assembled effectively. The motivation behind monitoring the release of
FOS from the PPy films for just 10 minutes compared to the 24 hour release
profiles analysed for PPy-PTS-DEX arises from the proposed application. An
epileptic seizure can last for anywhere between a few seconds to minutes at a
time251, so it was important to characterize the release of FOS in this critical time
frame.
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Figure 5.7 UV-vis spectra of FOS and PTS in PBS (50 mM, pH7.2) from 190-400 nm.
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PPy-FOS films were prepared both with and without a PPy-PTS prelayer and there
was negligible improvement in the release profile when the prelayer was present.
Additionally, PTS absorbs around 200 nm (Figure 5.7) and given that the PPy-FOS
film is thin it would be difficult to assign the absorbance reading at 210 nm to FOS
alone, when PTS could also be released and skew the results. For these reasons it
was decided not to use a prelayer for further experiments.
The electrochemistry of PPy-FOS thin films in Figure 5.8 (a) shows two defined
redox couples (labelled A/A1 and B/B1). Street et al. suggest that the reason
polypyrrole usually has one set of redox peaks is the short conjugation length,
which only allows space for one polaron state. As discussed in Chapter 1,
polypyrrole usually incorporates approximately one doping anion per four pyrrole
units, however, this will depend on the efficiency of the doping molecule to
effectively balance the charge on the polymer backbone. Thus it may be the case
that the conjugation lengths in the PPy-FOS system are long enough to support
doubly oxidised states (bipolarons) and account for the two oxidation states
observed252. This may also reflect the efficiency of FOS to act as a dopant. One
feature of FOS that may contribute to the doping efficiency is the presence of two
aromatic functional groups (Figure 5.1 b) that could pi stack with the aromatic
polypyrrole backbone and restrict charge mobility. It is widely documented that the
properties of PPy change dramatically depending on the type of dopant and the
growth conditions used224.
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Figure 5.8 (a) CV of a PPy-FOS film in PBS (50 mM, pH 7.4 under Nitrogen at 10 mV/s) from
-0.8 to 0.6 V (vs. Ag|AgCl) (b) Release profiles (bar graph) of FOS out of the PPy-FOS films
stimulated at +o.2 V (black), -0.4 V (green) and passive release (purple) measured by UV-Vis
at 210 nm. Charge profiles (line graph) for +0.2 V (solid) and -0.4 V (dashed) measured by
ZRA. Error bars represent standard deviation (*p=0.03).
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From Figure 5.8 (a), the oxidation peak around +0.2 V and the reduction peak at 0.4 V were selected for FOS release experiments, shown in Figure 5.8 (b). The
charge generated per square cm was very similar for both stimulation potentials
and can be related back to the nearly identical anodic and cathodic currents realized
in the cyclic voltammogram. A thinner conducting polymer film allows the entire
film to charge quicker when a potential is applied, allowing faster switching times.
The release profiles in Figure 5.8 (b) show the release of FOS from PPy when
stimulated at different potentials, namely 0.2 V (oxidising) and -0.4 V (reducing), in
comparison with a passive release profile (i.e. when no electrical stimulation is
applied). The results show no statistical difference between the passive release and
the release measured at -0.4 V however, a statistically significant increase (*p=0.03)
was observed when the film was stimulated at +0.2 V. The opposite of this response
was observed for the PPy-PTS-DEX system presented in Figure 5.6. A complex
mechanism describes the release of a dopant from a conducting polymer, as outlined
in Chapter 1, and for thin films the amount of charge injected may influence the
release of the dopant more than the applied potential does. An explanation for the
observed release profiles could be that the reduction potential selected is overreducing the PPy, which may not release as much dopant, as discussed previously
for the PPy-PTS-DEX samples in Figure 5.6 (b).
In general, conducting polymers as bioactive molecular delivery systems suffer
from several major limitations; (i) Passive loss of loaded drug molecules by
diffusion, (ii) loss of loaded drug molecules as a result of anion exchange with the
surrounding environment, (iii) inherently low drug loading levels, (iv) poor control
and unpredictability of the binding and release kinetics, and finally, (v) low diffusion
coefficients of the released drug through dense semi-crystalline polymer fibrils
resulting in poor release kinetics. It is a combination of these features that
contribute to the large error bars associated with the controlled release of
molecules from conducting polymers like polypyrrole, as observed for the PPy-FOS
system in Figure 5.8 (b). To understand the underlying mechanisms for this system,
the FOS release was powered by an enzymatic bioelectrode (according to Figure
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5.4) and experimental parameters like bioelectrode potential and charge output, and
FOS release were measured simultaneously.

5.4.3 Controlled drug delivery powered by a bioelectrode
The following experiments were set up according to Figure 5.4 with the
bioelectrode output measured simultaneously with the release of FOS from PPy.
Initial experiments using the PPy-PTS-DEX samples showed that the output of the
rGO-MWNT-GOx-PEi bioelectrode was insufficient to charge and instigate
release from films of 1cm2, hence the following study was carried out with PPyFOS films of 0.0625 cm2 as a pilot study. It was hypothesized that by changing the
conditions for the enzyme in the anodic cell, the bioelectrode output would increase
and, if enough power was generated (approximately 10 uW for a PPy-FOS sample),
could instigate the delivery of FOS in the release cell. Figure 5.9 (a) shows the
charge generated from bioelectrodes under different anodic cell conditions when
connected to the PPy-FOS sample in the release cell. It is evident that when
glucose is present, a larger charging current is generated compared to open circuit
potential (OCP) when no glucose is present. The immobilised GOx can contribute
this extra catalytic current through the oxidation of glucose (1.5.4). Figure 5.9 (b)
shows the corresponding release profile of FOS in the connected release cell and
demonstrates that an increase in the rate of FOS released is observed when the
glucose concentration increases from 0 mM to 150 mM in the bioelectrode cell.
Linear extrapolation of the release profiles show that there is an increase in the
FOS release rate from 20 ng/min to 35 ng/min when the conditions in the
bioelectrode cell are changed. There is a statistically significant difference between
the release profiles at the 10 minute time point (*p=0.02).
While a more positive potential was recorded in the presence of glucose, there was
no statistical difference between the values for the cell potential (Figure 5.9 a). This
supports the hypothesis that for thin films, the charging current will significantly
affect the release of dopant, while the cell potential plays a less critical role. Due to
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experimental limitations, data could not be obtained within the one minute time
frame to determine if a clinically relevant amount of FOS can be immediately (< one
second) and reproducibly released from a PPy-FOS film. This is a critical
experiment to do to understand if the system can operate in the time frame relevant
for epileptic seizure activity. A more sophisticated experimental set up will be
established in the laboratory for future research in this area to detect drug release
with appropriate detection sensitivity at short time frames.
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Figure 5.9 (a) The bioelectrode charge output (bar graph) at 0 mM (black) and 150 mM
(green) glucose concentration in the bioelectrode half-cell, when the bioelectrode cell and the
release cell are galvanically coupled. Cell potential profiles (line graph) for 0 mM (black) and
150 mM (green) glucose concentration measured by ZRA (b) The release of FOS from PPyFOS measured at 0 mM (black) and 150 mM (green) glucose concentrations in response to
the bioelectrode cell charge output. Error bars represent standard deviation (*p=0.02).
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Figure 5.9 represents an encouraging result for the feasibility of fabricating a
completely implantable controlled drug delivery device. If the necessary control
over the rate and amount of drug released can be achieved using the power
generated from a bioelectrode, a first prototype of the device can be developed. The
next stage of experimentation involved addressing some of the specific
requirements for a device to treat epilepsy.
The previous experiments were performed with a minimum of 3 fresh polymer
samples measured for each data point however, in the proposed application we
envisaged a single polymer film to undergo a series of on-off switches in response to
repetitive seizure activity. Hence, it was of interest to change the conditions in the
anodic cell during experimentation and monitor the changes in bioelectrode output
alongside any changes in the rate of FOS release from the PPy-FOS film. Figure
5.10 shows the response of the system maintained at OCP (i.e. 0 mM glucose) up to
10 minutes before a spike of 150 mM glucose was added to the anodic cell. Figure
5.10 (a) shows the charge and voltage output of the bioelectrode while (b) shows the
corresponding release profile as detected by UV-vis.
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Figure 5.10 The two half-cells are connected and no glucose is present in the bioelectrode
cell for the first 10 minutes. At 10 minutes, the bioelectrode cell is spiked to a glucose
concentration of 150 mM. (a) Bioelectrode charge output (squares) and measured cell
potential (diamonds) and (b) the corresponding release of FOS from PPy-FOS in response to
the above mentioned bioelectrode output.
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From the bioelectrode output graph presented in Figure 5.10 (a), there is a slight
increase in the slope of the charge profile which can be attributed to the
contribution of the catalytic current and a corresponding increase in potential was
observed. A significant change in the rate of FOS release is observed in Figure 5.10
(b) in response to the change in bioelectrode conditions presented in Figure 5.10 (a).
Linear extrapolation of the release profiles show that prior to addition of glucose
the passive release rate was 24 ng/min (R2 = 0.969), and upon the addition of
glucose the release rate doubled to 47 ng/min (R2 = 0.992). Error bars tend to be
larger after the glucose is added indicating inconsistency in sample response to the
change in bioelectrode output. The data represents an average of 4 identical
samples grown under the same conditions. The large errors may be explained by
the limitations of drug release from conducting polymers outlined previously
(5.4.2). Variability may also be introduced during film growth due to the
concentration of monomer and dopant decreasing with consecutive film growth. It
was not feasible to use a new solution for each sample because of the limited supply
of materials. Instead, after each sample was prepared the growth solution was put
back into the stock solution and after gentle mixing a new growth solution of the
same volume was taken out. This was a necessary step to ensure the most
consistent film growth, because if the solution was not refreshed, the next film
showed poor electrode coverage with inconsistent growth. It could be that the FOS
is used up in the growth procedure and if the solution is used again there is limited
availability of the doping anion, hindering the formation of a homogenous film. An
attempt was made to increase the FOS concentration to address this issue however
inconsistent films resulted when the FOS concentration in the growth solution
exceeded 2.5 mM when all other parameters were kept constant (Figure 5.11).
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Figure 5.11 Photographs taken of PPy-FOS samples with different concentrations of FOS in
the growth solution. Other growth parameters remained consistent.

Figure 5.12 shows the consequence of leaving the PPy-FOS film in a passive release
state (i.e. not connected to the bioelectrode) before connecting the two cells. The
bioelectrode output and the FOS release profile were monitored in the same way as
the previous experiment. At the 10 minute mark the electrical connection was made
between the two cells and 150 mM of glucose was added to the bioelectrode cell.
Although there was very little change in the voltage recorded, a large charging
current was generated (Figure 5.12 a). There was an increase in FOS released as a
result of this charging current from 20 to 35 ng/min (Figure 5.12 b). Large error
bars associated with this data set indicate variability in the release of FOS between
samples, even when in a passive release state (i.e. 0-10 minutes). This may again be
attributed to the limitations of the conducting polymer release system and the
depletion of FOS in the growth solution between consecutive samples.
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Figure 5.12 (a) Bioelectrode charge output (squares) and measured cell potential (diamonds)
where the anodic cell and the release cell are not galvantically coupled until after 10 minutes.
Before this the release cell is recorded in a passive release state and after the 10 minute time
point the two cells are connected and 150 mM glucose is immediately spiked into the anodic
cell, and (b) the corresponding release of FOS from PPy-FOS in response to the above
mentioned bioelectrode output.

152 | P a g e

Chapter Five| Controlled drug delivery from polypyrrole: powered by enzymebased bioelectrodes
!
Critical for the efficient operation of a drug delivery device in response to an
epileptic seizure is the instantaneous release of FOS from the polypyrrole system.
In further prototypes of the device additional circuitry may be included so that the
bioelectrode can charge a capacitor and when a seizure is detected the capacitor
could discharge onto the polymer film and initiate the release of drug. This concept
will be discussed further in Chapter 6 however, the results presented above
demonstrate the proof of concept for the given materials.
In the development of such a sophisticated device it is difficult to know how much
drug is clinically relevant when delivering the drug directly to the brain. Current
methods of delivering FOS are restricted due to the debilitating side effects it
causes and is usually administered intravenously57, as discussed in Chapter 1. Large
amounts of drug are given so that it can pass throughout the whole body and for
enough to penetrate the blood brain barrier and have a therapeutic effect. It is
therefore critical to take the dosage amount into consideration when developing an
implantable drug delivery device. If too much is delivered or if the drug leaks out it
could have toxic effects on the brain. This is a major unknown requirement in this
line of study and once a suitable device is developed, animal studies will be done to
improve the prototype to deliver the appropriate amount of drug.

5.5 Conclusions
The control over the release of DEX from polypyrrole films was greatly enhanced
when a PPy-PTS prelayer was incorporated into the electrode structure. The
prelayer may improve polymer growth by shielding the gold mylar from the DEX
and also may contribute to a higher surface area and better foundations for PPyDEX growth. When stimulated at a reducing potential a larger amount of DEX
was released compared to stimulation at an oxidising potential. This result aligns
with other findings in literature. The 2 cm2 film of PPy-PTS-DEX film could not
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be powered by the given bioelectrode (characterized in Chapter 4) because the
bioelectrode output was not sufficient to instigate release.
Fosphenytoin (FOS) is a strong anti-convulsant drug, whose release from
conducting polymer electrodes was not previously reported. The release of FOS
from polypyrrole thin films was subsequently quantified. PPy-FOS samples were
galvantically coupled with the anodic cell containing an rGO-MWNT-GOx-PEi
bioelectrode (previously characterised in Chapter 4) and the conditions were
changed from 0 mM to 150 mM glucose concentration in the anodic cell. There was
an increase in the charge output of the bioelectrode when glucose was present due
to the additional current generated by the oxidation of glucose. The measured
potential of the whole device did not change dramatically under these conditions,
however, an increase in the amount of FOS measured in the release cell was
observed. This was a promising result to prove that such a device is feasible.
For the proposed application of the treatment of epilepsy, release of the drug has to
be rapid to quickly respond to the onset of a seizure. It would also be beneficial if a
single polymer film could be switched on and off and demonstrate a repeatable
release profile. Experimental limitations did not allow the measurement of FOS
release in less than one-minute time intervals, however, with a modified
experimental set up this could be achieved. Thus it was not conclusive in this study
if a therapeutic amount of FOS can be instantaneously released from the PPy
electrodes. Data points at 1 minute indicate that approximately 20 ng of FOS is
released in the first minute and it is difficult to put this into context given the
absence of information regarding what a therapeutic amount of FOS delivered
directly to the brain is. Experiments were performed to determine if a single
polymer film could be switched on in response to the catalytic bioelectrode output
through the addition of glucose to the anodic cell. It was determined that an
increase in release rate from 24 to 47 ng/mL was observed in response to a switch
between OCP and high glucose concentration.
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6. Conclusions and future work
6.1 Conclusions
6.1.1 Overview
The aim of this thesis was to evaluate the validity of using enzyme based
bioelectrodes to power the release of drug from conducting polymer scaffolds with
the intention of developing a device to treat epilepsy. Chapters 3 and 4 were
concerned with the fabrication and characterisation of two separate bioelectrodes
based on carbon nanomaterials, whilst Chapter 5 investigated the performance of a
drug delivery device prototype. The following sections give a brief overview for
each body of work, and future work considerations are proposed.

6.1.2 Solvated graphene bioelectrodes
Solvated graphene electrodes (SGE) loaded with glucose oxidase (GOx) were
characterised to determine their final composition and structure, as well as their
ability to facilitate direct electrical communication with immobilised enzyme.
Protein and kinetic biological assays performed on the as formed solvated graphene
electrodes (SGE) showed that the glucose oxidase (GOx) enzymes are both present
and active within the structure. It was also shown that the electrode fabrication
procedure was very reproducible through water content and GOx retention studies.
Various electrochemical studies were performed on the electrodes including cyclic
voltammetry (CV), electrochemical impedance spectroscopy (EIS), amperometry
and fourier transform alternating current voltammetry (FTACV). It was concluded
from electrochemical analysis that the enzymes are not efficiently electrically wired
to the graphene and as such cannot directly transfer the electrons generated from
the oxidation of glucose to the nanostructured electrode. Scanning electron
micrographs show that in the presence of GOx the graphene sheets delaminate due
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to aggregation of the enzyme into discreet layers. This aggregation of the GOx
may explain why very little direct electron transfer is observed and offer an
explanation to the relatively high resistances recorded through EIS. Amperometry
showed irreproducible catalytic current responses to the addition of glucose to the
electrolyte solution. When an electrode showed a positive result it’s response time
was on the order of minutes, making it unsuitable for real-time reaction to an
epileptic seizure. Additional circuitry could be incorporated into the device to
remove this requirement (discussed further in future work) however; the
inconsistent catalytic response to glucose renders these electrodes unsuitable as
bioelectrodes.

6.1.3 Reduced graphene oxide - carbon nanotube composite
bioelectrodes
A materials feasibility study was performed to determine the stability of rGOMWNT composite dispersions and showed that rGO effectively acts as a dispersing
agent for MWNTs. Traditionally, surfactants have been used to disperse carbon
nanotubes in aqueous systems due to their insolubility, however this is usually
detrimental to the electrical properties of the resulting electrode. For the
dispersions presented in this thesis, two highly conducting forms of carbon
nanomaterial were suspended in water without any insulating surfactants, namely,
carbon nanotubes and graphene. The dispersions remained stable for > 50 days and
did not form aggregates even with the addition of GOx, as indicated by particle size
analysis. Electrodes were fabricated from the dispersions and show well-defined
direct electron transfer redox peaks during cyclic voltammetry. The small (15 mV)
separation between anodic and cathodic peak potentials indicated a surface confined
fast electron-transfer process. When glucose was added to the system an increase in
anodic peak height corresponded to the catalytic current generated from the
oxidation of glucose by GOx. Upon optimisation of the rGO:MWNT ratio and the
GOx loading it was determined that the specific catalytic current generated (µA/
µg of GOx) was 3-fold higher than the closest literature value for similar drop-cast
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systems. The optimised bioelectrode presented in this chapter was utilised in the
following chapter to power the release of drug from conducting polymer scaffolds.

6.1.4 Controlled drug delivery from polypyrrole: powered by enzymebased bioelectrodes
The release of therapeutic drugs Dexamethasone (DEX, an anti-inflammatory) and
Fosphenytoin (FOS, an anti-convulsant) were characterised from the conducting
polymer polypyrrole (PPy). Polypyrrole was selected as a drug release scaffold due
to its biocompatibility and its capability to switch between oxidation states and, by
charge balance mechanisms, control the release of the drug dopant. When the PPyFOS films were connected to the rGO-MWNT-GOx bioelectrodes (Chapter 4)
there are observable changes in the rate of release of FOS that can be directly
related to changes in the bioelectrode output fuelled by the oxidation of glucose by
GOx. From a materials science perspective, the concept of galvanically coupling
enzyme based bioelectrodes with drug loaded conducting polymers to fabricate a
controlled drug delivery device prototype was validated. Optimisation of the
prototype is required to make it suitable for effective epilepsy treatment and some
considerations for this proposal will be discussed in section 6.2.

6.2 Future work
This thesis successfully showed from a materials perspective that the delivery of
anti-epileptic drug can be powered by an enzyme-based bioelectrode. The concept
was validated with the intention of fabricating an implantable device to treat
epilepsy. For a technology like this to be realized and implemented, some key issues
need consideration. This section aims to outline not only what can be done from a
materials development approach to advance the technology, but also to discuss
other avenues to achieve the ultimate goal.
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To achieve immediate release of drug from a conducting polymer film it requires an
immediate large charging current. This type of response is difficult to achieve
reproducibly using an enzyme-based bioelectrode and as such, additional circuitry
may be required to attain the desired response. For example, the enzymatic
bioelectrode could continuously work to charge a capacitor and when a seizure
occurs the capacitor could discharge and provide the relevant power to drive drug
release. There is also the limitation of the enzyme-based bioelectrode lifetime. It is
difficult to determine the longest operation time from the literature122 because
many papers report either storage lifetime253 or intermittent lifetime where the
electrode is refrigerated between experiments254. This is far from the conditions an
enzyme-based bioelectrode would encounter in vivo. In this thesis, the electrodes
presented in Chapter 4 showed that approximately 30% of the catalytic current was
lost in the first 4 hours of electrochemical cycling when maintained at a simulated
in vivo environment. Ideally the implant will last a few years, if not the patient’s
entire lifetime and as such the longevity of such electrodes has been a major target
of research for many years122,190,255 however, it is fundamentally limited by the
enzyme’s lifetime. One alternative would be to anchor an electrode to the inside of
the intestines or bowel. In this environment the electrode would experience a
constant flow of microbes naturally present in the intestinal tract256, and as such, if
the electrons produced by the microbial processes could be harnessed, they could be
used to power a controlled drug delivery system or other implantable bionic device.
The biocatalyst, in this case, would be naturally replenished and negate the issue of
bioelectrode lifetime.
Another materials science consideration is the ability of conducting polymer
scaffolds to repeatedly deliver a clinically relevant amount of anti-epileptic drug. A
limited amount of drug can be incorporated into a conducting polymer film, as well
as their ability to reproducibly release the same amount of drug with consecutive
stimulations81, and this will limit the lifetime of the final device. Too address this
issue, a microelectrode array could be used that has around 100 small conducting
polymer films, which can be individually addressed one at a time. This would allow
each microelectrode to release its entire contents but would limit the amount of
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treatable seizures to the number of microelectrodes present. For a person who has
frequent seizures this would not be suitable. Alternatively, a reservoir system could
be adopted where the conducting polymer acts like a gate or valve. This introduces
the added risk of releasing toxic levels of drug if the reservoir bursts, but may
address one aspect of the issues related to device longevity.
Additionally, seizure detection (or prediction) will be a critical component of the
final device. Recent advances in this technology from our collaborators at St
Vincent’s hospital in Melbourne, and backed by American company NeuroVista,
have successfully predicted the onset of seizure activity with high likelihood seizure
prediction sensitivity between 65 and 100%257. In the 2013 analysis, Cook et al.
tested 11 patients for the first in-human study of it’s kind and plan to up scale the
testing population to gain a better understanding of seizure generation. In parallel
studies, which have subsequently been patented, it has been shown that seizures can
be controlled through counter electrical stimulation258. Once the accuracy of
predicting seizures improves the combination of these two features in one unit will
possibly see the first real device in this area enter the market.

6.2.1 Solvated graphene – an interesting discovery
The Bradford protein assay was used to characterise the solvated graphene
electrodes presented in Chapter 3 and was implemented to determine the amount
protein present in the hydrated electrodes. The following section will introduce the
Bradford protein assay followed by the results observed during experimentation
and suggestion of a practical use for the material.

6.2.1.1 Bradford protein assay introduction
The Bradford Reagent can be used to determine the concentration of protein in
solution and is a standard assay widely used by cellular biologists. The driving
mechanism of the assay relies on the formation of a complex between the dye,
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Brilliant Blue G, and the protein. The protein-dye complex causes a shift in the
absorption maximum of the dye from 465 to 595 nm, correlating to the
disappearance of a brown colour and the appearance of a blue colour, and the
amount of absorption at 595 nm is proportional to the protein concentration259.

6.2.1.2 Bradford protein assay results
When the solvated graphene electrodes (SGEs) were tested, the brown colour of the
Bradford reagent was observed to disappear over time and failed to produce the
blue colour change as expected. It was determined that The Bradford reagent was
complexing with the protein and as such was also becoming immobilised within the
solvated graphene electrode. This presented an interesting discovery that if a
protein, or other molecule, is immobilized within the solvated graphene structure
and an appropriate complexing agent is in it’s immediate environment, the agent
will be effectively extracted from solution. The large surface area of graphene and
the high water content could lend this material to applications of extraction, given
that binding agents can be filtered and entrapped in the structure, and the process is
scalable and cost effective.
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